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Abstract		Williams-Beuren	Syndrome	(WBS)	and	7q11.23	microduplication	syndrome	associated	to	autistic	spectrum	disorders	(7dup)	,	two	multi-systemic	developmental	disorders,	arise	from	symmetrical	copy	number	variations	of	the	same	region	on	chromosome	7q,	comprised	of	26-28	genes.	In	WBS	patients	this	region	is	deleted,	whereas	it	is	duplicated	in	7dup	individuals.	These	syndromes	display	a	striking	combination	of	shared	and	opposite	clinical	manifestations	at	the	level	of	neuro-cognitive,	craniofacial	and	cardiovascular	features,	thus	pointing	to	a	remarkable	dosage-sensitive	effect	of	a	small	group	of	genes	on	the	development	and	maintenance	of	complex	traits	such	as	sociality,	language	and	facial	morphology.		We	harnessed	the	power	of	somatic	cell	reprogramming	to	derive	a	large	cohort	of	induced	pluripotent	stem	cells	(iPSCs)	from	samples	with	WBS,	7dup	and	from	healthy	controls,	and	we	demonstrated	that,	already	at	the	pluripotent	state,	the	transcriptome	is	dysregulated	in	pathways	that	map	onto	clinical	aspects	such	as	neuronal,	cardiovascular	and	craniofacial	development.	Moreover,	these	pathways	were	selectively	dysregulated	in	differentiated	lineages,	thus	demonstrating	an	unforeseen	anticipatory	power	of	the	pluripotent	state.	Indeed,	genes	in	the	region	that	are	involved	in	the	regulation	of	transcription	and	translation	are	highly	expressed	in	iPSCs,	and	their	expression	mirrors	the	CNV	dosage	across	samples.	Building	on	these	results,	my	PhD	project	is	aimed	at	expanding	the	view	on	the	dysregulation	in	pluripotency,	by	measuring	three	layers	of	gene	expression:	transcriptome,	translatome	and	proteome.	We	mapped	the	propagation	of	differences	across	layers	by	integrating	two	innovative	technologies,	ribosome	profiling	and	SWATH-MS,	and	we	probed	the	extent	to	which	a	translation	initiation	factor	included	in	the	CNV,	EIF4H,	was	responsible	for	the	regulation	of	translation.	We	found	that	each	layer	of	gene	expression	has	its	own	differentially	expressed	genes,	
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and	the	degrees	of	propagation	can	change	between	layers.	Moreover,	differentially	expressed	genes	can	cluster	by	different	ways	of	propagation	when	they	are	compared	to	the	levels	of	EIF4H.	We	then	showed	that	protein	degradation,	measured	by	pulse-Stable	Isotope	Labeling	in	Culture	(pSILAC)	coupled	to	SWATH-MS,	does	not	explain	changes	in	protein	abundance	across	samples	in	this	system,	and	we	provided	some	examples	of	gene	expression	modeling	in	which	degradation	rates	do	not	increase	the	precision	of	the	model.	Finally,	we	set	up	a	large	cohort	of	scalable,	homogeneous	inducible	neurons	that	are	amenable	to	high-throughput	experiments	and	promise	to	greatly	enhance	our	understanding	of	the	molecular	and	cellular	basis	of	Williams-Beuren	Syndrome	and	7q11.23	microduplication	syndrome
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Introduction		Williams-Beuren	 Syndrome	 (WBS	 –	 OMIM	 194050)	 and	 7q11.23-microduplication	syndrome	(7dup,	also	known	as	Somerville-van	der	Aa	Syndrome	–	OMIM	609757)	arise	 from	 a	 symmetrical	 copy	 number	 variation	 (CNV)	 of	 a	 1.5-1.8	 Mbp	 region,	containing	26-28	genes,	and	named	Williams	Beuren	Syndrome	Chromosome	Region	(WBSCR).	WBS	and	7dup	are	caused	by	 the	hemizygous	deletion	and	duplication	of	the	WBSCR	respectively.	The	prevalence	estimates	for	WBS	are	of	1	every	7,500	live	births,	whereas	only	a	few	cases	(around	100)	of	7dup	have	been	reported.	
Features	of	WBS	and	7dup			Both	 Williams-Beuren	 Syndrome	 and	 7q11.23	 microduplication	 syndrome	 are	multisystemic	developmental	disorders,	with	an	autosomal	dominant	inheritance,	in	which	 many	 systems	 are	 affected.	 These	 CNVs	 give	 rise	 to	 altered	 neurocognitive,	craniofacial,	 cardiovascular,	 metabolic,	 skeletal	 and	 genito-urinary	 features,	 in	 a	combination	that	presents	both	shared	and	opposite	abnormalities	between	the	two	syndromes	(fig.	1).	
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	Figure	 1:	 A	 schematic	 representation	 of	 clinical	 features	 in	 both	 syndromes.	 Purple	 text:	 shared	features;	 red	 text:	 opposite	 features.	 SVAS:	 supravalvular	 aortic	 stenosis;	 ADHD:	 attention	 deficit-hyperactivity	disorder.		The	 combination	 of	 shared	 and	 opposite	 features	 in	 many	 different	 systems	 and,	especially,	 in	 high-order	 neurological	 functions	 such	 as	 language,	 sociality	 and	visuospatial	construction,	points	to	the	WBSCR	region	as	a	small	cluster	of	genes	that	is	 able	 to	 control	 a	 diverse	 set	 of	 developmental	 features	 in	 a	 remarkably	 dosage-sensitive	fashion.	I	will	briefly	summarize	the	key	clinical	aspects	of	both	syndromes	to	give	the	reader	a	flavour	of	both	the	peculiar	aspects	of	these	pathologies	and	the	variability	across	patients.			
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Craniofacial	features	WBS	patients	have	been	historically	identified	for	a	characteristic	facial	morphology	that,	 in	 the	 early	 60s,	 was	 defined	 as	 elfin1.	 	 Epicanthal	 folds,	 a	 broad	 forehead,	swollen	 lips,	 long	 philtrum	 (the	 area	 between	 nose	 and	 upper	 lip),	 widely	 spaced	teeth,	collapse	of	the	nasal	bridge,	and	squint	all	contribute	to	a	facies	that	had	been	initially	 described	 by	 Williams	 (Williams	 et	 al.,	 1961)	 and	 Beuren(Beuren	 et	 al.,	1962).	 Some	 cases	 of	microcephaly	 have	 also	 been	 reported(Knudtzon	 et	 al.,	 2008;	Pérez	 Jurado	et	al.,	1996).	 Initial	attempts	at	 linking	craniofacial	dysmorphism	with	hypercalcemia	have	been	disproved	already	in	the	early	days	of	the	definition	of	the	syndrome;	we	now	know	 that	many	genes	 in	 the	WBSCR	are	 likely	 to	have	 a	 large	impact	 on	 the	 craniofacial	 morphology	 (see	 Genes	 involved	 in	 the	 the	 CNV).		Conversely,	 7dup	 patients	 have	 a	 combination	 of	 facial	 traits	 that,	 although	 having	different	 expressivity,	 is	 in	many	 cases	 the	opposite	 of	 the	WBS	gestalt:	 thin	 lips,	 a	short	philtrum,	high	nasal	bridge	and	long	nasal	tip,	retrognathia	and	macrocephaly.	Although	not	always	present,	the	broad	forehead	seems	to	be	the	shared	craniofacial	feature	between	the	two	syndromes;	a	 few	reports	of	cleft	 lip	and	palate	have	been	published,	mainly	for	7dup	patients	(Torniero	et	al.,	2008).	Clinicians	only	attempt	at	correcting	dental	dysmorphisms	by	means	of	dentistry	interventions.				
Cardiovascular	features	The	 predominant	 condition	 of	 WBS,	 affecting	 70%	 of	 patients	 (Pober,	 2010a),	 is	supravalvolar	 aortic	 stenosis	 (SVAS),	 due	 to	 the	 haploinsufficiency	 of	 the	 elastin	(ELN)	gene.	As	the	name	suggests,	it	consists	in	the	narrowing	of	the	aorta	just	above	
																																																								1	Although	there	have	been	some	calls	to	stop	describing	patients	with		this	term	(Whether	or	not	these	
children	have	elfin	facies	is	difficult	to	establish,	for	while	examples	of	the	syndrome	are	common,	this	
author	has	never	seen	an	elf.	The	term	should	be	dropped.	Burn,	1986)	it	has	survived	and	even	adapted	to	different	cultural	contexts:	in	Germany	WBS	is	also	called	“koboldgesicht	syndrom”,	in	Spain	“síndrome	del	duende”,		and	so	on.	
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the	aortic	valve,	and	is	often	accompanied	by	stenosis	of	 the	pulmonary	artery.	 It	 is	the	 major	 cause	 of	 death	 for	 WBS	 patients	 and	 is	 generally	 treated	 with	 surgical	interventions	 ranging	 from	 aortoplasty	 to	 autografts.	 Conversely,	 7dup	 patients	display	aortic	dilation	 in	46%	of	 the	 cases	 (Mervis	 et	 al.,	 2015)	and,	 in	~9%	of	 the	cases,	 patent	 ductus	 arteriosus,	 i.e.	 failure,	 shortly	 after	 birth,	 to	 close	 a	 vessel	connecting	the	aorta	and	the	pulmonary	artery.			
Neuro-cognitive	features	The	 unique	 neuro-cognitive	 profile	 of	 WBS	 patients	 had	 gained	 them	 yet	 another	nickname:	 cocktail	 party	 personality.	 The	 openness	 and	 lack	 of	 social	 inhibition	towards	 strangers	 is	 indeed	 one	 of	 the	most	 striking	 behavioural	 features	 of	 these	patients	 (Pober,	 2010).	 	 Although	 they	 are	 affected	 by	 mild	 to	 severe	 intellectual	disability	 (ID)	 -	 their	 intelligence	 quotient	 (IQ)	 is	 often	 compared	 to	 that	 of	 Down	syndrome	patients	 -	 their	 linguistic	 abilities	are	 spared,	 as	 they	are	able	 to	express	themselves	 with	 a	 rich	 vocabulary	 and	 complex	 syntactic	 constructs.	 	 Many	 WBS	patients	 have	 attention	 deficit	 –	 hyperactivity	 disorder	 (ADHD),	 are	 anxious	 and	develop	 obsessions,	 especially	 concerning	 objects.	 	 Another	 remarkable	 feature	 of	WBS	patients	is	their	severely	compromised	ability	to	construct	space.	They	are	not	able	 to	 mentally	 rotate	 objects,	 or	 to	 discern	 relative	 distances	 and	 positions	 of	elements,	 even	 simple	 ones;	 this	 feature	 seems	 to	 be	 spared	 in	 IQ-matched	 Down	syndrome	 patients	 (fig.	 2)(Bellugi	 et	 al.,	 1999),	 pointing	 again	 to	 a	 remarkably	selective	 action	 of	 these	 genes	when	 it	 comes	 to	 specific	 areas	 of	 cognition2.	 	WBS	
																																																								2	Jerry	Fodor’s	idea	of	modularity	of	mind	(Fodor,	1983),	i.e.	the	existence	of	discrete	parcels	of	cognition	with	functional	independence,	information	encapsulation	and	a	fixed	neural	architecture	has	been	proposed	to	be	validated	by	cases	such	as	William’s	Syndrome.	However,	the	variability	and	nuances	in	cognition	defects,	their	inter-dependence,	their	developmental	origin	combined	with	the	inescapable	fact	that	affected	skills,	however	relatively	strengthened,	are	still	affected,	led	to	a	confutation	of	this	theory.	For	a	review	see	(Meyer-Lindenberg	et	al.,	2006)			
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patients	 perform	 poorly	 on	 tasks	 in	 which	 planning	 and	 counting	 are	 required	(Paterson	et	al.,	2006).		
	Figure	2:	A	 comparison	of	 drawing	 tasks	performed	by	WBS	patients	 and	Down	 syndrome	patients.	From	Bellugi	et	al.,	1999.		Other	more	variable	features	involve	hyperacusis	–	many	WBS	patients	have	“perfect	pitch”,	the	ability	to	discern	a	musical	note	only	based	on	its	absolute	frequency	–	and	sensorineural	hearing	loss	(Marler	et	al.,	2005).		Conversely,	while	7dup	patients	still	retain	 intellectual	 disability	 and	 ADHD,	 their	 language	 abilities	 are	 severely	compromised,	and	can	often	reach	the	harshness	of	full	blown	autism	(Mervis	et	al.,	2015);	moreover,	7dup	patients	are	socially	withdrawn	or	aggressive,	and	engage	in	repetitive	behaviour.	Taken	 together,	 these	 features	 represent	hallmarks	of	 autistic	spectrum	disorders	(ASD),	for	which	the	7q11.23	duplication	has	been	reported	as	a	strong	 risk	 factor	 (Sanders	 et	 al.,	 2011).	 Indeed,	 20%	 of	 7dup	 patients	 can	 be	considered	as	 frankly	autistic	based	on	gold	standard	ASD-scoring	methods	(Mervis	et	al.,	2015)3.																																																											3	A	previous	interpretation	of	the	behavioural	features	of	WBS	patients	led	the	medical	community	to	classify	it	as	“the	polar	opposite	of	autism”	(Jones	et	al.,	2000).	While	this	characterization	was	dropped	over	time,	the	boundaries	of	this	definition	have	been	made	sharper	by	the	association	of	7dup	with	ASD,	for	which	the	symmetry	of	the	genetic	aberration	warrants	a	comparison	between	WBS	and	ASD.	However,	the	existence	of	WBS	patients	with	ASD	(Tordjman	et	al.,	2012)	blurs	again	the	boundaries,	and	perhaps	urges	us	to	rethink	the	diagnostic	criteria,	scales	and	scoring	methods	we	use	to	define	ASD.	A	genotype-first	approach,	in	which	the	classification	of	different	subsets	of	ASD	depends	on	the	mutation	underlying	it	(Stessman	et	al.,	2014),	may	provide	a	valuable	alternative.		
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Neurological	 abnormalities	 probed	 by	 magnetic	 resonance	 imaging	 (MRI)	 have	shown	 that	WBS	 patients	 have	 a	 10-15%	 reduction	 in	 encephalon	 volume,	 with	 a	proportional	reduction	in	cerebrospinal	fluid	(Capitão	et	al.,	2011).	Interestingly,	the	cortex	of	WBS	patients	appears	to	have	local	reductions	in	thickness	and	an	increase	in	the	number	and	length	of	gyri	compared	to	healthy	cortices	(Torniero	et	al.,	2007).	Functional	MRI	studies	have	shown	how	the	activation	of	specific	areas	of	the	visual	cortex	 is	 compromised	 in	patients:	when	presented	with	specific	visuospatial	 tasks,	the	ventral	stream	circuit	(the	“what”)	is	activated	as	in	healthy	people,	whereas	the	dorsal	stream	circuit	(the	“where”)	is	not	(Meyer-Lindenberg	et	al.,	2004).	Similarly,	the	 amygdala,	 deputed	 to	 emotion	 processing,	 is	 not	 activated	 when	 patients	 are	presented	with	aggressive	 faces,	while	 it	 is	 strongly	 responsive	 towards	non-social,	menacing	 stimuli	 (Meyer-Lindenberg	 et	 al.,	 2005).	 	 On	 the	 contrary,	 MRI	 on	 7dup	patients	shows	an	overall	increase	in	cortical	thickness	and	in	the	total	brain	volume,	simplified	 gyri	 complexity,	 ventriculomegaly	 and	 other	 brain	 malformations	(Torniero	et	al.,	2007);	functional	MRI,	albeit	on	a	single	case	to	date,	has	revealed	a	normal	 functioning	 of	 the	 visual	 cortex,	 contrasted	 by	 an	 inactivation	 of	 the	 limbic	system	 and	 the	 emotion-processing	 areas	 (Prontera	 et	 al.,	 2014).	 These	 findings	underscore	again,	this	time	from	a	neuroanatomical	and	even	functional	perspective,	the	symmetry	between	clinical	manifestations	of	these	syndromes.		
Other	features	
Abnormal	calcium	metabolism:	 between	 5	 and	 50%	 of	WBS	 patients	 have	 a	 severe	form	of	hypercalcemia	and	hypercalciuria	in	their	infancy,	which	then	progresses	to	a	milder	 manifestation	 as	 they	 age.	 A	 link	 with	 vitamin	 D	 metabolism	 has	 been	proposed,	 but	 never	 fully	 demonstrated.	 No	 calcium	 abnormalities	 have	 been	reported	in	7dup	patients	to	our	knowledge.	
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Diabetes	mellitus	and	glucose	intolerance:	impaired	glucose	intolerance	affects	around	75%	 of	 adults	 with	 WBS,	 many	 of	 which	 also	 have	 been	 diagnosed	 with	 diabetes	
mellitus	(Pober	et	al.,	2010).	Some	studies	in	animal	models	suggest	a	role	for	MLXIPL	and	STX1A	(see	Genes	involved	in	the	CNV).	As	in	the	case	for	calcium	abnormalities,	no	 reports	 have	 shown	 occurrence	 of	 neither	 glucose	 intolerance	 nor	 diabetes	 in	7dup	patients.		
Genetic	rearrangements	at	chromosome	7q11.23			The	 presence	 and	 peculiar	 arrangement	 of	duplicons,	 i.e.	 duplicate	 elements	with	 a	high	sequence	homology	within	the	WBSCR,	is	responsible	for	the	aberrant	alignment	of	 sister	 chromatids	 for	 crossing	 over	 during	 meiosis	 I.	 During	 gamete	 formation,	non-allelic	 homologous	 recombination	 (NAHR)	 events	 taking	 place	 between	centromeric	 and	medial	 or	 telomeric	 duplicons	 result	 in	 an	 incorrect	 crossing-over	that	causes	the	hemizygous	deletion	–	and	simultaneous	duplication	–	of	the	WBSCR	(fig.	3).		The	inversion	of	this	region	has	been	reported	as	a	polymorphism	that,	when	occurring	 in	 a	 healthy	 individual,	 is	 more	 likely	 to	 cause	 a	 deletion	 in	 his	 or	 her	children	(Hobart	et	al.,	2010;	Morris	et	al.,	2011).	
	Figure	3:	Schematic	representation	of	NAHR	occurring	at	7q11.23	causing	deletion	and	duplication	of	the	WBSCR.	Adapted	from	(Pober,	2010).		Turner	and	colleagues	(Turner	et	al.,	2008)	have	demonstrated	how	the	frequency	of	NAHR	 does	 not,	 in	 principle,	 give	 rise	 to	 an	 equal	 number	 of	 gametes	 with	 the	
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deletion	 and	 gametes	with	 the	 duplication.	 The	 deletion	 should	 rather	 be	 twice	 as	frequent	as	the	duplication.	However,	the	prevalence	of	WBS	patients	is	much	higher	than	 that	 of	 7dup	 patients	 (1	 in	 7,500	 against	 a	 few	 dozen	 cases	 reported)	with	 a	proportion	 that	 is	 bigger	 than	what	 would	 be	 expected	 by	 taking	 in	 consideration	only	 NAHR	 frequencies.	 This	 inequality	 can	 have	 different	 explanations.	 From	 a	purely	 cellular	 perspective,	 haploid	 cells	 lacking	 the	WBSCR	may	 be	more	 fit	 than	their	 duplicated	 counterparts,	 thus	 making	 it	 more	 unlikely	 for	 a	 7dup	 gamete	 to	effectively	 give	 rise	 to	 a	 fertilized	 egg.	 There	 are	 however,	 to	 our	 knowledge,	 no	studies	in	which	the	impact	of	7q11.23	CNVs	was	investigated	in	gametes;	moreover,	there	 are	 reports	 of	 individuals	 bearing	 7q11.23	 duplication	 who	 were	 diagnosed	only	 after	 receiving	 the	 same	 diagnosis	 for	 a	 child/grandchild	 (Mervis	 et	 al.,	 2015;	Patil	et	al.,	2015).	These	adults	had	only	minor	 learning	disabilities	and/or	sociality	issues	 that	were	 not	 previously	 categorized	 in	 any	 particular	 intellectual	 disability	syndrome	(Patil	et	al.,	2015)4;	other	probands	that	tested	positive	for	the	duplication	had	no	 intellectual	 disability	 at	 all	 (Mervis	 et	 al.,	 2015).	 This	 points	 to	 a	milder,	 or	more	 nuanced	 effect	 of	 the	 duplication	 compared	 to	 the	 deletion,	 which	makes	 its	clinical	 manifestations	 less	 evident	 and	 therefore	 less	 amenable	 to	 a	 correct	diagnosis.	Finally,	 taking	 in	consideration	also	a	historical	point	of	view,	while	WBS	has	 been	 first	 defined	 in	 the	 60s	 as	 a	 very	 characteristic	 set	 of	 clinical	 traits,	 the	genetics	 of	 which	were	 only	 later	 precisely	 identified	 by	means	 of	 a	 traditional	 or	“forward”	genetics	approach,	7dup	was	 identified	only	recently	 in	a	small	 cohort	of																																																									4	It	is	interesting	to	note,	in	the	context	of	this	reference,	the	description	of	the	father	transmitting	the	duplication:	“On	history,	it	was	found	that	the	father	had	a	history	of	delayed	speech.	He	never	had	any	formal	education	and	now	he	works	as	daily	wage	laborer.”.	The	socioeconomical	context	in	which	such	diagnoses	of	intellectual	disability	are	made	is	likely	to	play	an	important	role:	how	did	the	lack	of	formal	education	impact	on	the	cognitive	abilities	of	this	individual,	whose	genetic	aberration	went	undetected	for	years?	Or,	from	another	point	of	view,	how	did	the	socioeconomic	environment	impact	on	the	assessment	of	his	disability?	This	recognition	points	to	the	socially	constructed	nature	of	(intellectual)	disability,	and	its	interdependence	with	cultural,	biomedical	and	socio-economic	factors.	For	an	analysis	of	the	social	construction	of	disability,	see	Susan	Wendell's	"The	Rejected	Body"	(Wendell,	1996),	especially	chapter	2	and	the	introduction	to	Lennard	J.	Davis’	“The	Disability	Studies	Reader”	(Davis,	1997).	
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samples	(Kirchhoff	et	al.,	2007;	Kriek	et	al.,	2006;	Somerville	et	al.,	2005;	Thomas	et	al.,	 2006)	 and	 later	 (Sanders	 et	 al.,	 2011)	 in	 a	 genome-wide	 association	 study	on	 a	cohort	of	ASD	patients.	A	single	event	of	de	novo	 triplication	of	 the	region	has	been	reported	 in	 a	 patient	 displaying	 even	 more	 severe	 dysmorphisms	 and	 speech	impairment	(Beunders	et	al.,	2010)	,	strengthening	the	link	between	the	amplification	of	 this	 region	 and	 a	 neurocognitive/morphological	 syndromic	 outcome.	 	 Taken	together,	 all	 these	 reports	 point	 to	 the	 duplication	 as	 pathological	 variant	 that,	although	 being	 less	 diagnosed,	 showing	 less	 penetrance	 and	 more	 variable	expressivity	when	compared	 to	 the	deletion,	 is	 responsible	 for	a	 clinical	phenotype	that	has	both	shared	and	opposite	features	of	Williams-Beuren	Syndrome.	The	size	of	the	 genetic	 rearrangement	 is	 usually	 between	 1.55	 Mbps	 (95%	 of	 cases)	 and	 1.8	Mbps	(5%	of	cases),	and	the	position	of	its	breakpoints	are	highly	variable	within	the	duplicons(Bayés	et	al.,	2003).	A	few	interesting	cases	of	atypical	deletions	have	been	reported	 (Chailangkarn	 et	 al.,	 2016;	 Ferrero	 et	 al.,	 2010;	 Fusco	 et	 al.,	 2014),	which	spare	 specific	 regions	 of	 the	WBSCR	 and	 allow	more	 precise	 correlations	 between	WBS	genes	and		the	clinical	phenotype:	depending	on	the	portion	of	the	region	that	is	missing,	 these	 patients	 display	 a	 subset	 or	 a	 milder	 manifestation	 of	 pathological	traits,	 such	 as	 intellectual	 disability	 with	 no	 dysmorphism,	 or	 exclusively	cardiovascular	problems.	
Genes	involved	in	the	CNV		As	 briefly	 mentioned	 before,	 duplicons	 contain	 tandem	 repeats	 of	 duplicated	sequences	 with	 very	 high	 homology	 (~99.7%).	 These	 sequences	 are	 mostly	pseudogenes	or	duplications	of	sequences	that	are	enclosed	between	the	centromeric	and	medial	duplicons,	i.e.	the	functional5	region	of	the	WBSCR,	with	the	sole	exception																																																									5	I	employ	here	a	liberal	definition	of	function,	that	postulates	the	existence	of	a	transcript	and/or	protein	that	is	expected	to	yield	an	effect	on	other	molecules	and	on	cellular	functions.	Yet,	
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of	the	medial	B	duplicon,	which	contains	the	functional	GTF2I,	NCF1	and	GTF2IRD2	sequences,	and	the	medial	C	duplicon,	which	contains	the	functional	FKBP6,	TRIM60.		All	 the	 sequences	 contained	 in	 the	 functional	 region	 are	 duplicated	 in	 at	 least	 one	duplicon,	with	the	exception	of	ELN	(Pober,	2010a).	The	functional	WBSCR	is	in	turn	made	of	28	protein-coding	genes	1	micro-RNA	and	1	antisense	lncRNA	(fig.	4).		
	Figure	4:	Schematic	representation	of	the	genes	comprised	in	the	WBSCR.	Blue	boxes:	duplicons.	Grey	arrows:	genes.			The	WBSCR	harbours	a	diverse	set	of	genes,	whose	function	and	involvement	in	WBS	is	summarized	for	the	reader’s	comfort	in	table	1.	
																																																																																																																																																																							pseudogenes	in	the	duplicons	are	transcribed	and	in	some	cases	translated,	even	though	their	contribution	to	a	molecular	or	cellular	phenotype,	if	any,	has	not	yet	been	investigated.	For	an	updated	read	on	the	notions	of	function	regarding	genomic	loci	see	Germain,	Ratti	and	Boem,	Junk	or	functional	
DNA?	ENCODE	and	the	function	controversy,	Biology	and	Philosophy	(Germain	et	al.,	2014).	
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Gene	 Functional	product	 Involvement	in	WBS	 References	
TRIM50	
E3	ubiquitin	ligase	involved	in	the	alimination	of	misfolded	proteins	via	the	formation	
of	aggresomes	
Unknown	 (Fusco	et	al.,	2012)	
FKBP6	
Protein	co-chaperone	involved	in	the	PIWI-mediated	transposone	silencing	in	
spermatogenesis	and	in	cellular	proteostasis	
Unkown	 (Taipale	et	al.,	2014;	Xiol	et	al.,	2012)	
NSUN5	 28S	rRNA	methylase,	influences	the	diet-associated	lifespan	of	C.elegans	 Unknown	 (Schosserer	et	al.,	2015)	
FZD9	 Wnt	receptor,	negative	regulator	of	the	beta-catenin	pathway	
Involved	in	apoptosis	of	neural	precursors	and	in	the	determination	of	
dendritic	spine	number,	calcium	oscillation	and	connectivity	in	upper	
layer	cortical	neurons	of	WBS	patients.	
(Chailangkarn	et	al.,	2016)	
BAZ1B	
Transcription	factor,	tyrosine	phosphatase	for	histone	H2A.X,	chromatin	remodeler	in	
WICH	and	SWI/SNF	complexes.	Involved	in	neural	crest	formation	and	migration	
Deletion	in	mice	causes	craniofacial	dysmorphisms	comparable	to	those	
of	WBS	patients.	Homozygous	KO	mice	have	major	heart	defects,	which	
are	milder	but	still	present	in	heterozygosity.	
Accounts	for	~40%	of	the	transcriptional	dysregulation	in	WBS	neurons.	
(Ashe	et	al.,	2008;	Lalli	et	al.,	2016;	Soldi	and	
Bonaldi,	2013)	
	
BCL7B	
Tumor	suppressor,	negative	regulator	of	Wnt	signaling,	member	of	SWI/SNF	
complexes	
Unknown	
(Kadoch	et	al.,	2013;	Middeljans	et	al.,	2012;	
Uehara	et	al.,	2015)	
	
TBL2	 Binds	60S	ribosomal	subunit	and	enhances	translation	of	ATF4	during	ER	stress	 Unknown	 (Tsukumo	et	al.,	2015,	2016)	
MLXIPL	
b-HLH	transcription	factor,	binds	carbohydrate-responsibe	elements	and	regulates	
triglyceride	synthesis	
Possibly	involved	in	the	metabolic	aspects	of	WBS	including	diabetes	and	
glucose	intolerance.	
(Palacios-Verdú	et	al.,	2015)	
VPS37D	 Member	of	the	ESCRT-I	complex,	involved	in	removal	of	poly-ubiquitinated	proteins	 Unknown	 (Schuh	and	Audhya,	2014)	
DNAJC30	 Chaperone,	contains	a	DNA-J	domain	 Unknown	 	
WBSCR22	 Methylates	18S	rRNA	in	the	nucleus,	necessary	for	ribosome	biogenesis	 Unknown	
(Õunap	et	al.,	2015;	Zorbas	et	al.,	2015)	
	
STX1A	 Involved	in	the	docking	of	synaptic	vesicles	in	the	presynaptic	membrane	
Possibly	involved	in	white	matter	development	in	the	encephalon.	
Expression	levels	are	statistically	associated	to	intelligence	in	WBS	
patients.	Also	involved	in	the	regulation	of	insulin	secretion	in	KO	mice	
models.	
(Gao	et	al.,	2010;	Hoeft	et	al.,	2014;	Lam	et	al.,	
2005)	
ABHD11	 Poorly	characterized.	Reports	of		serine	hydrolase	activity.	 Unknown	 (Navia-Paldanius	et	al.,	2016)	
ABHD11-as	 Antisense	lncRNA	in	the	ABHD11	locus	 Unknonw;	neuroprotective	in	mice	models	of	Huntington’s	disease	 (Francelle	et	al.,	2015)	
CLDN3	 Claudin	involved	in	tight	junctions	 Unknown	 	
CLDN4	 Claudin	involved	in	tight	junctions	and	regulation	of	Ca2+	paracellular	concentration	 Unknown	 	
WBSCR28	 Poorly	characterized.	Repressed	by	androgen-receptor	mediated	pathways.	 Unknown	 (Prescott	et	al.,	2007)	
ELN	 Elastin,	involved	in	the	formation	of	connective	tissue	with	contractile	features	 Responsible	for	SVAS	and	cutis	laxa	
(Li	et	al.,	1997;	Micale	et	al.,	2010;	Tassabehji	
et	al.,	1997)	
LIMK1	 LIM-domain	kinase	involved	in	the	formation	of	dendrites	and	synaptic	transmission	 Involved	in	the	visuospatial	construction	deficit.	 (Frangiskakis	et	al.,	1996;	Gray	et	al.,	2006)	
EIF4H	
Translation	initiation	factor	involved	in	the	scanning	of	the	5’	untranslated	region	of	
mRNAs	
KO	mice	models	display	a	reduction	in	number	and	complexity	of	CNS	
neurons,	and	learning	deficits	
(Capossela	et	al.,	2012)	
mir590	
Included	in	an	intron	of	EIF4H.	Inhibits	EMT	by	upregulating	E-cadherin.	Involved	in	
cardiac	regeneration	
Unknown	 (Eulalio	et	al.,	2012;	Liu	et	al.,	2015)	
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	Table	1:	Summary	of	genes	in	the	WBSCR	and	their	function	
LAT2	 Aminoacid	transporter	involved	in	immune	system	activation	(B	and	T	cells)	 Unknown	 (Orr	and	McVicar,	2011)	
RFC2	
DNA	replication	factor	C	subunit,	necessary	for	the	elongation	of	primed	regions	by	
DNA	polymerase	
Unknown	 (Gupte	et	al.,	2005)	
CLIP2	 Links	microtubules	and	organelles	in	dendrites	
Undecided.	Atypical	deletions	implicate	it	in	neurocognitive	phenotypes,	
but	individuals	with	hemizygous	deletion	are	healthy.	
(van	Hagen	et	al.,	2007;	Vandeweyer	et	al.,	
2012)	
GTF2IRD1	 Transcription	factor	involved	in	chromatin	regulation	
Involved	in	visuospatial	processing,	in	sensorineural	hearing	loss	and	in	
craniofacial	dysmorphisms.	
(Antonell	et	al.,	2010a;	Broadbent	et	al.,	2014;	
Canales	et	al.,	2015;	Edelmann	et	al.,	2007;	
Hirota	et	al.,	2003;	Tassabehji,	2005)	
	
GTF2I	 Transcription	factor	involved	in	chromatin	regulation	
Involved	in	intellectual	disability,	sociality,	visuospatial	processing,	
craniofacial	dysmorphisms,	calcium	intake.	Accounts	for	~	20%	of	
transcriptional	dysregulation	in	iPSCs	
(Adamo	et	al.,	2014;	Antonell	et	al.,	2010a;	
Edelmann	et	al.,	2007;	Hirota	et	al.,	2003;	
Malenfant	et	al.,	2011;	Sakurai	et	al.,	2011)	
	
NCF1	 Member	of	the	NADPH-oxidase	complex	
When	deleted	in	hemizygosity	it	is	a	protective	factor	against	
hypertension	
(Del	Campo	et	al.,	2006)	
GTF2IRD2	 Transcription	factor	arising	from	a	fusion	of	a	portion	of	GTF2I	and	a	retrotransposon	
Deleted	only	in	the	1.8	Mbp	CNV,	which	shows	more	severe	clinical	
manifestations	
(Bayés	et	al.,	2003;	Tipney	et	al.,	2004)	
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Groups	 of	 genes	 in	 this	 region	 converge	 towards	 CNS-specific	 functions	 (FZDN9,	STX1A,	 LIMK1,	 CLIP2,	 GTF2I),	 cardiovascular	 development	 (ELN,	 NCF1),	 metabolic	regulation	(MLXIPL,	ABHD11),	craniofacial	development	(GTF2I,	BAZ1B,	GTF2IRD1),	or	 towards	 more	 general	 processes	 such	 as	 transcription,	 	 translation	 and	degradation	(GTF2I,	WBSCR22,	NSUN5,	EIF4H,	TRIM50,	VPS37D).		It	 is	 beyond	 the	 scope	 of	 this	 introduction	 to	 provide	 an	 in-depth	 review	 of	 the	characterization	of	all	 these	genes,	but	I	will	summarize	some	important	aspects	on	EIF4H	 and	GTF2I	 that	 have	 emerged	 from	 genetic	 studies,	work	 on	 animal	models	and	 in	 vitro	 patient-derived	 cellular	 models,	 including	 work	 performed	 in	 this	laboratory.		
EIF4H		The	 eukaryotic	 Initiation	 Factor	 4H	 is	 a	 small	 (25-27	KDa)	 protein	 involved	 in	 the	regulation	of	 the	 initiation	 step	of	 translation,	which	has	been	 regarded	as	 the	 rate	limiting	 step	 where	 most	 of	 the	 regulation	 is	 thought	 to	 occur	 (Sonenberg	 and	Hinnebusch,	2009)	6.	It	interacts	with	the	EIF4F	complex	at	the	stage	of	unwinding	of	the	secondary	structures	of	the	5’	untranslated	region	(5’UTR)	of	mRNAs,	a	necessary	step	to	allow	the	43S	pre-initiation	complex	(PIC)	to	scan	the	UTR	and	reach	the	AUG	start	 codon	 (Parsyan	 et	 al.,	 2011).	 The	 PIC	 is	 composed	 by	 the	 small	 ribosomal	subunit	40S	and	a	series	of	 initiation	factor	complexes	(fig.	5).	EIF4H	has	a	paralog,	EIF4B,	which	 regulates	 translation	 initiation	 in	 the	 same	 complex.	 The	 sequence	 of	EIF4B	is	homologous	to	the	whole	length	of	EIF4H,	with	the	addition	of	longer	N-	and	C-	 terminal	 domains	 that	 can	 be	 phosphorylated	 as	 a	 result	 of	 signaling	 cascades	(Dennis	et	al.,	2012a).																																																									6	This	tenet	has	been	challenged	lately	by	the	idea	that	also	the	initial	clearance	and	elongation	steps	of	translation	(i.e.	the	joining	of	the	first	tRNAMet	and	the	subsequent	traslocation	along	the	open	reading	frame)	are	closely	related	to	initiation	rate-limiting	steps	(Chu	et	al.,	2014).	The	optimization	of	codons,	the	availability	of	free	40S	subunits,	the	recycling	of	monosomes	all	play	an	important	part	in	the	regulation	of	translation	kinetics.	I	will	however	consider	a	more	traditional	model	for	simplicity,	keeping	in	mind	that	it	is	unlikely	to	be	the	only	explanation	to	changes	in	protein	synthesis	rates.		
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EIF4H	has	been	shown	 to	physically	 interact	with	 the	mRNA	helicase	EIF4A	and	 to	compete	with	EIF4B	for	its	binding	(Rozovsky	et	al.,	2008),	however,	in	vitro	studies	have	 shown	 that	EIF4B	 stimulates	 translation	5	 times	more	 than	EIF4H;	moreover,	their	relative	stoichiometry	varies	across	different	tissues	(Richter	et	al.,	1999),	with	EIF4B	being	less	expressed	in	the	heart	and	in	the	brain.	The	exact	order	of	events	for	the	 EIF4A-EIF4H/EIF4B	 interaction	 has	 not	 yet	 been	 fully	 described,	 but	 a	 few	models	have	been	built	on	experimental	data.	EIF4H	enhances	the	processivity	of	the	unfolding	by	acting	simultaneously	on	both	EIF4A	and	the	mRNA.	It	binds	unwound,	single-strand	 mRNA	 via	 its	 RNA	 Recognition	 Motif	 (RRM),	 thus	 stabilizing	 it	 and	preventing	the	formation	of	secondary	structures	(Marintchev	et	al.,	2009;	Sun	et	al.,	2012);	 it	 also	 stimulates	ATP	hydrolisis	by	EIF4A,	which	makes	 its	helicase	activity	more	processive	and	unidirectional	 (Marintchev	et	al.,	2009;	Spirin,	2009).	Another	model	has	been	proposed	in	which	EIF4A	is	seeded	on	the	5’UTR	together	with	EIF4B	and	EIF4H,	polymerizing	on	 the	mRNA	and	allowing	 for	 faster	 initiation	on	already	processed	 5’UTR	 (Lindqvist	 et	 al.,	 2008).	 	 Beside	 its	 biochemical	 characterization,	
EIF4H	 has	 been	 studied	 in	 cancer	 as	 an	 oncogene	 (Vaysse	 et	 al.,	 2015;	 Wu	 et	 al.,	2011),	 building	 into	 the	 notion	 of	 translation	 initiation	 as	 a	 pathway	 that	 can	 be	targeted	by	anticancer	drugs	(Bhat	et	al.,	2015).	These	reports	also	show	that	EIF4H	is	 able	 to	 influence,	 in	 cultured	 tumoral	 cell	 lines,	 translation	 at	 a	 global	 level.	 The	expression	 of	 EIF4H	 across	 many	 tumoral	 lines	 seems	 to	 be	 remarkably	 stable	(Macrae	 et	 al.,	 2013),	 to	 the	 extent	 that	 it	 is	 being	 proposed	 as	 a	 replacement	 for	GAPDH	or	TBP	as	a	normalizer	in	qRT-PCR	measurements.	Only	one	report	has	linked	EIF4H	 to	 intellectual	 disability	 by	 generating	 and	 phenotyping	 Eif4h	 null	 mice	(Capossela	et	al.,	2012).	These	mice	presented	an	overall	reduction	in	size	and	weight,	but	more	importantly	showed	a	decrease	in	encephalon	size,	and	a	reduced	number	and	complexity	of	cortical	neurons.	Neurological	abnormalities	were	indeed	reflected	
	 28	
by	 a	 series	 of	 behavioural	 phenotypes	 that	 are	 reminiscent	 of	 some	 WBS	neurocognitive	 traits:	 inability	 to	 develop	 spatial	 memory,	 hyperreactivity	 to	novelties,	defects	in	fear-associated	learning.	Quite	paradoxically,	the	authors	report	that	translation	in	bulk	brain	extracts	–	as	assessed	by	polysome	profiling	–	does	not	change	 in	 Eif4h	 null	 mice	 compared	 to	 WT,	 leaving	 the	 tissue-specificity	 of	 the	translational	effect	of	EIF4H	open	to	debate.	
GTF2I		The	 General	 Transcription	 Factor	 II-I,	 together	 with	 GTF2IRD1	 and	 GTF2IRD2,	belongs	to	the	TF-II-I	family	of	transcription	factors,	characterized	by	the	presence	of	multiple	helix-loop-helix	domains	termed	I-repeats.	GTF2I	and	GTF2IRD1	are	always	deleted	in	WBS	cases,	while	GTF2IRD2	is	only	deleted	in	large	(~1.8	Mbp)	deletions.		GTF2I	 has	 been	 characterized	 as	 a	 basal	 transcription	 factor	 able	 to	 bind	 initiator	(Inr)	 elements	 at	 core	 promoters	 to	 initiate	 transcription	 (Roy,	 2001).	 It	was	 later	discovered	 that	 it	 can	 also	 integrate	 the	 response	 from	 extracellular	 signals	 upon	phosphorylation	and	translocation	 in	 the	nucleus,	where	 it	would	bind	E-boxes	and	exert	either	a	positive	or	negative	effect	on	transcription	of	specific	genes	(Hakre	et	al.,	2006).	Five	isoforms	of	GTF2I	exist	(α,	β,	γ,	Δ,	ε)	with	different	expression	levels	and	patterns	across	 tissues,	 and	different	 subcellular	 localizations;	GTF2I	 γ	 is	more	expressed	in	the	brain,	in	which	α and Δ	isoforms	are	instead	absent.	Several	lines	of	evidence	converge	towards	GTF2I	as	one	of	the	major	determinants	of	many	clinical	outcomes	in	Williams-Beuren	Syndrome	and	in	7q11.23	microduplication	Syndrome.	Patients	 with	 atypical	 deletions	 that	 always	 encompass	 GTF2I	 still	 show	 the	neurocognitive	profile	(Antonell	et	al.,	2010a;	Dai	et	al.,	2009;	Edelmann	et	al.,	2007),	whereas	a	patient	with	an	atypical	deletion	sparing	GTF2I	has	a	normal	IQ	(Ferrero	et	al.,	 2010).	 Moreover,	 two	 single	 nucleotide	 polymorphisms	 (SNPs)	 in	 GTF2I	 have	been	associated	to	autism	(Malenfant	et	al.,	2012)	(and,	in	the	healthy	population,	one	
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of	these	SNPs	has	been	associated	with	social	anxiety,	reduced	social	communication	skills,	and	amygdala	activation	by	avversive	stimuli	(Crespi	et	al.,	2014;	Swartz	et	al.,	2015).	Many	 animal	 models	 have	 proven	 how	 homozygous	 KO,	 and	 heterozygous	 KO	 or	duplication	 of	 Gtf2i	 lead	 to	 behavioural,	 neuronal	 and	 craniofacial	 phenotypes	reminiscent	 of	 the	 clinical	 traits	 of	 either	 syndrome	 (Mervis	 et	 al.,	 2012;	 Osborne,	2010).	 Further	 linking	 the	 role	 of	 Gtf2i	 with	 the	 neurocognitive	 phenotype,	 an	interesting	 work	 has	 recently	 been	 carried	 out	 in	 mice	 models	 in	 which	 the	 Gtf2i	deficiency	 is	 rescued	 by	 administering	 an	 adeno-associated	 viral	 (AAV)	 vector	overexpressing	 Gtf2i	 cDNA	 directly	 in	 the	 mouse	 encephalon	 by	 intracisternal	injection	(Borralleras	et	al.,	2015).	The	authors	report	changes	in	both	the	expression	of	endogenous	Gtf2i	and	 in	 the	motor,	 social	and	behavioural	 features	of	mice,	 thus	even	pointing	to	a	potentially	therapeutic	use.	Our	 lab	 has	 demonstrated	 how,	 in	 induced	 pluripotent	 stem	 cells	 (iPSCs)	 derived	from	 patients	 carrying	 either	 the	 deletion	 or	 the	 duplication,	 GTF2I	 can	 be	 held	accountable	for	up	to	20%	of	the	transcriptional	dysregulation	(Adamo	et	al.,	2014).	By	co-immunoprecipitation	we	were	able	to	determine	that	in	iPSCs	GTF2I	assembles	a	 repressive	 complex	 by	 physically	 interacting	with	 the	 histone	 demethylase	 LSD1	and	 the	 histone	 deacetylase	HDAC2.	 Among	 its	 targets	 there	 are	 genes	 involved	 in	many	 clinical	 manifestations	 typical	 of	 WBS	 and	 7dupASD,	 such	 as	 neuronal	development,	cardiovascular	structure	development,	smooth	muscle	contraction	and	presynaptic	membrane	organization.	This	suggests	that	GTF2I,	among	other	 factors,	is	 able	 to	 seed	 at	 the	 earliest	 stages	 of	 development	 a	 sizeable	 portion	 of	transcriptional	dysregulation	that	maps	onto	pathways	relevant	for	the	disease.	
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	Figure	5:	A	 simplified	model	of	 translation	 initiation	 (adapted	 from	Parsyan	et	 al.,	 2011).A:	 the	 cap-binding	protein	EIF4E	recognizes	the	5’	7meG	cap	and	docks	EIF4G	and	the	RNA	helicase	EIF4A	on	the	5’	untranslated	region.	EIF4A	starts	unwinding	 the	5’UTR	 in	a	5’->	3’	direction	 in	an	ATP-dependent	fashion,	stimulated	by	EIF4H,	EIF4B	and	EIF4G.	B:	the	pre-initiation	complex,	composed	by	the	small	ribosomal	 subunit,	 the	 initiator	 Met-tRNAiMet	 in	 the	 P	 (peptidyl)	 site,	 and	 a	 series	 of	 multi-subunit	eukaryotic	initiation	factors	lands	on	the	5’UTR,	now	stabilized	in	a	form	that	can	be	scanned.	C:	The	AUG	 in	 the	open	 reading	 frame	 is	 recognized	by	 the	 initiator	Met-tRNAiMet.	D:	 upon	hydrolization	of	GTP,	 the	PIC	 is	 disassembled.	The	 large	 ribosomal	 subunit,	 helped	by	 the	GTP-ase	 activity	 of	 EIF5B,	joins	the	small	subunit	 for	 initiation	clearance	and	the	first	translocation.	Translation	of	the	ORF	can	now	begin.	 	
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		Among	 WBSCR	 genes,	 EIF4H	 and	 GTF2I	 are	 the	 two	 most	 expressed	 ones	 at	 the	pluripotent	state	in	WBS	and	7dup	patients	(Adamo	et	al.,	2014),	and	their	expression	closely	 mirrors	 gene	 dosage.	 It	 is	 then	 reasonable	 to	 expect,	 by	 means	 of	 their	involvement	 in	 general	 pathways	 of	 transcription	 and	 translation,	 that	 these	 genes	have	a	broad	effect	on	gene	expression	from	the	very	first	stages	of	development.			
Regulation	of	gene	expression		The	central	dogma	of	molecular	biology	states	that	there	is	a	unidirectional	transfer	of	information	from	DNA	to	RNA	to	protein	(Crick,	1970).	A	properly	functioning	cell	(and	 even	moreso	 a	 properly	 functioning	 organism)	 has	 to	 carefully	 control	 three	aspects	of	 this	 information	 transfer:	what	 information	 is	needed,	when	 it	 is	needed,	and	how	much	of	 it	 is	needed.	 	The	 implementation	and	maintenance	of	 this	control	has	been	studied	for	decades	under	the	name	of	“gene	expression	regulation”.		The	notion	of	regulation	 implies	 that	a	set	of	 instructions	 is	being	used	to	steer	 the	combination	of	the	three	aspects	towards	a	specific	goal,	which	can	be	a	cell	state,	a	cell	 type,	 its	 localization,	 the	 replicative	 status	 to	 name	 a	 few;	 borrowing	 from	computer	science,	these	sets	of	instructions	have	been	defined	as	“programs”.	In	 fact,	 accompanying	 the	unidirectional	 flow	of	 information	defined	by	 the	 central	dogma,	 there	 is	 a	multidirectional	 flow	of	 information	 that	 integrates,	 among	many	other	 processes,	 feedback	 loops,	 intracellular	 and	 extracellular	 signals,	 covalent	modifications	and	subcellular	 localization	in	order	to	ensure	that	RNA,	proteins	and	metabolites	are	produced	and	placed	according	to	the	needs	of	every	program.		Although	for	historical	and	technological	reasons	the	transcription	of	RNA	had	been	placed	 on	 the	 central	 stage	 for	 a	 long	 time,	 it	 has	 now	 emerged	 clearly	 how	 gene	
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expression	 programs	 are	 tightly	 regulated	 at	 every	 possible	 step	 in	 the	 flow	 of	information	transfer.	We	can	in	fact	represent	gene	expression	as	a	discrete	number	of	 processes,	 each	 of	 them	 encompassed	 by	 a	 particular	 set	 of	 molecular	 species,	series	of	actors	and	peculiar	mechanisms	that	identify	a	“mode	of	regulation”	(fig.	6).	As	 the	very	 first	studies	on	gene	expression	already	pointed	out	(Jacob	and	Monod,	1961),	 each	process	 is	 able	 to	 cross-talk	 and	 influence	 the	 regulation	of	 the	others,	converging	 towards	 a	 cellular	 phenotype	 that,	 depending	 on	 the	 program,	 can	 be	thought	 of	 as	 static	 (homeostasis,	 quiescence,	 etc.)	 or	 dynamic	 (differentiation,	proliferation,	apoptosis,	etc.).			
	Figure	6:	A	simple	model	of	gene	expression.			I	 will	 touch	 briefly	 upon	 some	 of	 the	 main	 axes	 of	 regulation	 (transcription,	translation	 and	 protein	 degradation),	 with	 a	 special	 focus	 on	 how	 they	 relate	 to	neurodevelopmental	and	craniofacial	disorders.				
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Transcriptional	regulation		The	 regulation	 of	 transcription	 was	 initially	 studied	 as	 the	 interaction	 between	transcription	 factors	 (TFs)	 and	 specific	 DNA	 sequences	 on	 the	 genome.	 TFs	would	bind	 these	 control	 elements	 and	 recruit	 the	 transcription	machinery	 (composed	by	RNA	 polymerases	 and	 multi-subunit	 general	 transcription	 factors)	 on	 the	transcription	start	site.	Shortly	after	the	initial	description	of	transcriptional	control	by	Jacob	and	Monod,	studies	predicted	and	then	demonstrated	a	correlation	between	chromatin	 state	 (accessibility,	 presence	 of	 post-translational	 modifications,	 3D	organization)	 and	 the	 regulation	 of	 mRNA	 synthesis,	 leading	 to	 what	 is	 now	 the	current	 consensus	 model	 (reviewed	 in	 Lee	 and	 Young,	 2013).	 In	 this	 model,	 the	chromatin	 state	 is	 deeply	 interconnected	 with	 the	 recruitment	 and	 function	 of	transcription	 factors,	with	 the	 initiation,	 pause	 or	 stalling	 of	 RNA	polymerases	 and	with	 transcriptional	 elongation.	 A	 “histone	 code”	 had	 been	 initially	 compiled	according	 to	 which	 specific	 histone	 modifications	 (or	 “marks”)	 correspond	 to	different	 regulatory	 elements	 and	 to	 different	 activities	 of	 these	 elements	 (tab.	 2).	Chromatin	remodelers,	broadly	classified	as	readers,	writers	and	erasers,	are	able	to	decipher	and	modify	 this	code	by	means	of	physical	 interactions	with	histone	post-translational	 modifications.	 Depending	 on	 the	 mark,	 remodelers	 locally	 modify	chromatin	 in	 order	 to	 compact	 or	 relax	 DNA	 packaging,	 or	 recruit	 factors	 for	 the	establishment	 of	 long-range	 interactions	 between	 distal	 nucleosomes.	 Subsequent	studies	have	demonstrated	how	the	combinatorial	nature	of	histone	marks		is	not	as	simple	 as	 initially	 thought,	 revealing	 an	 intricate	 combination	 of	modifications	 that	confuted	the	existence	of	anything	resembling	a	“code”	(Wang	et	al.,	2008)	.	However,	functional	genomics	studies	still	make	wide	use	of	histone	modifications	as	predictors	of	transcriptional	activity,	which	become	especially	relevant	in	combination	with	high	throughput	RNA	sequencing	(RNA-seq)	and	ChIP-seq	for	chromatin	remodelers	with	
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a	known	activity.	Histone	modifications	are	highly	dynamic	and	reversible,	but	they	are	 heritable	 through	 cell	 divisions	 and,	 in	 some	 cases,	 through	 generations	(Brykczynska	et	al.,	2010;	Hammoud	et	al.,	2009)	Another	 reversible	 modification	 of	 DNA	 that	 is	 able	 to	 influence	 transcription	regulation	 is	 the	 methylation	 of	 cytosines	 in	 CpG	 dinucleotides.	 Deposed	 by	 DNA	methyltransferases	(DNMTs),	these	covalent	modifications	cover	roughly	70	to	80%	of	 CpGs	 in	 vertebrates,	 with	 the	 exception	 of	 “CpG	 islands”.	 In	 these	 loci	 the	dinucleotide	 is	 over-represented	and	under-methylated,	 and	 they	 tend	 to	 cluster	 in	the	vicinity	of	promoters,	suggesting	an	anti-correlation	between	methylation	of	CpGs	near	promoters	 and	 transcriptional	 activation.	Hypermethylated	promoters	 repress	transcription	 by	 means	 of	 steric	 hindrance.	 The	 analysis	 of	 the	 genome-wide	distribution	 of	 methylated	 CpGs	 reveals	 cell-type	 specific	 patterns	 (Deaton	 et	 al.,	2011;	 Illingworth	 et	 al.,	 2008),	which	 can	 be	 reshaped	 according	 to	 the	 expression	program	needed	for	another	cell	type.	As	already	mentioned	for	histone	marks,	CpG	methylation	 is	 heritable	 and	 is	 indeed	 responsible	 for	 the	 parental	 imprinting	 of	genomic	loci	(Felsenfeld	and	Bell,	2000).	The	set	of	reversible,	heritable	modifications	in	chromatin	and	DNA	methylation	are	commonly	referred	to	as	“epigenetic	marks”7.		The	 history	 of	 the	 discovery	 of	many	 of	 chromatin	 remodelers	 is	 deeply	 entwined	with	 the	 history	 of	 developmental	 biology.	 Two	 key	 chromatin	 remodeling	complexes,	 the	 Polycomb	 group	 (PcG)	 and	 the	 Trithorax	 group	 (TrxG)	 are	 named	after	 Drosophila	 melanogaster	 developmental	 phenotypes	 caused	 by	 their	 loss	 of	function	 (Ingham,	 1983;	 Lewis,	 1949),	 the	 homeotic	 transformation	 of	 body	segments.	 Polycomb	 group	 proteins	 are	 assembled	 in	 repressive	 complexes	 that																																																									7	Although	the	term	epigenetics	is	an	ambiguous	term	that	has	gone	through	many	rounds	of	re-definition	(Meloni	and	Testa,	2014),	mainly	as	a	function	of	the	technological	advances	that	capture	with	increasing	depth	the	identities	and	abundances	of	biomolecules,	it	is	still	tightly	linked	to	transcriptional	regulation	through	heritable,	reversible	chromatin	and	DNA	modifications.	
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catalyze	 the	 ubiquitination	 of	 lysine	 119	 on	 histone	 H2A	 (performed	 by	 Polycomb	Repressive	 Complex	 1,	 PRC1)	 and	 the	 trimethylation	 of	 lysine	 27	 on	 histone	 H3	(performed	by	Polycomb	Repressive	Complex	2,	PRC2).	Conversely,	Trithorax	group	proteins	 catalyze	 all	 the	 three	 methylations	 of	 lysine	 4	 on	 histone	 H3,	 which	 are	marks	 that	 activate	 gene	 expression	 and	 are	 deposed	 at	 enhancers	 (H3K4me1),	promoters	 (H3K4me3)	 and	 in	 broader	 regions	 of	 chromatin	 around	 enhancers	(H3K4me2).	 These	 catalytic	 activities	 classify	 these	 two	 complexes	 as	 chromatin	
writers,	which	depose	histone	marks	able	 to	 influence	gene	expression	by	means	of	steric	 hindrance,	 	 and,	 more	 importantly,	 by	 recruiting	 chromatin	 readers.	 Briefly,	chromatin	 readers	 i)	 can	 induce	 architectural	 changes	 in	 chromatin	 (relaxation	 or	compaction,	 looping,	 distal	 interactions),	 ii)	 can	 change	nucleosome	occupancy	 and	expose	or	withdraw	traits	of	DNA,	 iii)	can	mask	nucleosomes	to	other	readers	or	to	RNA	 polymerase,	 iv)	 can	 propagate	 specific	 histone	marks	 along	 loci	 by	 recruiting	other	writers	 or	 erasers,	 and	 v)	 can	 recruit	 other	 factors	 involved	 in	 transcription,	replication	 or	 DNA	 damage	 repair.	 As	 briefly	 mentioned	 before,	 the	 existence	 of	sharply	distinct	activating/repressing	 chromatin	marks	has	been	questioned	by	 the	experimental	 evidence	 on	many	 combinations	 of	 marks	 that	 do	 not	 ascribe	 to	 the	notion	 of	 an	 on/off-like	 switch	 of	 transcription.	 For	 instance,	 the	 presence	 of	 both	H3K27me3	and	H3K4me3,	a	repressive	and	an	active	mark,	has	been	identified	on	the	promoters	 of	 genes	 that	 are	 poised	 for	 activation	 in	 mouse	 embryonic	 stem	 cells	(Bernstein	et	al.,	2006).	These	“bivalent	domains”	allow	for	a	more	rapid	activation	or	silencing	 of	 specific	 loci	 upon	 differentiation,	 thus	 shaping	 the	 transcriptome	 and	ultimately	cell	identity.		The	activity	of	RNA	polymerase	is	controlled	at	the	initiation	of	transcription	and	at	its	 elongation.	 TFs	 bind	 DNA	 at	 specific	 loci	 and	 recruit	 cofactors,	 which	 in	 turn	interact	 directly	with	 the	 RNA	 polymerase	 or	 through	 the	Mediator	 complex,	 a	 big	
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(1.3	MDa)	multi-subunit	complex	that	bridges	the	RNA	polymerase	and	its	associated	GTFs	 with	 more	 distal	 transcription	 factors	 and	 cofactors.	 The	 RNA	 polymerase	transcribes	 then	 a	 stretch	of	 25-50	nucleotides,	 after	which	 it	 pauses	 (Rougvie	 and	Lis,	 1988).	 The	 release	 from	 the	 pause	 depends	 on	 the	 interaction	with	 elongation	factors	 that	 phosphorylate	 the	 RNA	 polymerase	 carboxy-terminal	 domain;	 if	 this	clearance	is	not	granted,	the	RNA	polymerase	will	detach	from	DNA	releasing	a	small	fragment	of	RNA,	otherwise	 it	will	 go	on	 transcribing	until	 reaching	a	 transcription	termination	sequence.		The	 regulation	 of	 transcription	 can	 be	 then	 summarized	 as	 the	 product	 of	 the	concerted	action	of	chromatin	remodelers,	which	act	 through	their	modifications	 to	influence	the	accessibility	of	DNA	and	its	protein	interactors,	which	in	turn	activate	or	repress	the	transcription	of	downstream	sequences	by	positioning	and	modifying	the	RNA	polymerase.	A	wealth	of	literature	has	demonstrated	how	the	precise	regulation	of	each	of	these	steps	is	crucial	for	development.	Naming	a	few	cases:	the	removal	of	the	 PRC2	 mark,	 catalyzed	 by	 the	 Jmjd3	 demethylase,	 is	 essential	 for	 neuronal	development	(Burgold	et	al.,	2008,	2012;	see	Testa,	2011	for	a	review);	the	deposition	of	 activating	marks	 by	TrxG	proteins	 is	 essential	 for	 gastrulation,	 spermatogenesis,	and	corticogenesis	(Andreu-Vieyra	et	al.,	2010;	Glaser	et	al.,	2009);	bivalent	domains	in	ES	cells	and	in	development	have	been	extensively	studied,	with	a	special	focus	on	neuronal	development	(Azuara	et	al.,	2006;	Bernstein	et	al.,	2006);	WICH	complexes,	containing	 BAZ1B,	 are	 involved	 in	 cardiovascular	 development	 (Han	 et	 al.,	 2011);	histone	demethylase	KDM1A/LSD1,	an	interactor	of	GTF2I,	regulates	early	stages	of	neuronal	 differentiation	 (Laurent	 et	 al.,	 2015).	 The	 number	 of	 evidences	 is	unsurprisingly	long,	and	steadily	grows	longer.		It	 is	 then	interesting	to	note	how	many	disorders	affecting	neuronal,	cardiovascular	and	craniofacial	development	are	caused	by	mutations	in	genes	that	are	involved	in	
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virtually	 all	 the	 steps	 of	 transcription	 regulation:	 readers	 and	 writers	 of	 DNA	methylation,	 chromatin	 remodelers,	 specific	 and	 general	 transcription	 factors	 and	RNA	polymerase	subunits	(tab.	2).		As	an	increasing	number	of	genome-wide	association	studies	on	trios	and	exomes	of	patients	 with	 autism	 spectrum	 disorder	 and	 intellectual	 disability	 are	 being	performed	and	published,	a	staggering	amount	of	genes	is	being	associated	to	these	conditions,	prompting	some	researchers	and	clinicians	to	propose	a	genotype-based	approach	 to	 classify	 ASD	 and	 ID,	 rather	 than	 the	 commonly	 used	 psychiatric	categories.	
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	Table	2:	Transcription	regulators	involved	in	developmental	disorders.	
Gene	 Complex	 Function	 Associated	syndrome	 Clinical	phenotypes	 Inheritance	 References	
EED,	EZH2	 PRC2	 Trimethylation	of	H3K27	(repressive)	 Weaver	Syndrome	 ID,	craniofacial	dysmorphisms,	overgrowth	 Autosomal	dominant	
(Cohen	et	al.,	2015;	
Gibson	et	al.,	2012)	
KANSL1	 MLL1/NSL1	
Acetylation	of	H4K5	and	H4K16	
(activating)	
Koolen-de	Vries	syndrome	 ID,	craniofacial	dysmorphism,	epilepsy	 Autosomal	dominant	 (Koolen	et	al.,	2012)	
KMT2D,	
KDM6A	
COMPASS	
(KMT2D)	
Mono-,	di-	and	tri-methylation	of	H3K4	
(KMT2D),	demethylation	of	H3K27	
(KDM6A)	(activating)	
Kabuki	syndrome	
ID,	craniofacial	dysmorphism,	heart	defects,	
genito-urinary	abnormalities	
Autosomal	dominant	
(Van	Laarhoven	et	al.,	
2015;	Miyake	et	al.,	
2013)	
NSD1	 	 Methylation	of	H3K36	and	H4K20	(repressive	or	activating)	 Sotos	syndrome	 ID,	overgrowth	 Autosomal	dominant	 (Höglund	et	al.,	2003)	
POLR1C,	
POLR1D	
Subunits	of	RNA	
polymerases	I	
and	III	
Core	components	of	the	transcriptional	
machinery	
Treacher-Collins-Franceschetti	Syndrome	 Severe	craniofacial	dysmorphisms	
Autosomal	dominant	
(POLR1C),	autosomal	
recessive	(POLR1D)	
(Bowman	et	al.,	2012;	
Vincent	et	al.,	2016)	
ADNP	 SWI/SNF	
Chromatin	remodeler	and	transcription	
factor	
Helmsmoortel-van	der	Aa	syndrome,	ADNP-
associated	autism	spectrum	disorder	
ID,	ASD,	craniofacial	dysmorphism	 Autosomal	dominant	
(Helsmoortel	et	al.,	
2014)	
CHD7,	
CHD8	
	
Chromatin	remodeler	with	repressive	
function	
Autism	spectrum	disorder,	CHARGE	syndrome	
ID,	ASD,	craniofacial	dysmorphism,	heart	
defects	
Autosomal	dominant	
(CHARGE)	
(Bernier	et	al.,	2014;	
Lalani	et	al.,	2006)	
BAZ1B	 WICH,	B-WICH	
Chromatin	remodeler	involved	in	
transcriptional	regulation,	DNA	damage	
response,	DNA	replication	
Williams-Beuren	syndrome,	
7q11.23	duplication	syndrome	
ID,	ASD,	craniofacial	dysmorphism,	heart	
defects,	genito-urinary	anomalies,	
metabolic	anomalies	
Autosomal	dominant	 (Pober,	2010a)	
GTF2I	
In	complex	with	
HDAC2	and	
LSD1	
General	transcription	factor	
Williams-Beuren	syndrome,	
7q11.23	duplication	syndrome	
ID,	ASD,	craniofacial	dysmorphism,	heart	
defects,	genito-urinary	anomalies,	
metabolic	anomalies	
Autosomal	dominant	 (Pober,	2010a)	
MED12	 Mediator	
Bridging	of	transcription	
factors/cofactors	and	RNA	polymerase	
Lujan-Fryns	syndrome	 ID,	craniofacial	dysmorphism,	heart	defects	 X-linked	dominant	 (Schwartz	et	al.,	2007)	
ARID1A,	
ARID1B,	
SMARCA4,	
SMARCB1,	
SMARCE1	
SWI/SNF	
Chromatin	remodeler	complex	with	
ATPase	activity	
Coffin-Siris	syndrome	
ID,	craniofacial	dysmorphism,	heart	defects,	
genito-urinary	anomalies	
Autosomal	recessive	
(Santen	et	al.,	2012;	
Tsurusaki	et	al.,	2012)	
DNMT3B	 	 Methylates	CpG	dinucleotides	
Immunodeficiency,	Centromere	instability	and	
Facial	anomalies	(ICF)	syndrome	
Craniofacial	dysmorphism,	
immunodeficiency,	predisposition	to	cancer	
Autosomal	recessive	 (Xu	et	al.,	1999)	
HEMT1	 E2F6	
Mono-	and	di-methylation	of	H3K9	
(repressive)	
Kleefstra	syndrome	
ID,	severe	speech	impairment,	craniofacial	
dysmorphism	
Autosomal	dominant	 (Kleefstra	et	al.,	2012)	
MECP2	 	 Binding	of	methylated	CpG	 Rett	syndrome	 ID,	ASD,	microcephaly,	epilepsy	 X-linked	dominant	
(Amir	et	al.,	1999;	
Wan	et	al.,	1999)	
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Translation	regulation		The	 regulation	 of	 protein	 synthesis	 represents	 another	 crucial	 step	 of	 gene	expression	 control.	 Cells	 regulate	 translation	 to	 rapidly	 adapt	 to	 extrinsic	 and	intrinsic	cues,	to	maintain	homeostasis,	and	to	finely	tune	gene	expression	programs	in	 a	 spatio-temporally	 regulated	 fashion.	 Translation	 control	 was	 initially	characterized	 in	biochemistry	 and	molecular	biology	 experiments	on	 cells	 and	 cell-free	 extracts,	 resulting	 in	 landmark	 discoveries	 on	 the	 function	 and	 structure	 of	ribosomes	 (Ban	 et	 al.,	 2000),	 the	 identification	 of	 translation	 initiation,	 elongation	and	termination	factors	(Pestova	and	Kolupaeva,	2002),	and	the	circular	topology	of	actively	 translated	mRNA	 (Wells	 et	 al.,	 1998).	 	 Subsequent	 technological	 advances	have	 shed	 light	 on	 the	 complexity	 and	 the	 variety	 of	 protein	 and	 RNA	 factors	 that	exert	this	regulation	(fig.	7).	As	mentioned	earlier,	 initiation	is	regarded	as	the	chief	regulatory	 locus	 of	 translation,	 being	 the	 rate-limiting	 step	 for	 protein	 synthesis	kinetics.		The	 cap-binding	 protein	 EIF4E	 recognizes	 the	 5’	 7meG	 cap	 of	 mature	mRNAs	 and	recruits	 the	EIF4F	 complex,	 composed	by	EIF4G	 and	 the	mRNA	DEAD-box	helicase	EIF4A.	 EIF4A	 is	 an	 ATP-dependent	 helicase	 tasked	 with	 unwinding	 the	 secondary	structures	 of	 the	 5’	 untranslated	 regions;	 its	 directionality	 and	 processivity	 are	enhanced	 by	 EIF4H	 and	 EIF4B	 as	 already	 described	 in	 the	 first	 section	 of	 the	introduction.	EIF4G	interacts	with	the	poly-A	binding	protein	PABP,	bound	at	the	3’	of	the	 mRNA,	 in	 order	 to	 create	 a	 closed-loop	 conformation.	 This	 conformation	enhances	the	binding	of	mRNA	to	the	PIC,	a	multi-subunit	complex	composed	by	the	40S	small	ribosomal	subunit,	initiation	factors	1,	1A,	2	and	3,	the	initiator	Met-tRNA,	and	a	GTP	molecule	bound	to	eIF2.	The	PIC	scans	the	5’	untranslated	region	until	the	Met-tRNA	matches	the	AUG	start	codon:	upon	this	interaction,	scanning	is	halted	and	
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GTP	 is	 hydrolized	 to	 GDP,	 thus	 stimulating	 the	 disassembly	 of	 the	 PIC	 and	 leaving	room	for	the	large	ribosomal	subunit	60S	to	constitute	the	80S	initiating	ribosome.		
	Figure	7:	Schematic	representation	of	the	main	cis-	and	trans-acting	elements	involved	in	translation	regulation.	 UTR:	 untranslated	 region;	 PIC:	 pre-initiation	 complex;	 RBP:	 RNA-binding	 protein;	 uORF:	upstream	open	 reading	 frame;	 IRES:	 internal	 ribosomal	 entry	 site;	dORF:	downstream	open	 reading	frame;	RBP:	RNA-binding	protein;	PABP:	poly-A-binding	protein.			The	 initiation	 step	 can	 be	 regulated	 at	 many	 different	 roadblocks.	 EIF4E	 can	 be	inhibited	 by	 the	 hypophosphorylated	 form	 of	 the	 EIF4E-binding	 protein	 1	(EIF4EBP1).	 Stimuli	 such	 as	 insulin	 signaling	 and	 nutrient	 starvation	 activate	 the	mTOR	 pathway	 which	 ultimately	 results	 in	 the	 phosphorylation	 of	 EIF4EBP1,	 its	release	from	EIF4E	and	the	assembly	of	the	EIF4F	complex.	A	recent	report	(Lee	et	al.,	2016)	 identified	 EIF3D	 as	 a	 novel	 cap-binding	 protein	 that	 is	 required	 for	 the	translation	 of	 specific	 mRNAs	 involved	 in	 cell	 proliferation	 and	 development	 and	competes	with	EIF4E.	EIF4B	can	be	phosphorylated	by	the	S6K	kinase	as	a	result	of	mTOR	(mammalian	Target	Of	Rapamycin)	pathway	activation	(Dennis	et	al.,	2012b),	thus	 enhancing	 5’UTR	 unwinding.	 mRNA	 helicases	 such	 as	 DDX3X	 or	 DHX29	 can	assist	 the	 unwinding	 by	 directly	 binding	 and	 relaxing	 secondary	 structures.	 5’UTR	secondary	 structures	 can	 also	 be	 recognized	 by	 RNA-binding	 proteins	 in	 order	 to	repress	translation.		Upstream	AUGs	and	upstream	open	reading	frames	(uORFs)	can	be	 recognized	 by	 the	 PIC	 and	 trigger	 initiation.	 Upstream	 AUGs	 and	 uORFs	 are	considered	 to	 act	 mostly	 by	 negative	 regulation	 of	 translation	 in	 non-stressful	conditions,	by	creating	a	decoy	initiation	that	greatly	reduces	translation	of	the	main	
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ORF,	or	recognizing	a	premature	stop	codon	that	initiates	nonsense-mediated	decay	(NMD)	of	 the	 transcript	 (reviewed	 in	Barbosa	 et	 al.,	 2013).	 Conversely,	 in	 stressful	conditions	such	as	starvation,	uORFs	can	enhance	the	translation	of	the	main	ORF	by	leaky	 scanning	 and	 bypass	 of	 the	 premature	 stop	 codon,	 thus	 reducing	 NMD	 and	increasing	 protein	 synthesis.	 	 Although	 uORFs	 have	 been	 detected	 in	 49%	 of	 the	human	 transcriptome	 (Calvo	 et	 al.,	 2009),	 they	 are	 over-represented	 in	 genes	involved	 in	 differentiation	 and	 proliferation;	 however,	 very	 few	 experimental	evidences	have	been	provided	for	the	mechanisms	of	translation	regulation	via	uORF.	Complex	secondary	structures	such	as	Internal	Ribosomal	Entry	Sites	(IRES)	can	be	directly	 recognized	 by	 ribosomes,	 bypassing	 cap-dependent	 initiation.	 IRESs	 were	initially	identified	in	viral	transcripts	as	a	means	to	increase	the	translation	without	depending	on	 the	host	 eIFs.	However,	many	 studies	have	demonstrated	how	 IRESs	are	also	present	in	a	large	fraction	of	human	transcripts,	and	are	used	in	the	contest	of	survival	to	stress	(Schepens	et	al.,	2005).		The	recognition	of		the	AUG	start	codon	is	influenced	by	cis-elements,	such	as	a	favorable	sequence	context	(the	Kozak	sequence	or	 other	 cognate	 sequences),	 and	 by	 eIFs	 that	 are	 able	 to	 control	 for	 “poor	 AUG	contexts”	(eIF1,	eIF2,	eIF3;	reviewed	in	Hinnebusch	2011)		and	increase	the	fidelity	of	the	recognition	of	proper	start	sites.	The	clearance	of	initiation	is	heavily	dependent	on	eIF2	and	the	hydrolysis	of	its	associated	GTP	molecule.	When	the	EIF2	subunit	α	is	unphosphorylated,	 it	can	be	bound	by	its	guanine	nucleotide	exchange	factor	(GEF),	eIF2B,	 that	 is	 able	 to	 replace	 GDP	 with	 GTP	 and	 thus	 allow	 for	 a	 new	 cycle	 of	translation	 initiation.	 Phosphorylated	 EIF2α	 increases	 the	 affinity	 for	 EIF2B	 and	sequesters	 it,	 effectively	 abolishing	 the	 GEF	 activity	 on	 EIF2	 itself	 and	 therefore	repressing	 translation.	 EIF2	 phosphorylation	 is,	 as	 for	 many	 other	 mechanisms	 of	translation	regulation,	the	result	of	nutrient	or	oxidative	tress.	
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The	 elongation	 phase	 starts	 with	 the	 initial	 translocation	 from	 the	 AUG	 (fig.	 8).	Initiating	ribosomes	host	the	initiator	Met-tRNA	in	the	P	site.	The	second	tRNA	enters	the	A	(aminoacyl)	site,	so	that	the	peptidyl	transferase	activity	of	the	60S	subunit	can	catalyze	the	formation	of	the	first	peptidic	bond.	The	first	Met	is	then	relocated	in	the	E	 (exit)	 site	 by	 translocation	 of	 the	 ribosomal	 subunits,	 and	 the	 initiator	 tRNA	 is	released.	During	elongation,	 aa-tRNAs	enter	 the	A	 site	 and	are	 stabilized	by	 codon-anticodon	pairing	with	the	mRNA.	The	A-site	aminoacid	then	forms	a	peptidic	bond	with	the	aminoacid	positioned	in	the	P	site;	ribosomal	subunits	translocate	along	the	mRNA	so	that	aminoacids	follow	an	A-P-E	site	procession.	This	process	is	controlled	by	elongation	factors	EEF1	and	EEF2.	EEF1,	in	complex	with	GTP,	delivers	aa-tRNAs	and	 is	 released	 upon	 GTP	 hydrolisis,	 caused	 by	 a	 conformational	 change	 in	 the	ribosome.	EEF2	acts	as	a	translocase,	coordinating	the	movements	of	tRNA,	the	two	ribosomal	subunit	and	the	mRNA.	EEF2	is	fundamental	for	dictating	the	codon-wise	pace	of	translation,	which	must	be	tightly	regulated	to	avoid	shifts	 in	the	reading	of	the	ORF	(Kaul	et	al.,	2011).		Recent	data	on	ribosome	profiling	experiments	revealed	that	 the	 average	 speed	 of	 elongation	 is	 ~6	 aminoacids	 per	 second	 (Ingolia	 et	 al.,	2011).	 The	 elongation	 rate	 is	 also	 controlled	 by	 the	 codon	 optimality	 of	 conding	sequnces.	 Recent	 work	 in	 yeast	 has	 shown	 non-optimal	 codons	 slow	 down	translocation	 and	 increase	mRNA	degradation,	 unveiling	 a	previously	unrecognized	layer	of	gene	expression	control	at	the	level	of	elongation	(Presnyak	et	al.,	2015).			
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	Figure	8:	schematic	representation	of	translation	elongation.	A:	the	first	elongation	step	consists	in	the	insertion	at	the	A	site	of	the	first	aa-tRNA	after	the	initiator,	mediated	by	the	elongation	factor	EEF1A	via	 a	 GTP-dependent	 mechanism.	 B:	 Once	 the	 aa-tRNA	 is	 accommodated	 in	 the	 A	 site,	 the	peptidyltransferase	 activity	 of	 the	 28S	 ribosomal	 subunit	 forms	 a	 peptidic	 bond	 between	 the	 two	aminoacids.	 The	 two	 ribosomal	 subunit	 translocate	 along	 the	 mRNA	 and	 shift	 the	 positions	 of	 the	tRNAs	 in	the	P	and	E	sites,	with	the	assistance	of	EEF2.	D:	 immediately	after	 translocation	the	E-site	tRNA	is	discharged	and	another	cycle	of	elongation	begins.				The	 maintenance	 of	 the	 reading	 frame	 is	 important	 to	 ensure	 the	 fidelity	 of	translation.	 	 However,	 alternative,	 overlapping	 ORFs	 can	 be	 encoded	 in	 the	 same	main	ORF	and	can	be	used	by	regulating	the	action	of	elongation	factors,	as	in	the	case	of	 	many	 viral	 transcripts	 and,	 in	 animals,	 of	 ornythine	 decarboxylase	 (Shantz	 and	Pegg,	 1999).	 	 This	 enzyme	 catalyzes	 a	 key	 step	 of	 polyamine	 synthesis.	 When	intracellular	 polyamine	 levels	 are	 high,	 they	 are	 able	 to	 induce	 a	 +1	 ribosomal	frameshifting	that	replaces	the	enzyme	ORF	with	the	reading	frame	for	the	antizyme,	a	polypeptide	that	th	enzyme	and	targets	it	for	ubiquitin-mediated	degradation.	This	is	another	example	of	how	translation	regulation,	in	this	case	at	the	elongation	step,	allows	 to	 control	 for	 quick	 changes	 in	 the	 environment	 and	 to	 adapt	 the	 gene	expression	program	accordingly.	Upon	reaching	 the	stop	codon,	 ribosomal	subunits	are	relieved	by	the	entry	in	the	A	site	of	class	I	release	factors,	which	hydrolize	the	aa-tRNA	bond	of	the	last	aminoacid	in	the	P	site	and	release	the	complete	polypeptide.	The	 two	 subunits	 are	 then	 dissociated	 and	 get	 recycled	 for	 subsequent	 rounds	 of	translation.		
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Failure	 to	 recognize	 the	 stop	 codon	 results	 in	 read-through	 translation,	 by	 which	proteins	gain	an	extended	C-terminus	which	alters	 their	 function	causing	abnormal	aggregation	or	 localization.	Several	safeguards	are	 in	place	to	avoid	this	outcome:	 if	read-through	 translation	encompasses	 the	whole	3’UTR	until	 the	poly-A	 tail,	mRNA	and	 protein	 undergo	 degradation	 via	 nonstop-mediated	 decay	 (van	Hoof,	 2002).	 If,	however,	 another	 stop	 codon	 is	 encountered	 before	 the	 poly-A	 tail,	 proteins	 with	extended	 C-termini	 may	 still	 be	 produced.	 A	 recent	 study	 has	 shown	 how	 these	extended	termini	enhance	the	instability	of	the	protein,	thus	blunting	the	detrimental	effects	of	read-through	translation	(Arribere	et	al.,	2016).	A	 fraction	 of	 3’UTR	 regions	 can	 also	 harbour	 downstream	 ORFs,	 which	 are	 more	evolutionarily	 conserved	 than	 their	 neighboring	 untranslated	 sequences,	 but	 are	translated	 at	 a	 much	 lower	 efficiency	 than	 their	 upstream	 counterparts	 (Ji	 et	 al.,	2015).	The	function	of	dORFs	is	still	unknown.		The	 3’	 UTR	 has	 been	 studied	 extensively	 as	 the	 region	 hosting	 most	 of	 the	 post-transcriptional	 regulatory	elements:	miRNAs	and	RBPs	bind	 specific	 sequences	and	secondary	structures	in	order	to	exert	spatio-temporal	control	of	translation.	MiRNAs	bind	 target	 sequences	by	 complementarity	and	 regulate	 translation	 in	mainly	 three	ways:	 1)	 they	 recruit	 the	 RISC	 (RNA-Induced	 Silencing	 Complex)	 that	 initiates	endonucleolytic	 cleavage	 of	 the	 mRNA,	 which	 is	 rapidly	 degraded.	 This	 pathway,	however,	 requires	 perfect	 pairing	 between	 miRNA	 and	 target	 mRNA,	 a	 very	 rare	occurrence	 in	 mammals.	 2)	 they	 deadenylate	 the	 polyA	 tract,	 making	 the	 target	mRNA	less	stable	and	less	efficiently	translated.	3)	they	interact	with	components	of	the	 eIF4F	 complex,	 greatly	 reducing	 translation	 initiation	 (Meijer	 et	 al.,	 2013).	 The	expression	 programs	 of	 miRNAs	 are	 as	 crucial	 as	 those	 of	 mRNAs,	 since	 they	 are	heavily	 interweaved	and	represent	an	additional	 layer	of	control	of	 the	 information	flow,	and	are	tightly	regulated	in	an	evolutionarily	conserved	fashion.		
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RBPs	interact	with	the	3’UTR	to	influence	the	subcellular	localization	of	mRNAs	and	also	 their	 translation	 status,	 acting	 as	 sensors	 of	 environmental	 hazards	or	 even	of	defects	 in	 translation	 efficiency.	 Stalling	 initiation	 at	 various	 steps	 results	 in	 the	formation	 of	 repressive	 ribonucleoprotein	 complexes	 termed	 “stress	 granules”	(reviewed	 in	 Buchan	 and	 Parker,	 2009),	 which	 can	 also	 include	 the	 mRNA	 decay	machinery	 (in	 which	 case	 they	 are	 termed	 “P-bodies”).	 The	 architecture	 of	 the	translation	machinery	is	kept	intact	so	that,	upon	disassembly	of	the	granule,	protein	synthesis	 can	 rapidly	 continue.	 As	 in	 the	 case	 of	 chromatin	 remodelers,	 	 the	 first	discoveries	of	 this	class	of	 translation	regulators	were	made	in	Drosophila	mutation	screens.	 	 In	 the	earliest	 stages	of	Drosophila	 embryo	development,	 the	morphogens	Bicoid	and	Pumilio	bind	the	mRNAs	of	caudal	and	hunchback	to	ensure	the	initial	fate	specification	 of	 frontal	 and	 posterior	 segments	 by	 repressing	 their	 translation	(Murata	 and	Wharton,	 1995;	 Rivera-Pomar	 et	 al.,	 1996).	 The	Drosophila	RBP	 UNR	regulates	X-linked	inactivation	in	males	by	repressing	the	translation	of	male-specific	lethal	 2	 (msl-2)(Abaza,	 2006).	 In	mammals,	PRM1	 and	PRM2	 mRNAs,	 encoding	 for	sperm-specific	 protamines	 (the	 functional	 equivalent	 of	 histones),	 are	 kept	 in	 a	repressed	state	by	the	TB-RBP	(testis-brain	RBP)	protein,	which	binds	to	their	3’UTR	until	 spermatogenesis	 reaches	 an	 advanced	 stage.	 TB-RBP	 is	 also	 expressed	 in	 the	brain,	where	it	 is	 involved	in	translation	repression	and	transcript	localization	(Han	et	 al.,	 1995;	 Wu	 and	 Hecht,	 2000).	 Perhaps	 the	 most	 interesting	 example	 for	 this	study	 is	 FMRP,	 the	 protein	 econded	 by	 FMR1,	 whose	 mutation	 causes	 fragile-X	syndrome.	 FMRP	 is	 localized	 in	 the	 postsynaptic	 space	 of	 neuronal	 dendrites,	together	with	synapse-specific	mRNAs.	Upon	activation	of	the	metabotrope	glutamate	receptor	 (mGluR),	 FMRP	 is	 phosphorylated	 and	 binds	 to	 the	 3’UTR	 and	 5’UTR	 of	mRNAs	 coding	 for	 the	AMPA	 receptor	 (AMPAR).	 FMRP	 inhibits	 their	 translation	 in	two	 ways:	 it	 establishes	 a	 physical,	 inhibitory	 interaction	 with	 eIF4E	 (bridged	 by	
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CYFIP1)(Napoli	 et	 al.,	 2008)	 and	 it	 recruits	 RISC	 (Didiot	 et	 al.,	 2009).	 mRNAs	 and	proteins	 are	 then	 assembled	 in	 a	 repressive	 ribonucleoproteic	 complex,	 akin	 to	ribosomal	 stress	 granules.	 This	 regulation	 finely	 tunes	 the	 presence	 of	 AMPA	neurotransmitter	 receptors	 in	 synapses	 and	 heavily	 influences	 the	 connectivity	 of	neurons.	When	other	ligands,	such	as	the	brain-derived	neurotrophic	factor	(BDNF),	reach	 the	 synapse,	 a	 signalling	 cascade	 results	 in	 the	 dephosphorylation	 of	 FMRP,	disassembly	 of	 the	 mRNP	 and	 restart	 of	 translation	 (Bear	 et	 al.,	 2004).	 	 Loss	 of	function	 of	 FMR1	 results	 in	 the	 abrogation	 of	 this	 activity-dependent	 control	 of	translation	 at	 the	 synapses	 and	 therefore	 in	 aberrant	 connectivity.	 	 A	 link	 with	dysregulation	of	translation	an	developmental	disorders,	especially	ASD,	is	warranted	by	a	series	of	evidences,	both	in	animal	models	and	in	human	syndromes	(tab.	3A	and	3B).	Apart	 from	all	 the	 insights	gained	 from	 fragile	X	 syndrome,	 two	recent	 studies	have	 shown	 ASD-like	 features	 in	 mice	 models	 in	 which	 Eif4e	 expression	 was	constitutively	 upregulated	 (Gkogkas	 et	 al.,	 2013;	 Santini	 et	 al.,	 2012),	 pointing	 to	 a	“hyper-connectivity”	 phenotype	 in	 brain	 neurons	 and	 to	 an	 imbalance	 between	excitatory	and	inhibitory	neuronal	activities.	One	of	the	studies	has	also	shown	that	the	behavioural	phenotype	could	be	rescued	in	adult	mice	with	a	drug	targeting	Eif4e,	hinting	 at	 the	possibility	 that	 translation	 could	be	 a	 treatable	 axis	 of	 regulation	 for	ASD	patients.	Upstream	negative	 regulators	 of	 the	mTOR	pathway	 such	 as	TSC1/2,	NF1	and	PTEN	cause,	when	mutated,	syndromes	that	include	ASD	among	their	clinical	features	(see	table	3B)(Kumar	et	al.,	1995;	van	Slegtenhorst	et	al.,	1997),	albeit	with	different	penetrance.		 	
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Gene	 Complex	 Function	 Associated	syndrome	 Clinical	phenotype	 Inheritance	pattern	 References	
FMR1	 CYFIP1-EIF4E-FMR1	 Translation	repressor	 Fragile	X	syndrome	 ASD,	ID,	craniofacial	dysmorphisms,	 X-linked	dominant	
(Knight	 et	 al.,	
1993)	
EIF4H	
Interacts	with	 the	EIF4F	
complex	and	mRNA	
Translation	initiation	factor	
Williams-Beuren	 syndrome,	
7q11.23	duplication	syndrome	
ID,	 ASD,	 craniofacial	 dysmorphism,	 heart	
defects,	 genito-urinary	 anomalies,	 metabolic	
anomalies	
Autosomal	dominant	 (Pober,	2010)	
NSUN5	 	
Methylates	 28S	 rRNA	 possibly	 changing	
translation	programs	
Williams-Beuren	 syndrome,	
7q11.23	duplication	syndrome	
ID,	 ASD,	 craniofacial	 dysmorphism,	 heart	
defects,	 genito-urinary	 anomalies,	 metabolic	
anomalies	
Autosomal	dominant	 (Pober,	2010)	
WBSCR22	 	
Methylates	18S	rRNA,	necessary	for	ribosome	
biogenesis	
Williams-Beuren	 syndrome,	
7q11.23	duplication	syndrome	
ID,	 ASD,	 craniofacial	 dysmorphism,	 heart	
defects,	 genito-urinary	 anomalies,	 metabolic	
anomalies	
Autosomal	dominant	 (Pober,	2010)	
SBDS	 	 Triggers	release	of	60S	pre-ribosomes	 Schwachman-Diamond	syndrome	
Skeletal	 abnormalities,	 heart	 defects,	 speech	
impairment,	 pancreas	 and	 bone	 marrow	
abnormalities	
Autosomal	dominant	
(Boocock	 et	 al.,	
2002)	
PUS1	 	
Converts	uridine	in	pseudouridine	during	tRNA	
maturation	
Myopathy,	 lactic	 acidosis,	 and	
sideroblastic	anemia	1	(MLASA1)	
Moderate	 ID,	 myopathy,	 anemia,	 skeletal	
abnormalities	
Autosomal	recessive	
(Bykhovskaya	 et	
al.,	2004)	
TCOF1	
In	 complex	 	 with	
NOLC1,	 CUL3	 and	
KBTBD8	
Covalently	 modifies	 ribosomes	 to	 enhance	
translation	of	specific	mRNAs	
Treacher-Collins-Franceschetti	
syndrome	
Severe	craniofacial	dysmorphisms	 Autosomal	dominant	
(Bowman	 et	 al.,	
2012)		Table	3A:	Translation	regulators	involved	in	developmental	disorders		
NF1	 	
RAS	GTPase	 activating	protein,	 inhibits	mTOR	
pathway		
Neurofibromatosis	 –	 Noonan	
Syndrome	
ASD,	 craniofacial	 dysmorphisms,	 heart	 defects,		
skin	and	connective	tissue	abnormalities	
Autosomal	dominant	
(Bertola	 et	 al.,	
2005)	
PTEN	 	 Antagonist	of	PI3K,	inhibits	mTOR	pathway	
PTEN	 hamartoma	 tumor	 syndrome	
(PHTS)	
ASD,	 macrocephaly,	 predisposition	 to	 tumor	
formation	
Autosomal	dominant	
(Varga	 et	 al.,	
2009)	
TSC1,	
TSC2	
	 Inhibits	mTORC1	 Tuberous	sclerosis	complex	 ASD,	ID,	predisposition	to	benign	tumors	 Autosomal	dominant	
(Kumar	 et	 al.,	
1995;	 van	
Slegtenhorst	 et	
al.,	1997)	
	Table	3B:	Upstream	regulators	of	mTOR	involved	in	developmental	disorders.	
The	 mTOR	 pathway	 is	 a	 central	 node	 that	 integrates	 external	 signals	 of	differentiation,	 growth,	 inflammation,	 environmental	 stress	 and	 acts	 on	 translation	mainly	 by	 positively	 regulating	 the	 eIF4F	 complex	 activity	 (reviewed	 in	 Hay	 and	Sonenberg,	2004).	This	 is	an	additional	 line	of	evidence	that	converges	 towards	the	lack	 of	 negative	 regulation	 of	 translation,	 or	 excess	 thereof,	 as	 one	 of	 the	 possible	mechanisms	underlying	ASD.	Taken	 together,	 the	 phenotypes	 of	 both	 patients	 and	 animal	 models	 point	 to	translation	 regulation	as	 a	process	 that	 is	 able	 to	greatly	 influence	development	by	modifying	 the	 response	 to	 external	 cues	 or	 by	 altering	 protein	 abundance	homeostasis	 in	 a	 cell-intrinsinc	 manner,	 with	 particular	 regard	 to	 its	 spatial	 and	temporal	 regulation.	 Moreover,	 since	 protein	 levels	 have	 undergone	 a	 greater	selective	pressure	than	their	corresponding	transcripts	during	evolution	(Khan	et	al.,	2013),	 translation	 regulators	may	 also	 be	 extensively	 involved	 in	 buffering	 protein	levels,	 serving	 as	 a	 safeguard	 for	 abnormal	 fluctuations	 in	 protein	 abundance	 that	may	have	a	transcriptional	origin.			
Regulation	of	protein	degradation	Spatio-temporal	 regulation	 of	 protein	 abundances	 is	 not	 only	 carried	 out	 by	increasing	or	decreasing	their	production	rates,	but	also	by	actively	dissociating	them	into	 their	 component	 aminoacids.	 Degradation	 is	 a	 fundamental	 process	 for	maintaining	 cellular	 homeostasis,	 controlling	 the	 quality	 of	 protein	 folding,	presenting	 antigens	on	 the	 cell	 surface	 and	enabling	modifications	 to	 cell	 state	 and	cell	fate,	such	as	cell	division	and	differentiation.	Initially	thought	to	occur	exclusively	in	 specialyzed	 organelles	 called	 lysosomes,	 it	 is	 now	 understood	 as	 a	 multi-tiered	process	carried	out	mainly	by	 the	Ubiquitin-Proteasome	system	(UPS)	(reviewed	 in	(Glickman	 and	 Ciechanover,	 2002)).	 Other	 processes	 such	 as	 chaperone-mediated	degradation	 of	 misfolded	 proteins	 and	 autophagy	 of	 long-lived	 proteins	 and	
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organelles	can	be	coupled	 to	ubiquitination,	but	also	exist	as	ubiquitin-independent	pathways.	Ubiquitin	is	a	small	(76	aminoacids)	protein	that	is	covalently	attached	to	specific	 lysine	residues	of	proteins	by	E3	ubiquitin-protein	 ligase	enzymes,	often	as	poly-ubiquitin	 chains.	 Polyubiquitinated	 proteins	 were	 initially	 thought	 to	 be	targeted	for	degradation	by	the	multi-subunit	26S	proteasome,	but	further	studies	in	the	 biochemistry	 of	 ubiquitin,	 which	 has	 now	 the	 dignity	 of	 a	 field	 per	 se,	 have	revealed	 the	 existence	 of	 a	 complex	 “ubiquitin	 code”	 that	 depends	 on	 the	 length,	complexity	 and	 geometry	 of	 polyubiquitin	 chains.	 Monoubiquitination	 of	 lysines	 is	indeed	 a	 signal	 that	 regulates	 the	 recruitment	 of	 interactors	 of	 the	 tagged	 protein	rather	 than	 its	 degradation;	 however,	 it	 accounts	 for	 a	minority	 of	 ubiquitinations	(possibly	 also	 because	 it	 is	 a	 rather	 small	 modification	 to	 measure	 by	 standard	biochemical	and	even	mass-spectrometry	methods).	In	many	cases	the	first	ubiquitin	is	further	tagged	with	other	ubiquitin	molecules	on	any	of	its	7	lysines	(K6,	K11,	K27,	K29,	K33,	K48	or	K63),	giving	rise	to	a	wide	variety	of	combinations	of	polyubiquitin	chains	 –	 termed	 after	 the	 residues	 they	 are	 linked	 to	 –	 with	 different	 functional	outcomes	 (reviewed	 in	 Yau	 and	 Rape,	 2016).	 Fast	 protein	 degradation	 is	 mostly	achieved	 through	 K48-	 and	 K11-polyubiquitin	 tags	 (Chau	 et	 al.,	 1989;	 Meyer	 and	Rape,	2014).			Ubiquitination	 is	 carried	 through	 a	 3-component	 system.	 E1	 ubiquitin	 activating	enzymes	consume	an	ATP	molecule	to	create	a	highly	reactive,	high-energy	thioesther	bond	between	ubiquitin	and	a	cysteine	residue.	Ubiquitin	is	then	transferred	to	an	E2	ubiquitin	conjugating	enzyme	on	another	cysteine	residue	with	a	similar	 thioesther	bond.	 E2-Ub	 then	 interacts	with	 E3	 ubiquitin-protein	 ligases	 that	 confer	 the	 actual	substrate	 specificity,	 bridging	 E2-Ub	 with	 target	 proteins	 and	 allowing	 the	 final	transfer	 of	 ubiquitin.	 This	 tiered	 system	 has	 an	 increasing	 complexity:	 9	 genes	enconding	E1	enzymes	exist	 in	humans,	whereas	the	repertoire	is	slightly	larger	for	
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E2	 enzymes	 (41	 genes	 in	 humans)	 and	 maximally	 expanded	 for	 E3	 ligases	 (2821	genes	 in	 humans),	 so	 as	 to	 cope	 with	 the	 diversity	 of	 substrates	 that	 must	 be	recognized	and	targeted.	Targeted	proteins	are	recognized	by	the	26S	proteasome,	a	large	 complex	 composed	 of	 a	 20S	 cylinder	 in	 which	 the	 proteolytic	 activity	 takes	place,	enclosed	by	two	19S	regulatory	subunits.	The	proteasome	dissociates	ubiquitin	from	 its	 targets,	 thus	 allowing	 it	 to	 be	 recycled	 by	 other	 E1	 enzymes,	 and	 cleaves	targeted	 proteins	 in	 small	 peptides	 that	 can	 be	 further	 dissociated	 in	 single	aminoacids	by	non-specific	peptidases.		Defects	in	protein	degradation	have	been	associated	with	several	diseases,	especially	those	arising	with	cytotoxic	protein	aggregation	such	as	Parkinson’s	disease.	In	fact,	mutations	 in	 PARK2	 (parkin),	 an	 multi-subunit	 E3	 ligase,	 cause	 familial	 juvenile	parkinsonism	 (Tanaka	et	 al.,	 2004).	Parkin	 fails	 to	ubiquitinate	 target	proteins	 that	accumulate	 in	 dopaminergic	 neurons,	 thus	 causing	 cytotoxicity	 and	neurodegeneration.		Very	few	cases	of	developmental	disorders	have	been	linked	to	mutations	of	genes	in	the	 UPS	 or	 other	 protein	 degradation	 pathways,	 the	 most	 notable	 of	 which	 is	Angelman	 syndrome	 (AS).	 AS	 is	 a	 neurodevelopmental	 disorder	 caused	 by	 the	deletion	or	mutation	of	the	maternal,	non-imprinted	copy	of		UBE3A,	an	E3	enzyme.	UBE3A	 is	 paternally	 imprinted	 and	 is	 not	 expressed	 in	 the	 brain,	 thus	making	 the	maternal	 copy	 the	 only	 one	 active.	AS	patients	 have	 a	 severe	 intellectual	 disability,	speech	 impairment,	 hypotonia,	 craniofacial	 dysmorphisms	 and	 a	 conspicuously	happy	 disposition	 (reviewed	 in	 Clayton-Smith	 and	 Laan,	 2003).	 Two	 genes	 of	 the	WBSCR,	 TRIM50,	 an	 E3	 enzyme,	 and	 VPS37D,	 a	 member	 of	 the	 ESCRT	 complex	involved	 in	 the	 removal	 of	 poly-ubiquitinated	 proteins,	 are	 involved	 in	 the	 UPS	pathway	 (table	 1),	 pointing	 to	 a	 possible	 role	 in	 these	 pathologies	 for	 the	dysregulation	of	the	degradation	of	specific	targets	during	development.	
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Somatic	cell	reprogramming	as	a	platform	for	disease	modeling		The	molecular	 and	 cellular	 basis	 of	 human	 genetic	 diseases	 have	 been	 historically	modeled	 using	 two	 approaches,	 which	 can	 be	 roughly	 subdivided	 in	 in	vivo	 and	 in	
vitro.	 On	one	hand,	 animal	models	were	 engineered	with	mutations	 in	 orthologs	 of	disease-causing	 genes.	 These	models	 allow	 to	 observe	 the	 effect	 of	 mutations	 in	 a	complex,	 developing	 system,	 in	which	disease	phenotypes	 can	be	 scored	 at	 various	scales,	 from	 systems	 genomics	 levels,	 to	 molecular	 and	 subcellular	 features,	 up	 to	behavioural	 patterns.	 The	 evolutionary	 conservation	 of	 sequences	 and	 pathways	allows	 to	greatly	enhance	our	ability	 to	 test	hypotheses	 in	different	 complex	model	systems,	although	mice	models	have	been	the	most	widely	used	so	far.	Moreover,	the	use	 of	 syngenic	 animals	 allows	 to	 isolate	 the	 specific	 contribution	 of	 a	 gene,	 or	 a	group	of	genes,	to	a	developmental	phenotype	without	the	confounding	effect	of	the	genetic	background.	Animal	models	have	been	and	 still	 are	 an	 invaluable	 source	of	information	on	disease	and	development.		However,	many	important	differences	must	be	taken	into	account	when	trying	to	port	findings	 in	 mice	 to	 humans.	 Besides	 obvious	 macro-differences	 in	 reproductive,	physical	 and	 cognitive	 abilities,	 which	 pose	 a	 great	 challenge	 for	 the	 modeling	 of	speech	 impairment,	 sociality	 and	 learning,	 other	 less	 evident	 differences	 mar	 the	attempts	at	painting	the	complete	picture	of	human	disease	by	exclusively	using	mice	models.	 From	 a	 genetic	 point	 of	 view,	 up	 to	 20%	of	 essential	 human	 genes	 can	 be	disrupted	 in	mice	without	 causing	 lethality	 (Liao	 and	Zhang,	 2008).	Neuroanatomy	and	 neurophysiology	 of	 mice	 differ	 from	 those	 of	 humans,	 as	 the	 human	 brain	 is	gyrencephalic	 (i.e.	presents	 convolutions	of	 the	cortex)	whereas	 the	mouse	brain	 is	lissencephalic	 (no	 convolutions),	 possibly	 as	 a	 secondarily	 acquired	 trait	 during	
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evolution	 rather	 than	 the	maintenance	of	 an	 ancestral	 one	 (Kelava	 et	 al.,	 2013).	As	stated	above,	 the	syngeny	of	 inbred	 litters	can	be	a	great	advantage	when	trying	 to	isolate	the	contribution	of	genes	to	developmental	features,	but	does	not	recapitulate	the	 genetic	 reality	 of	 the	 vastly	 outbred	 human	 population,	 which	 is	 for	 instance	reflected	 in	 the	 variable	 penetrance	 and	 expressivity	 of	 phenotypes	 associated	 to	7q11.23	 CNVs.	 The	 other	 approach,	 instead,	 consists	 in	 using	 easily	 accessible	patient-derived	 cells,	 such	 as	 fibroblasts	 or	 Epstein-Barr	 Virus	 (EBV)-immortalized	lymphoblasts.	 By	 performing	 comparative	 genomic	 analyses	 on	 cells	 derived	 from	patients	and	from	healthy	controls,	one	can	 infer	disease-specific	genetic	signatures	that	arise	from	their	genotype,	in	a	human	genomic	context.	The	main	disadvantage	of	this	 approach	 is	 that,	 due	 to	 their	 tissue	 of	 origin,	 tissues	 used	 in	 these	 studies	(Antonell	 et	 al.,	 2010b;	 Henrichsen	 et	 al.,	 2011)	 are	 hardly	 affected	 in	 their	phenotypic	 manifestations	 by	 developmental	 disorders,	 thus	 effectively	 decreasing	their	 informative	 power	 regarding	 disease-specific	 alterations	 of	 developmental	trajectories.	 The	 ground-breaking	 technology	 of	 somatic	 cell	 reprogramming	managed	to	finally	overcome	these	limitations	by	bridging	the	boundaries	of	human	genotypes	and	their	developmental	phenotypes.		The	seminal	work	of	Sir	 John	Gurdon	with	Xenopus	laevis	 (Gurdon,	1962;	Gurdon	et	al.,	1975)	demonstrated	that	the	fate	acquired	by	terminally	differentiated	cells	was	reversible.	By	fusing	enucleated	oocytes	of	a	tadpole	with	the	nucleus	of	gut	cells	of	another	–	a	procedure	termed	somatic	cell	nuclear	transfer	(SCNT)	-	he	showed	that	the	somatic	nucleus	could	be	“reprogrammed”	to	the	totipotent	state,	insofar	as	being	able	 to	 give	 rise	 to	 a	 new	 individual	with	 exactly	 the	 same	 genome	 of	 the	 nucleus	donor	 tadpole.	 It	 was	 the	 first	 proof	 that	 cells	 with	 a	 high	 degree	 of	 potency	harboured	some	elements	in	the	cytoplasm	–	RNA	or	proteins	–	which	could	act	in	a	dominant	fashion	over	the	epigenome	of	the	donor	nucleus	(fig.	9).		This	plasticity	of	
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cell	 fate	 was	 showed	 to	 be	 conserved	 in	 mammals,	 albeit	 SCNT	 was	 not	 as	 easily	attainable:	initial	reprogramming	was	obtained	only	by	cell	fusion	of	pluripotent	cells	with	somatic	ones	(Kahan	and	Ephrussi,	1970),	but	it	was	eventually	accomplished	in	the	 famous	 case	 of	 the	 SCNT	 cloning	 of	Dolly	 the	 sheep	 (Wilmut	 et	 al.,	 1997),	 thus	definitively	opening	the	door	to	the	new	paradigm	of	therapeutic	(and	reproductive)	cloning.	The	understanding	of	what	brings	 cells	back	 to	pluripotency	 came	 through	the	 understanding	 of	what	 keeps	 them	 in	 the	 pluripotent	 state,	 and	 how	 to	 isolate	them.	 This	 quest	 had	 started	 shortly	 after	 Gurdon’s	 work,	 with	 the	 isolation	 of	pluripotent	cells	 from	teratocarcinomas,	benign	 tumors	 that	can	differentiate	 in	 the	three	 germ	 layers	 (Kleinsmith	 and	 Pierce,	 1964).	 It	 was	 however	 only	 with	 the	pioneering	work	of	Martin	Evans	and	Matthew	Kaufman	that	mouse	embryonic	stem	cells	 (ESCs)	 were	 isolated	 from	 the	 inner	 cell	 mass	 of	 blastula-stage	 embryos	 and	stabilized	in	culture	(Evans	and	Kaufman,	1981),	a	feature	that	was	reproduced	in	the	human	setting	by	James	Thomson	using	the	inner	cell	mass	of	blastulae	coming	from	discarded	 in-vitro	 fertilization	 attempts	 (Thomson	 et	 al.,	 1998).	 Cell	 fusion	experiments	 performed	 using	mouse	 ESCs	 and	 differentiated	 cells	 showed,	 as	 John	Gurdon	 did,	 that	 pluripotency	 is	 a	 dominant	 state	 over	 differentiation	 (Tada	 et	 al.,	2001);	these	findings	were	also	confirmed	in	humans	(Cowan,	2005)	(fig.	9).	Another	important	 field	 of	 stem	 cell	 biology	 had	 been	 then	 reactivated	 in	 the	 90s,	 with	landmark	 contributions	 from	 Austin	 Smith,	 Hans	 Schöler	 and	 colleagues,	 who	identified	and	characterized	the	proteins	that	were	responsible	for	the	maintenance	of	pluripotency	in	both	mice	and	humans:	Oct4	(Nichols	et	al.,	1998),		Sox2	(Avilion	et	al.,	2003),	Nanog	(Chambers	et	al.,	2003),	Klf4	(Li	et	al.,	2005),	c-Myc	(Cartwright	et	al.,	2005)	to	name	a	few.	It	is	important	to	note	that	the	vast	majority	of	these	genes	code	 for	 transcription	 factors	 that	 instruct	 a	 tightly	 regulated	 pluripotency	expression	program.	
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The	 revolutionary	 intuition	 of	 Shinya	 Yamanaka,	 scantily	 described	 in	 the	introduction	to	his	landmark	2006	paper	(Takahashi	and	Yamanaka,	2006),	was	that	the	ectopic	over-expression	of	these	pluripotency-maintenance	proteins	could	revert	the	 differentiated	 state	 of	 somatic	 cells	 and	 re-establish	pluripotency.	 In	 this	work,	Takahashi	and	Yamanaka	defined	the	minimal	set	of	factors	required	to	achieve	this	resetting:	 four	 transcription	 factors	 (Oct4,	 Sox2,	 Klf4	 and	 c-Myc)	which	were	 aptly	termed	 “Yamanaka	 factors”.	 Cells	 in	 which	 these	 factors	 were	 able	 to	 reinstate	pluripotency	 were	 named	 induced	 pluripotent	 stem	 cells	 (iPSCs).	 Not	 only	 iPSCs	display	morphology,	replicative	ability	and	expression	profiles	very	similar	 to	 those	of	ESCs,	but	they	have	the	same	degree	of	developmental	potential,	as	they	can	give	rise	 to	 all	 three	germ	 layers	 and,	when	 implanted	 in	 a	blastula,	 can	 contribute	 to	 a	chimera	 up	 to	 a	 certain	 extent	 (Takahashi	 and	 Yamanaka,	 2006).	 A	 year	 after,	Yamanaka	 demonstrated	 that	 reprogramming	 could	 be	 achieved	 in	 human	 cells	 as	well	 (Takahashi	 et	 al.,	 2007),	 thus	 revolutionizing	 the	 field	 of	 human	 disease	modeling.	In	fact,	since	reprogramming	protocols	and	pluripotency	culture	conditions	have	been	perfected,	it	is	now	possible	to	harvest	skin,	blood	or	dental	pulp	biopsies	from	 patients	 and	 derive	 several	 iPSC	 lines	 from	 them.	 These	 iPSCs	 have	 all	 the	genetic	information	of	their	donors,	with	the	added	advantage	of	having	the	intrinsic	potential	to	recapitulate	the	development	of	virtually	all	tissues	in	the	body.	In	other	words,	 they	 grant	 a	 privileged	 access	 to	 two	 axes:	 space	 -	 tissues	 that	 would	 be	otherwise	 almost	 physically	 impossible	 to	 reach,	 such	 as	 neurons	 of	 the	 cortex	 or	smooth	 muscle	 cells	 of	 the	 heart,	 and	 time	 –	 the	 witnessing	 in	 vitro	 of	 their	developmental	 stages,	making	 effectively	 visible	what	would	be	 otherwise	 invisible	(Nowotny	and	Testa).		After	the	pluripotent	state	was	isolated,	a	part	of	the	stem	cell	community	set	out	to	identify	 and	 standardize	 efficient	 and	 reproducible	 ways	 to	 derive	 differentiated	
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tissues.	Among	 them,	 the	derivation	of	neurons	has	been	assiduously	pursued,	 as	a	way	to	obtain	cells	that	would	serve	as	disease	models,	drug-screening	platforms	and	cell	 replacement	 therapy	 for	neurodegenerative	 and	neurodevelopmental	 disorders	(fig.	9).		
	Figure	 9:	 Pathways	 to	 pluripotency	 and	 their	 potential	 as	 a	 biomedical	 platform.	Black	solid	lines	indicate	changes	in	potency,	while	dotted	lines	indicate	experimental	procedures.		
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Systems	 based	 on	 small-molecule	 inhibition	 of	 signaling	 pathways	 have	 been	proposed	to	obtain	monolayer	cultures	of	neural	progenitors	(Chambers	et	al.,	2012),	cortical	 glutamatergic	 neurons	 (Shi	 et	 al.,	 2012a,	 2012b),	 dopaminergic	 neurons	(Kriks	et	al.,	2011)	and	 interneurons	(Nicholas	et	al.,	2013).	Neurons	obtained	with	these	 protocols	 can	 be	 probed	 with	 all	 the	 set	 of	 techniques	 that	 are	 normally	employed	 in	 cellular	 neuroscience,	 such	 as	 morphological	 analysis	 by	 imaging,	analysis	 of	 connectivity	 via	 multi-electrode	 arrays,	 study	 of	 electric	 currents	 and	calcium	influx,	and	many	more.	Moreover,	they	can	be	transplanted	in	mice	brains	to	assess	 their	 ability	 to	 integrate	 and	 form	 physiologically	 relevant	 interactions	 in	 a	more	controlled	model.	These	 protocols	 have	 offered	 great	 insights	 into	 the	 pathological	 phenotypes	 of	diseases	such	as	schizophrenia	(Brennand	et	al.,	2011),	Rett	syndrome(Marchetto	et	al.,	2010),	Timothy	syndrome	(Pasca	et	al.,	2011),	Alzheimer’s	disease	(Kondo	et	al.,	2013)	to	name	a	few.	However,	these	systems	display	a	high	variability	across	lines,	require	 long-term	culturing	and	several	manipulations	and	are,	 sometimes,	difficult	to	reproduce.	An	alternative	is	represented	by	the	ectopic	overexpression	of	master	regulators	of	lineage	commitment,	such	as	neurogenin-2	(Ngn2)	(Zhang	et	al.,	2013).	By	 infecting	 iPSCs	 with	 a	 lentiviral	 vector	 which	 carries	 an	 inducible	 Ngn2	 cDNA	coupled	 with	 an	 antibiotic	 resistance,	 cells	 can	 be	 readily	 converted	 to	 a	 cortical	neuronal	fate	in	as	little	as	21	days,	and	only	require	very	simple	manipulation	steps.	Moreover,	the	antibiotic	resistance	allows	to	select	for	the	activation	of	the	transgene,	thus	 increasing	 the	 homogeneity	 of	 the	 conditions.	 Ngn2	 neurons	 express	 cortical	markers,	have	a	reproducible	gene	expression	signature,	form	synapses	and	are	able	to	 integrate	 in	the	mouse	brain,	 thus	becoming	a	valuable	tool	 for	disease	modeling	and	 drug	 screening	 in	 the	 context	 of	 neurodevelopmental	 and	 neurodegenerative	diseases.	
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As	 mentioned	 earlier,	 iPSCs	 give	 us	 an	 unprecedented	 temporal	 resolution	 in	 the	study	 of	 developmental	 disorders.	 This	 means	 that	 the	 iPSC	 stage	 in	 itself	 can	 be	already	 very	 informative,	 as	 it	 captures	 a	 transient	 but	 crucial	 early	 stage	 of	development	(Adamo	et	al.,	2014;	Quadrato	et	al.,	2016).			 	
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Aim	of	the	thesis		 	During	the	first	part	of	my	PhD	I	have	contributed	to	the	establishment	of	iPSC	lines	derived	 from	WBS,	 7dup	patients	 and	healthy	 controls,	 and	 to	 their	 transcriptional	characterization.	We	 have	 demonstrated	 that	WBS	 and	 7dup	 patient-derived	 iPSCs	are	already	dysregulated,	at	 the	 level	of	 the	transcriptome,	 in	pathways	that	greatly	overlap	 with	 those	 involved	 in	 the	 onset	 of	 the	 pathology	 (Adamo	 et	 al.,	 2014).	Moreover,	 we	 showed	 that	 the	 dysregulation	 of	 these	 pathways	 is	 selectively	amplified	in	differentiated	lineages,	further	underscoring	the	anticipatory	potential	of	iPSCs	in	capturing	early	effects	at	a	systems	level.		The	 core	 of	 the	 thesis	 builds	 upon	 these	 findings	 and	 on	 the	 realization	 that	many	WBSCR	 genes	 impinge	 on	 pathways	 that	 regulate	 gene	 expression	 at	 the	 level	 of	transcription,	translation	and	protein	degradation.		The	aim	of	my	work	is	therefore	to	answer	three	fundamental	questions:			- how	 is	 transcriptional	 dysregulation	 propagated	 to	 translation	 and	 protein	abundance?	- what	new	information	do	we	gain	by	integrating	all	layers	of	gene	expression	at	the	pluripotent	state?		- what	is	the	role	of	the	translation	initiation	factor	EIF4H	in	this	regulation?		New	technologies	such	as	ribosome	profiling	and	data-independent	proteomics	have	emerged	in	the	last	few	years	and	allow	us	to	probe	more	in	depth	the	extent	to	which	transcriptional	differences	are	propagated	 from	the	 transcriptome	 to	 the	proteome,	yet	systems-wide	perspectives	that	integrate	different	layers	of	expression	in	human	samples	are	still	scarce	.	
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With	 this	work	we	want	 to	 fill	 the	 gap	 in	 the	 understanding	 of	 how	7q11.23	CNVs	disrupt	 gene	 expression	 during	 pluripotency,	 and	 lay	 the	 practical	 and	 theoretical	basis	to	explore	this	issue	in	more	differentiated	cell	types.							 	
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Contributions	This	project	is	a	highly	collaborative	endeavour	in	which	many	different	skillsets	have	been	 involved,	 and	 it	 is	 important	 to	 underline	 individual	 contributions	 at	 the	experimental	 and	 analytical	 level,	 with	 each	 figure	 in	 which	 each	 individual	 has	participated.		Contributions	 for	 the	 first	 part	 of	 the	 project	 (reprogramming,	 transcriptomic	analysis,	nanostring)	are	already	stated	in	Adamo	et	al.	2014.	For	 the	 second	 part	 of	 the	 thesis,	 the	 experiments	 were	 carried	 out	 by	 Marija	Mihailovic	and	me,	and	in	particular:	- The	establishment	of	feeder-free	lines	(fig.	2)	was	performed	by	Sina	Atashpaz,	Antonio	Adamo,	Matteo	Zanella	and	me.	- The	 luciferase	 plasmids	 (referred	 to	 in	 figs.	 6	 and	 7)	 were	 cloned	 by	 both	Marija	Mihailovic	and	me.	- The	 sineUP	 plasmids	 were	 cloned	 by	 me.	 The	 knock-down	 plasmids	 were	cloned	by	Marija	Mihailovic	who	also	validated	them	by	western	blot	(fig.	14)		- The	 viral	 particles	 for	 luciferase,	 sineUP	 and	 knock-down	were	 prepared	 by	me	(figs.	6,	7,	14)	- The	 cell	 culture	 for	 the	 lable-free	 proteomics	 and	 the	 ribosome	 profiling	experiments	 was	 carried	 out	 by	 both	 Marija	 Mihailovic	 and	 me	 (figs.	 4,	 8	through	13,	15	through	30)		- I	carried	out	the	cell	culture	for	both	pSILAC	experiments	(figs.	31	through	40).	- The	Ribosome	profiling	protocol	was	set	up	by	both	Marija	Mihailovic	and	me,	and	 most	 of	 the	 samples	 were	 prepared	 by	 Marija	 (figs.	 8,	 through	 12,	 15	through	30)	- For	 the	 label-free	 proteomics	 dataset,	mass-spec	 processing,	 acquisition	 and	primary	data	analysis,	were	performed	by	Yansheng	Liu	 in	 the	 lab	of	Rudolf	Aebersold	at	the	ETH	Zurich	(figs.	4,	13,	19,	24,	25,	26,	28	through	40)	
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- Secondary	 data	 analysis	 of	 label-free	 and	 pulse-SILAC	 proteomics	 data	 was	performed	in	our	lab	by	Pierre-Luc	Germain	and	myself	(figs.	4,	13,	33	through	40)	- I	performed	all	the	secondary	data	analysis	(figs.	8	through	13,	15	through	31,	33	 through	 40)	 with	 suggestions	 from	 Pierre-Luc	 Germain	 and	 Alessandro	Vitriolo.		- I	 established	 the	monoclonal	NGN2	 line	 establishment	 together	with	Matteo	Zanella	(figs.	41,	42)	- Immunofluorescence	 stainings	 were	 performed	 by	 Maddalena	 Lazzarin	 and	Francesca	Cavallo	(fig.	42	C,	D,	E,	F)	and	myself	(42	A,	B).	- All	schemes	and	cartoons	in	the	introduction	(with	the	exception	of	figure	2),	figure	 1	 in	 the	 materials	 and	 methods,	 and	 figures	 6,	 31,	 41	 in	 the	 results	section)	were	designed	and	drawn	by	me.	- This	study	was	conceived	and	supervised	by	Giuseppe	Testa.	 	
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Materials	and	methods	 		
Cell	culture	iPSCs	 were	 initially	 cultured	 on	 a	 feeder	 layer	 of	 mouse	 embryonic	 fibroblasts	inactivated	with	mitomycin	C,	as	described	in	Takahashi	et	al.,	2007	in	an	incubator	set	 at	 37°C,	 3%	 O2,	 5%	 CO2.	 For	 this	 condition,	 the	 medium	 is	 composed	 by	DMEM/F12	 (Gibco)	 in	a	1:1	 ratio,	20%	Knockout	Serum	Replacemente	 (Gibco),	1%	non-essential	 aminoacids,	 1%	 Pennicyllin	 –	 Streptomycin	 (Pen-Strep),	 1%	 L-Glutamine,	0.1%	2-mercaptoethanol,	10	ng/ml	basic	 fibroblast	growth	factor	(bFGF,	Gibco).	 Colonies	 were	 manually	 passed	 on	 other	 feeder	 layers	 by	 physical	fractionation	 with	 a	 22G	 sterile	 needle.	 Upon	 stabilization,	 iPSCs	 were	 adapted	 to	grow	 without	 the	 feeder	 layer	 in	 the	 commercial	 medium	 mTeSR-1	 (StemCell	Technologies)	supplemented	with	1%	Pen-Strep	and	on	hESC-qualified	Matrigel	(BD	Biosciences)	diluted	1:40	in	DMEM/F12	and	supplemented	with	1%	L-Glutamine	and	1%	 Pen-Strep.	 Mechanical	 separation	 of	 differentiating	 patches	 of	 colonies	 was	achieved	 using	 a	 sterile	 p200	 pipette	 tip	 under	 a	 brightfield	microscope.	 Cell	 lines	growing	 in	 feeder-free	 conditions	 were	 further	 passaged	 by	 dissociation	 to	 single	cells	using	 accutase	 for	3	minutes	 at	37°C,	 and	diluting	 cells	7	 to	8	 times	 for	 every	passage.	Single	cells	were	resuspended	in	mTeSR-1	supplemented	with	5	uM	Y-27632	(Sigma)	to	avoid	anoikis	(Watanabe	2007).		
RNAseq	and	Nanostring	measurements	Cells	 were	 lysed	 in	 the	 plate	 using	 the	 RNeasy	 RLT+	 buffer	 supplemented	 with	 2-mercaptoethanol	(Qiagen),	centrifuged	at	4°C	and	processed	according	to	manufacturer	instructions.	 Library	 preparation	 for	RNA	 sequencing	was	 performed	using	 Poly-A	 and	RiboZero	 kits	 (Illumina)	 according	 to	 manufacturer	 instructions)	 and	 libraries	 were	sequenced	on	a	HiSeq	2000	sequencer	(Illumina)	using	100	bp,	paired-end	reads.	Nanostring	samples	were	prepared	and	analyzed	according	to	manufacturer	instructions.		
	 63	
Cloning	In	 order	 to	 insert	 the	 CrPV	 IRES	 in	 the	 5’	 UTR	 of	 the	 Firefly	 luciferase,	 an	 additional	restriction	 site	 was	 added	 upstream	 of	 the	 Firefly	 cDNA	 in	 the	 commercial	 plasmid	pMirGLO	 (Promega).	 A	 PCR	 was	 performed	 using	 pMirGLO	 as	 a	 template	 adding	 the	restriction	site	PacI,	on	the	5’	end	of	the	amplicon	using	oligo	pair	n.	1	in	table	1.	The	PCR	product	was	digested	with	EcoRI	and	ScaI	and	was	cloned	in	the	pMirGLO	plasmid,	now	termed	 pMirGLO-host.	 The	 CrPV	 IRES	 was	 obtained	 as	 a	 dsDNA	 fragment	 by	 custom	synthesis	 (GeneArt	 –	 Thermo	 Fisher)	 using	 a	 deposited	 sequence	 (id	 number	 40	 on	IRESite)	and	 it	was	amplified	by	PCR	(oligo	pair	n.	2	 in	 table	1).	The	PCR	was	digested	using	PacI	and	ApaI	and	it	was	cloned	in	the	pMirGLO-host	plasmid.	The	 luciferase	 construct	 was	 obtained	 by	 performing	 a	 PCR	 on	 the	 cDNA	 of	 Firefly	luciferase	in	the	pMirGLO-host,	adding	the	restriction	sites	for	BamHI	(5’)	and	NheI	(3’),	using	oligo	pair	n.	3	in	the	table.	The	PCR	fragment	was	then	digested	and	subcloned	in	the	 pCDH-UbC-MCS-Ef1a-Hygromycin	 lentiviral	 backbone	 using	 BamHI	 and	 NheI,	resulting	 in	 pUbC-Luc	 and	 pUbC-CrPV-Luc.	 Short	 hairpins	 for	 EIF4H	 RNA	 interference	were	cloned	in	the	TRC	pLKO.1	lentiviral	backbone	using	AgeI	and	EcoRI	sites	and	ssDNA	oligo	pairs	4,	5	and	6	from	table	1	annealed	in	vitro.	
No.	 Clone	name	 Forward	oligonucleotide	 Reverse	oligonucleotide	
1	
pMirGLO-
host	
AGAGAATTCTTAATTAAACCATGGAAGATGCCAAAAA	 AGCGAGCTCGTTTAAACAACTAGA	
2	
pMirGLO-
CrPV	
AGATTAATTAACAACAACAAAAAGC	 TCTGGGCCCTTCTTAAT	
3	
pUbC-
Luc/pUbC-
CrPV-Luc	
ATATAGCTAGCAGCCCAAGCTTGGCAAT	
TATATGGATCCAACTAGAATTACACGGCGAT
CTT	
4	
EIF4H	sh1	
	
CCGGGACTCCAGCTTAAACCTCGAACTCGAGTTCGAGG
TTTAAGCTGGAGTCTTTTTG	
AATTCAAAAAGACTCCAGCTTAAACCTCGAA
CTCGAGTTCGAGGTTTAAGCTGGAGTC	
5	
EIF4H	sh2	
	
CCGGGATCTCAGCATAAGGAGTGTACTCGAGTACACTC
CTTATGCTGAGATCTTTTTG	
AATTCAAAAAGATCTCAGCATAAGGAGTGT
ACTCGAGTACACTCCTTATGCTGAGATC	
6	 EIF4H	shSCR	
CCGGAACTTGCTATGAGAACAAATTCTCGAGAATTTGTT
CTCATAGCAAGTTTTTTTG	
AATTCAAAAAAACTTGCTATGAGAACAAATT
CTCGAGAATTTGTTCTCATAGCAAGTT	
7	 pLKO-host	 CCGGTCAACAACAACTGCAGCAACAACAAG	 AATTCTTGTTGTTGCTGCAGTTGTTGTTGA	
8	
EIF4H	binding	
domain	
TCGAGGGCCCGATCGTCGTAGGTGTCGAAGTCCGCCAT
TTGCCGTCTCCGCTCCGAGAGGAACCAGGGTGAGCGAG
GA	
GGCCCGATCGTCGTAGGTGTCGAAGTCCGC
CATTTGCCGTCTCCGCTCCGAGAGGAACCA
GGGTGAGCGAGGA	
9	 EIF4H	sineUP	 TATAACCGGTGGCCCGATCGTC	
TATACTGCAGAAGAGACTGGAGCTAAAGAG	
	Table	1:	Oligonucleotides	used	for	cloning.		
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To	clone	 the	 sineUP	constructs	 in	 the	 same	pLKO.1	TRC	backbone,	 it	had	 to	be	 slightly	modified	by	adding	an	additional	PstI	restriction	site	between	the	AgeI	and	EcoRI	sites.	This	was	achieved	by	cloning	two	annealed	ssDNA	oligos	(n.	7	in	table	1)	between	AgeI	and	EcoRI,	bearing	the	additional	PstI	site.	The	resulting	clone	was	termed	pLKO-host.		The	EIF4H	sineUP	construct	was	obtained	by	first	subcloning	the	EIF4H	binding	domain,	obtained	by	two	annealed	ssDNA	oligonucleotides	(n.	8	 in	 table	1),	 in	 the	pCDNA	3.1(-)	miniSINEUP	plasmid	(a	gift	of	S.	Gustinchich)	using	EcoRV	and	XhoI	restriction	sites.	The	full	 lenght	 of	 the	 sineUP	 (binding	 domain	 +	 inverted	B2	 domain)	was	 then	 isolated	 by	PCR	using	oligonucleotides	(n.	8	in	table	1)	that	changed	the	restriction	sites	from	XhoI	to	AgeI	and	EcoRV	to	PstI.	PCR	fragments	were	digested	and	subcloned	in	the	pLKO-host.	All	PCR	 reactions	 were	 carried	 out	 using	 Phusion	 DNA	 polymerase	 with	 HF	 buffer	 (New	England	Biosciences).	All	clones	were	checked	by	Sanger	sequencing.	
HeLa	transfection	of	luciferase	constructs	5x105	60%	confluent	HeLa	cells	were	transfected	with	2	ug	of	the	pMirGLO,	pUbC-CrPV-Luc,	pUbC-Luc	and	pUbC-host-Luc	plasmids	using	Lipofectamine	2000	 (Thermo	Fisher)	and	assayed	24	hours	after	using	a	Glomax	96	plate	reader	(Promega)	and	the	Dual-Glo	Luciferase	Assay	kit	(Promega).		
Lentivirus	preparation	All	 plasmids	 were	 extracted	 through	 the	 Nucleobond	 Xtra	 Maxi	 kit	 (Macherey-Nagel),	according	 to	 manufacturer’s	 instructions.	 Vectors	 were	 produced	 using	 a	 second	generation	system	(envelope	plasmid:	pMD2-VSV-G;	packaging	plasmid:	pCMV-Δ8.9).	All	 lentiviral	vectors	were	generated	 through	calcium	phosphate	 transfection	of	human	embryonic	kidney	293T	(HEK293T)	cells.	5x106	of	HEK293T	cells	were	plated	in	a	10-cm	dish	in	Iscove’s	Modified	Dulbecco’s	Medium	(IMDM)	(Sigma	Aldrich),	10%	FBS,	1%	Pen-Strep	 and	 1%	 L-Glutamine	 and	 incubated	 at	 37°C,	 21%	O2,	 5%CO2.	 The	 day	 after,	 1h	before	 transfection,	medium	was	replaced	with	10	ml	of	 fresh	 IMDM.	 In	 the	meanwhile	the	following	mix	was	prepared:	transfer	vector:	10	μg		
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pVSV-G:	3.5	μg	pCMV-Δ8.9:	6	μg	ddH2O	to	a	final	volume	of	500	µl.	Finally,	61	μl	of	2.5	M	CaCl2	were	added	to	 the	mix	and	the	 tube	was	put	on	a	rotating	wheel	for	at	least	20	minutes.	DNA	precipitate	was	obtained	by	drop	wise	addition,	on	vortex	at	full	speed,	of	50	µl	2X	HBS	solution	(281	mM	NaCl,	100mM	HEPES,	1.5	mM	Na2HPO4	pH	7.12,	0.22	µM	filtered)	to	 the	 500	 µl	 mix	 previously	 prepared.	 This	 preparation	 was	 immediately	 added	 to	HEK293T	cells	supernatant.	Cells	were	successively	incubated	at	37°C,	21%	O2,	5%	CO2	for	14	hours	and	afterwards	medium	 was	 replaced	 with	 10	 ml	 of	 fresh	 IMDM	 medium.	 30	 hours	 after	 medium	changing,	 the	 supernatant	was	 filtered	 through	a	0.22	µm	pore	nitrocellulose	 filter	and	ultracentrifuged	 at	 20000	 rpm	 in	 SW32Ti	 rotor	 (Optima	 L-60	 preparative	Ultracentrifuge;	Beckman)	for	2	hours	at	20	°C.	Pellets	were	resuspended	in	80	ul	of	PBS	and	stored	at	-80°C	in	10	ul	aliquots.	
Infection	Cells	were	split	using	accutase	and	resuspended	in	mTeSR-1	supplemented	with	5	uM	Y-27632.	 Approximately	 4x105	cells	 were	 infected	 using	 2	 ul	 of	 concentrated	 lentiviral	particles	 while	 cells	 were	 still	 in	 suspension.	 Cells	 were	 infected	 overnight	 and	 fresh	media	 was	 supplemented	 after	 ~12	 h.	 Cells	 infected	 with	 pLKO-derived	 vectors	 were	selected	with	puromycin	(10	ug/ml)	for	2	days,	whereas	cells	infected	with	the	luciferase	reporter	were	selected	with	hygromycin	(100	ug/ml)		for	up	to	7	days.		
Western	Blot	Around	1x106	cells	were	harvested	by	detaching	with	accutase,	resuspending	in	ice-cold	PBS	 and	 centrifuged	 for	 5	 minutes	 at	 5000	 rpm	 at	 4°C	 on	 a	 refrigerated	 benchtop	centrifuge.		Proteins	were	extracted	using	RIPA	buffer	(10	mM	Tris-HCl	pH	8,	1%	Triton	X-100,	0.1%	SDS,	0.1%	Sodium	Deoxycholate,	140	mM	NaCl,	1	mM	EDTA).	4	volumes	of	RIPA	buffer	
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were	added	to	cell	pellets	and	tubes	were	put	at	4	°C	on	a	rotating	wheel	for	30	minutes.	Extracts	were	 centrifuged	 for	30	minutes	at	13000	rpm	at	4	 °C	and	supernatants	were	transferred	in	new	tubes	and	store	at	-80	°C.	Before	usage	the	protease	inhibitor	cocktail	(PIC	)	and	PMSF	(1mM)	were	added.	Proteins	 were	 quantified	 at	 the	 spectrophotometer	 (λ	 595nm),	 using	 the	 Bradford	protein	assay	as	follows:	200μl	of	protein	Assay	Dye	reagent	Concentrate	(BioRad),	800μl	of	ddH2O,	1	μl	of	protein	extract,	using	BSA	(NEB)	to	derive	a	standard	curve.	For	 blotting,	 40	 μg	 of	 protein	 extract	 were	 loaded	 on	 a	 4-12%	 bisacrilamide-trisacrilamide	 using	 the	 Novex	 Sharp	 Pre-stained	 Protein	 Standard	 (ThermoFisher	Scientific)	 as	 molecular	 weight	 marker.	 The	 electrophoretic	 run	 was	 executed	 in	 the	NuPAGE	SDS	Running	buffer	(20X)	(Thermo	Fisher)	at	room	temperature,	initially	at	80	V	and,	when	the	bands	started	to	separate,	at	100	V.	Wet	transfer	was	performed	at	4	°C,	30V	on	a	nitrocellulose	0.2	μm	membrane	(Sigma	Aldrich)	in	700	ml	transfer	buffer	(200	ml	 methanol,	 100	 ml	 TB	 buffer	 10X	 (Tris	 base	 0.15M,	 glycine	 1.9M),	 400	 ml	 ddH2O).	Transfer	 efficiency	and	quality	was	 checked	by	Ponceau	 staining	and	membranes	were	washed	with	TBS-T	(Tris	25	mM,	NaCl	150	mM,	KCl	2	mM,	Tween-20	0.1%).	The	primary	rabbit	 anti-EIF4H	 (Abcam,	 ab112966)	 and	 mouse	 anti-GAPDH	 antibodies	 	 were	incubated	 in	 5%	milk	 in	 agitation	 overnight	 at	 4°C	 ,	 using	 1:1000	 (EIF4H)	 and	 1:200	(GAPDH)	ratios	respectively.	After	3	washes	in	TBS-T,	the	membrane	was	incubated	with	the	 secondary	 antibodies,	 diluted	 1:10000	 in	 5%	 milk,	 1h	 in	 agitation	 at	 room	temperature.	 Afterwards	 the	membrane	was	washed	 3	 times	with	 TBS-T	 and	 then	 the	ECL	 Prime	Western	 Blotting	 detection	 reagent	 was	 used	 (Sigma-Aldrich)	 for	 detection	with	a	BioRad	Chemidoc	imaging	system.	
Ribosome	profiling	Ribosome	 profiling	 allows	 the	 quantification	 of	 translation	 at	 a	 genome-wide	 scale	 by	sequencing	of	mRNA	fragments	occupied	by	ribosomes	(Ingolia	et	al.,	2009,	2011).	This	protocol	allows	the	isolation	of	and	preparation	of	a	sequencing	library	containing	small	ribosome-protected	 fragments	 (RPF)	 of	 RNA.	 The	 protocol	 consists	 in	 the	 stalling	 of	
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ribosomes	 using	 cycloheximide,	 a	 drug	 that	 inhibits	 ribosome	 translocation,	 and	 the	purification	 by	 size	 selection	 of	 monosomes	 (fig.	 1).	 RNA	 is	 then	 enzimatically	fragmented	using	RNase	 I,	 so	 that	 the	 ribosome	protects	 a	 fragment	of	~28-30	nt.	 The	resulting	 fragments	are	depleted	of	 ribosomal	RNA	using	magnetic	beads,	 and	 they	are	size-selected	 on	 a	 denaturing	 poly-acrilamide	 gel,	 after	 which	 their	 ends	 are	 repaired,	they	 are	 ligated	 to	 sequencing	 adaptors	 and	 they	 are	 converted	 to	 cDNA	 by	 reverse	transcription.	 The	 cDNA	 is	 further	 purified	 on	 a	 denaturing	 polyacrylamide	 gel	 and	 is	then	circularized.	Circularized	cDNA	is	amplified	by	PCR,	in	which	sequencing	indexes	are	inserted.	The	PCR	is	further	size-selected	on	a	native	polyacrylamide	gel	and	its	quality	is	assessed	using	high	sensitiviy	electrophoresis	systems	such	as	the	Bioanalyzer.		
	Figure	1:	Schematic	representation	of	the	ribosome	profiling	protocol	for	the	generation	of	 ribosome-protected	 fragments	 and	 total	 RNA	 libraries.	 CHX:	 cycloheximide.	 CDS:	coding	 sequence.	 RT:	 reverse	 transcription.	 PCR:	 polymerase	 chain	 reaction.	 UTR:	untranslated	region.		The	ribosome	profiling	protocol	allows	to	prepare	in	parallel	and	with	very	similar	steps	a	 total	RNA	 library,	which	 is	used	 to	measure	 the	 transcriptome.	The	only	difference	 is	the	 absence	 of	RNase	 I	 digestion	 and	 the	presence	 of	 a	 heat-fragmentation	 step	before	end	 repair.	 In	 this	 study,	 ~1.5-2x107	 cells	 were	 treated	 with	 10	 ug/ml	 cycloheximide	
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(Sigma-Aldrich)	while	detaching	with	accutase	at	37°C.	Cells	were	then	centrifuged	at	4°C	and	cell	pellets	were	frozen	in	dry	ice	at	-80°C.	Samples	were	then	processed	according	to	the	manual	instructions	for	the	TruSeq	Ribosome	Profiling	Kit	(Illumina).	RNA	depletion	was	 performed	 using	 the	 RiboZero	 Magnetic	 Gold	 kit	 (Illumina).	 All	 three	 PAGE	separations	were	performed	for	RPF	preparation.	The	first	separation	was	performed	to	separate	 ribosome-protected	 fragments	on	a	denaturing	15%	acrilamide/bisacrilamide,	TBE-Urea	8M	gel.	Gel	bands	were	cut	between	26	and	32	nucleotides	approximately	and	retained	for	further	processing.	For	both	RPF	and	total	RNA	libraries,	a	denaturing	10%	acrilamide/bisacrilamide	TBE-Urea	8M	gel	was	used	to	isolate	bands	between	80-100	nt	(total	 RNA)	 and	 70-80	 nt	 (RPF).	 PCR	 products	 were	 further	 purified	 in	 a	 native	 10%	acrilamide/bisacrilamide	TBE	gel,	where	bands	at	around	150	nucleotides	were	cut	 for	further	processing.	All	gels	used	were	precast	Novex	gels	(Thermo	Fisher).		Library	quality	was	assessed	with	a	Bioanalyzer	High	Sensitivity	DNA	chip	(Agilent)	and	libraries	 of	 both	 total	 RNA	 and	 RPF	 RNA	were	 sequenced	 using	 50	 bp,	 single	 end,	 30	million	reads	in	a	HiSeq	2000	sequencer	(Illumina).		
Ribosome	profiling	and	RNA-seq	data	analysis	
Read	preparation	As	ribosome	protected	fragments	(RPF)	are	smaller	than	50bp,	the	majority	of	RPF	reads	contain	 adapter	 sequences.	 To	 eliminate	 these	without	 creating	 biases	 between	mRNA	and	RPF,	we	 trimmed	adapter	sequences	 from	all	 reads	of	both	 types	of	 libraries	using	scythe	 0.981	 (and	 the	 set	 of	 adapter	 sequences	 specified	 by	 the	 protocol),	 discarding	trimmed	reads	with	15	nucleotides	or	less.	We	then	proceeded	with	two	different	kinds	of	analyses,	aligning	the	reads	either	on	the	genome	or	the	transcriptome	(below).	
Genome	alignment	We	used	HISAT2	2.0.1	to	perform	SNP-aware	spliced	alignment	of	the	reads	on	the	hg38	genome	using	the	RefSeq	transcript	annotation	for	known	splice	junctions.	We	used	this	data	for	sample	quality	control	on	the	basis	of	codon	periodicity.	Codon	periodicity	was	assessed	by	taking	the	1000	most	expressed	transcripts	and	counting	proportion	of	reads	
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falling	 on	 each	 base	 pair	 starting	 from	 the	 beginning	 of	 the	 coding	 sequence.	 Samples	with	very	low	number	of	aligned	reads	or	which	did	not	display	a	clear	codon	periodicity	were	considered	failed	and	discarded.	
Transcriptome	alignment	and	quantification	To	 quantify	 genes	 and	 transcripts,	 we	 used	 RSEM	 1.2.22	 (with	 empirical	 read	 start	position	distribution	estimate),	which	according	to	our	benchmark		(Germain	et	al.,	2016)	showed	a	very	good	accuracy,	especially	for	absolute	quantification,	which	is	critical	for	our	present	purposes.	Since	the	visual	inspection	of	the	reads	on	the	genomic	alignment	showed	 a	 non-negligible	 proportion	 of	 the	 RPF	 reads	 falling	 in	 allegedly	 untranslated	regions,	we	decided	to	perform	quantifications	on	two	types	of	indexes:	1)	on	the	whole	RefSeq	 transcripts,	 and	2)	 splitting	coding	sequence	 (CDS,	adding	15bp	on	each	side	 to	account	for	the	size	of	the	ribosome),	3'	UTR	and	5'UTR	of	each	transcript	(which	were	considered	all	together	for	the	purpose	of	calculating	normalization	factors).	
Differential	expression	analysis	For	 total	RNA	and	RPF	data,	we	 tested	 for	differential	 expression	 analysis	using	 edgeR	v.3.12.1	 (Robinson	 et	 al.,	 2010)	 on	 the	 TMM-normalized	 estimated	 fragment	 counts,	which	performed	best	in	our	benchmark.	We	included	in	the	analysis	features	that	had	at	least	10	reads	in	at	least	3	samples.	When	doing	pairwise	comparisons	of	the	genotypes,	we	 use	 edgeR's	 classical	 dispersion	 model	 (based	 on	 a	 negative	 binomial	 model)	 and	chose	differentially	expressed	genes	that	passed	a	false	discovery	rate	(FDR)	threshold	of	<	0.1.		
Slope	calculation	For	total	RNA	and	RPF,	slopes	were	calculated	as	log2(FC)	values	from	edgeR’s	classical	dispersion	 model	 using	 the	 log-transformed	 values	 of	 label-free	 protein	 intensity	 (see	below)	as	the	covariate.		
GO	enrichment	Gene	 ontology	 enrichments	were	 performed	 using	WebGestalt	 (Zhang	 et	 al.,	 2005),	 by	using	the	hypergeometric	test	and	choosing	the	top	10	significantly	enriched	categories.	
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Treemaps	 were	 drawn	 by	 taking	 only	 the	 enriched	 children	 categories	 that	 had	 non-overlapping	parents.			
Pulse-SILAC	
Pilot	experiment	Cells	 from	a	control	 line	(3391-S)	were	growing	 in	single-cell	condition	 in	mTeSR-1	and	then	adapted	for	2	passages	in	a	custom	medium,	composed	as	follows:	DMEM,	Knockout	Serum	Replacement	15%	(Sigma),	Pen-Strep	1%,	Non-essential	aminoacids	1%,	Glutamine	1%,	Probumin	0.5%	(Millipore),	2-mercaptoethnaol	0.1	mM,	L-Proline	500	mg/l	(Sigma),	FGF2	10	ng/ml	(Peprotech).	The	medium	was	conditioned	for	24	hours	 on	 a	 mouse	 embryonic	 fibroblast	 layer	 inactivated	 with	 mitomycin-C	 and	filtered	before	use.		In	 the	 SILAC	version	of	 the	medium	a	 custom	DMEM	(Lonza)	without	 arginine	 and	lysine	was	complemented	with	84	mg/l	 13C6	 15N4	Arg10	 (Sigma)	and	146	mg/l	 13C6	
15N2	Lys8	(Sigma).	 	Cells	were	scraped	and	washed	 in	cold	PBS	upon	reaching	70%	confluence	approximately	for	protein	harvest	at	1.5,	4.5	and	13.5	hours	after	medium	swap.	Each	plate	was	seeded	and	harvested	in	duplicate.	
pSILAC	experiment	Cells	 growing	 in	mTeSR-1	 (light	 condition)	were	 swapped	with	 a	 custom	mTeSR-1	medium	without	 arginine	 and	 lysine,	 complemented	with	 84	mg/l	 13C6	 15N4	 Arg10	(Sigma)	and	146	mg/l	13C6	15N2	Lys8	(Sigma).		Cells	were	scraped	and	washed	in	cold	PBS	upon	reaching	60%	confluence	approximately	for	protein	harvest	at	2,	4,	6,	and	8	hours	after	medium	swap.	Each	plate	was	seeded	and	harvested	in	triplicate.	
Proteomic	analysis	To	better	quantify	subtle	differences	in	protein	abundance	we	harnessed	ther	power	and	 resolution	 of	 a	 data-independent	 mass-spectrometry	 approach,	 Sequential	Acquisition	 of	 all	 Theoretical	 MS2-spectra	 (SWATH-MS).	 In	 SWATH-MS,	 precursor	ions	 are	 scanned	 at	 a	 high	 speed	 across	 small	 (25	Da)	windows	 of	mass	 to	 charge	
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(m/z)	 that	 cover	 a	 range	 of	 m/z	 values	 from	 40	 to	 1200.	 All	 the	 fragmented	 ions	coming	 from	 these	 small	 precursor	 windows	 are	 acquired,	 thus	 allowing	 a	 high	resolution	measurement	of	the	peptides	present	in	the	precursor	windows.	The	mass	spectrometer	 cycles	 continuously	 through	 these	 windows,	 thus	 allowing	 a	 time-resolved	 measurement	 of	 chromatographic	 peaks	 (Gillet	 et	 al.,	 2012).	 SWATH-MS	allows	to	reproducibly	identify	and	quantify	proteins	at	a	low	abundance	with	a	high	dynamic	range.	
Protein	extraction	and	in-solution	digestion	Around	107	 cells	were	harvested	by	dissociating	 them	with	 accutase,	washing	with	ice-cold	PBS	and	centrifuging	at	4°C	at	5000	rpm	for	5	minutes.	All	 the	cell	pellets	were	suspended	 in	10M	Urea	 lysis	buffer	and	complete	protease	inhibitor	 cocktail	 (Roche),	 ultrasonically	 lysed	 by	 sonication	 at	 4°C	 for	 2	 minutes	using	a	VialTweeter	device	(Hielscher-Ultrasound	Technology),	and	then	centrifuged	at	 18,000	 g	 for	 1	 hour	 to	 remove	 the	 insoluble	 material.	 The	 supernatant	 protein	mixtures	were	reduced	by	10mM	Tris-(2-carboxyethyl)-phosphine	(TCEP)	for	1	hour	at	 37°C	 and	 20	 mM	 iodoacetamide	 (IAA)	 in	 the	 dark	 for	 45	 minutes	 at	 room	temperature.	 All	 the	 samples	 were	 further	 diluted	 by	 1:6	 (v/v)	 with	 100	 mM	NH4HCO3	 and	 digested	 with	 sequencing-grade	 porcine	 trypsin	 (Promega)	 at	 a	protease/protein	ratio	of	1:25	overnight	at	37°C.	The	amount	of	the	purified	peptides	was	 determined	 using	Nanodrop	ND-1000	 (Thermo	 Scientific)	 and	 1.5	 μg	 peptides	were	injected	in	each	LC-MS	run.	
SWATH	and	shotgun	mass	spectrometry	Peptide	 samples	 after	 digested	 were	 measured	 by	 SWATH	 mass	 spectrometry	(SWATH-MS)	or	shotgun	analysis	as	previously	published	(Collins	et	al.,	2013;	Gillet	et	 al.,	 2012;	 Liu	 et	 al.,	 2013).	 Specifically	 a	 120-min	 liquid	 chromatographic	 (LC)	gradient	was	used	for	shotgun	analysis	and	SWATH-MS	measurement	on	the	pSILAC	samples,	 whereas	 a	 60-min	 LC	 gradient	 was	 used	 for	 steady	 proteome	 expression	
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SWATH	 analysis.	 In	 the	 present	 SWATH-MS	mode,	 the	 SCIEX	 5600	 plus	 TripleTOF	instrument	 was	 specifically	 tuned	 to	 optimize	 the	 quadrupole	 settings	 for	 the	selection	of	64	variable	wide	precursor	ion	selection	windows.	SWATH	MS2	spectra	were	 collected	 from	 50	 to	 2,000	m/z.	 The	 collision	 energy	 (CE)	was	 optimized	 for	each	 window	 according	 to	 the	 calculation	 for	 a	 charge	 2+	 ion	 centered	 upon	 the	window	with	a	spread	of	15	eV.	An	accumulation	time	(dwell	time)	of	50	ms	was	used	for	all	 fragment-ion	 scans	 in	high-sensitivity	mode	and	 for	each	SWATH-MS	cycle	a	survey	scan	in	high-resolution	mode	was	also	acquired	for	250	ms,	resulting	in	a	duty	cycle	of	~3.45	s.		
SWATH-MS	data	analysis:	steady	state	expression	data	The	SWATH-MS	 identification	was	performed	by	OpenSWATH	software	 (Röst	et	al.,	2014)	 searching	 against	 a	 previously	 established	 SWATH	 assay	 library	 which	contains	 mass	 spectrometric	 query	 parameters	 for	 10,000	 human	 proteins	 with	unique	Swiss-Prot	identities	(Rosenberger	et	al.,	2014).	OpenSWATH	firstly	identified	the	 peak	 groups	 from	 all	 individual	 SWATH	 maps	 at	 a	 target	 FDR=1%	 and	 then	aligned	between	SWATH	maps	with	extension	FDR=5%	using	a	novel	TRIC	(TRansfer	of	 Identification	Confidence)	 algorithm	 that	was	 specifically	 developed	 for	 targeted	proteomic	data	analysis	(Röst	et	al.,	2016).	Peptide	intensities	were	first	normalized	using	median	 normalization	 of	 log-transformed	 intensities,	 and	 technical	 replicates	were	aggregated	using	median	values.	For	each	protein	that	had	at	 least	5	peptides,	peptides	 poorly	 correlated	 to	 the	 others	 (<0.7	median	 correlation)	 were	 excluded.	Protein	 intensity	 was	 then	 calculated	 as	 the	 median	 of	 the	 top	 3	 most	 intense	peptides	after	 filtering.	To	 increase	 the	protein-level	 confidence,	only	 those	peptide	signals	 identified	 in	 at	 least	 ten	 out	 of	 49	 samples	were	 accepted	 (requantification	enabled).	
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SWATH-MS	data	analysis:	pSILAC	data	To	 analyze	 pSILAC	 SWATH	 data,	 we	 first	 generated	 a	 sample	 specific	 library	containing	 the	 light	 and	 heavy	 peptide	 assays.	 All	 the	 shotgun	 runs	 of	 the	 “Light”	samples	 (those	 from	 steady	 proteome	 as	 well	 as	 the	 first	 time	 point-	 samples	 in	pSILAC	 experiment)	were	 firstly	 searched	 against	 human	 Swissprot	 database	using	the	 iPortal	pipeline	 (Kunszt	et	 al.,	 2015).	Profile-mode	 .wiff	 files	 from	shotgun	data	acquisition	were	centroided	and	converted	to	mzML	format	using	the	AB	Sciex	Data	Converter	 v.1.3.	 iPortal	 utilized	 iProphet	 schema	 (Shteynberg	 et	 al.,	 2011)	 to	integrate	 the	 search	 results	 from	 X!Tandem,	 Omessa,	 Myrimatch,	 and	 Comet	 at	peptide	 level	FDR	=1%.	Especially,	peptide	 tolerances	at	MS	and	MS/MS	 level	were	set	to	be	50	ppm	and	0.1	Da	respectively.	Up	to	two	missing	trypsin	cleavages	were	allowed.	 Oxidation	 at	 methionine	 was	 set	 as	 variable	 modification	 whereas	carbamidomethylation	at	cysteine	was	set	as	fixed	modification.	The	light	version	of	the	raw	spectral	library	was	generated	from	all	valid	peptide	spectrum	matches	and	then	refined	into	the	non	redundant	consensus	libraries	using	SpectraST	(Lam	et	al.,	2007).	Using	the	spectrast2tsv.py	function	in	OpenSWATH	(Röst	et	al.,	2014)	we	then	generated	the	light	and	heavy	MS	assays	as	the	final	library	constructed	from	top	3-6	most	intense	fragments	with	Q3	range	from	400	to	1200	m/z	excluding	those	falling	in	 the	 precursor	 SWATH	 window	 were	 used	 for	 targeted	 data	 analysis	 of	 SWATH	maps.	The	 light	 library	 contained	55,857	peptide	 sequences	 (light	 and	heavy	 forms	with	 the	 consideration	 of	 modifcations)	 of	 3317	 unique	 proteins.	 OpenSWATH	analysis	 were	 run	 with	 the	 same	 options	 as	 above	 for	 protein	 expression	 data,	however,	 as	 in	 the	 shotgun	 proteomic	 analysis,	 requantificated	 data	 points	 were	discarded	for	protein	turnover	calculation	(Lam	et	al.,	2007).	
Differential	protein	expression	As	 the	 error	 in	 protein	 intensities	 is	 log-normally	 distributed,	 we	 tested	 for	differential	 protein	 expression	 using	 t-test	 (for	 categorical	 conditions)	 on	 log-
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transformed	 intensities.	For	 regression	on	measured	quantitative	variables,	 such	as	effective	expression	 levels,	we	 tested	 for	a	 standardized	major	axis,	SMA	(using	 the	smatr	 3	 R	 package)	 between	 the	 log-transformed	 expression	 and	 the	 independent	variable.	Contrarily	to	least-squares	regression,	which	minimizes	error	on	the	Y	axis	and	assumes	 that	 the	x	axis	 is	determined,	SMA	simultaneously	minimizes	error	on	both	 axes,	 thereby	 accounting	 for	 potential	 errors	 in	 the	 measurement	 of	 the	independent	variable.	
Determination	of	degradation	rates	Relative	 isotope	 abundance	 (RIA)	was	 calculated	 for	 each	 peptide	 and	 fitted	 to	 an	exponential	decay	model	using	nonlinearleast-squares	to	estimate	the	rate	of	loss	of	the	 light	 isotope	 (Kdeg).	 To	 establish	 protein-level	 Kdeg,	 we	 tried	 three	 different	methods:	1)	using	the	median	of	the	peptide-level	kloss	values,	2)	refitting	a	model	on	the	 RIA	 of	 all	 peptides,	 and	 3)	 doing	 a	 weighted	 mean	 of	 the	 peptide-level	 Kdeg	values,	using	as	weights	the	number	of	datapoints	divided	by	the	standard	deviation	of	the	coefficient	estimation.	(We	also	tried	a	combination	of	the	RIA-based	approach	with	 a	 linear	model	 on	 the	 ln(Heavy/Light+1)	 values).	 The	weighted	mean	method	was	selected	because	it	minimized	the	median	deviation	between	replicates.	
Generation	of	NGN2	monoclonal	lines	Lentiviral	 particles	 containing	 the	 NGN2-EGFP	 and	 UbC-rtTA	 transgenes	 were	prepared	 as	 described	 above	 using	 Tet-O-FUW-NGN2-EGFP-Puro	 and	 UbC-rtTA	plasmids	 (a	 gift	 of	 Thomas	 Suedhof).	 3x104	 cells	 were	 infected	 with	 0.5	 ul	 of	concentrated	 viral	 particles	 and	 cells	 were	 expanded	 until	 reaching	 an	 amount	 of	~6x106	 .	 During	 this	 period,	 exhausted	 medium	 was	 kept	 and	 filtered.	 Filtered	medium	 was	 mixed	 1:1	 with	 fresh	 medium	 to	 create	 a	 “conditioned”	 medium	 for	post-sorting	recovery.	Cells	were	then	incubated	with	DAPI	to	check	for	vitality,	and	only	DAPI-negative	 cells	were	 sorted	 as	 single	 cells	 using	 a	 FACSAria	 II	 sorter	 (BD	Biosciences)	 in	 96	 well	 plates	 coated	 with	 1:40	 hESC-qualified	 matrigel	 and	
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containing	 the	 conditioned	medium.	 Cells	were	 kept	 in	 culture	 in	 this	 format,	with	daily	 media	 change	 starting	 from	 day	 7	 with	 conditioned	 medium,	 until	 a	 single	colony	was	easily	visible;	based	on	the	colony	shape	and	morphology,	which	should	suggest	 a	 single-cell	 origin,	 3-5	 colonies	 per	 line	 were	 chosen	 and	 expanded.	 The	expansion	 was	 performed	 by	 stepwise	 increases	 of	 surface	 culture,	 from	 96	 well	plates	to	48,	then	to	24.	While	passaging	cells	from	48-well	plates	to	24-well	plates,	two	 wells	 were	 seeded	 per	 line.	 One	 of	 the	 wells	 was	 kept	 for	 induction	 with	doxycycline	 (2	 μg/ml)	 and	 scored	 for	 GFP	 positivity	 the	 day	 after.	 Positive	 clones	were	 further	 expanded	 in	 a	 stepwise	 fashion	 until	 reaching	 the	 6	 cm	 format,	 after	which	they	were	frozen.	Cells	were	then	differentiated	as	in	(Zhang	et	al.,	2013).			
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Results		
1.	Generation	and	 stabilization	of	 feeder-free	 iPSC	 lines	 from	a	 cohort	of	WBS,	
control	and	7dup	patients		iPSC	lines	were	generated	starting	from	patient-derived	skin	fibroblasts	using	a	non-integrating	reprogramming	method	based	on	daily	transfections	of	mRNA	coding	for	reprogramming	 factors	 (Adamo	 et	 al	 2015,	 Warren	 et	 al.	 2011).	 Successfully	reprogrammed	 cells	 were	 stabilized	 in	 the	 pluripotent	 state	 by	 co-culturing	 them	with	 a	 mouse	 embryonic	 fibroblast	 (MEF)	 feeder	 layer	 in	 a	 chemically	 defined	medium.	However,	in	order	to	perform	high-throughput	genomics	experiments	such	as	RNA-seq,	Ribo-seq,	proteomics	without	 the	confounding	effect	of	murine	RNA	or	proteins,	 iPSC	 lines	must	be	adapted	and	stabilized	 in	 feeder-free	conditions,	which	require	 a	 change	 of	 culture	 substrate	 and	 a	 different	 chemically	 defined	 culture	medium.		Previously	 reprogrammed	 lines	 from	 4	WBS	 patients,	 1	 atypical	 patient,	 3	 healthy	controls,	 of	 which	 1	 relative	 of	 a	 WBS	 patient,	 and	 3	 7dup	 patients	 (fig.	 1)	 were	adapted	to	grow	in	feeder-free	conditions	by	passaging	them	from	the	MEF	layer	to	1:40	matrigel-coated	plates,	thus	creating	pure	iPSC	lines	(fig.	2A)				
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	Figure	1:	Schematic	representation	of	the	cohort	of	iPSC	lines	used	in	this	study.	Each	clone	 is	 represented	 by	 a	 full	 circle,	 whereas	 each	 patient	 is	 identified	 by	 its	alphanumeric	code.				
	Figure	2:	establishment	and	stabilization	of	feeder-free	iPSC	lines.	A)	representative	images	of	feeder-free	iPSC	lines	from	a	WBS,	a	7dup	and	a	CTL	patient.	B)	feeder-free	line	show	patches	of	differentiating	cells	(circled	by	a	red	dashed	line).	C)	mechanical	ablation	of	differentiated	patches	from	the	colonies.		 	Some	 lines,	 regardless	of	 the	phenotype,	were	prone	 to	spontaneous	differentiation	more	 frequently	 in	 feeder-free	 condition	 than	 on	 feeders	 (fig.	 2B).	 This	 effect	 was	reduced	by	a	 combination	of	passaging	and	mechanical	 separation	of	differentiated	regions	(fig.	2C).		
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With	 few	 exceptions,	 after	 an	 average	 of	 5-6	 passages	 combined	 with	 separation,	feeder-free	iPSC	lines	greatly	reduced	occurrences	of	spontaneous	differentiation.			
2.	Williams-Beuren	Syndrome	Chromosomal	Region	genes	are	expressed	at	 the	
pluripotent	stage	and	mirror	gene	dosage.		The	expression	of	WBSCR	genes	in	iPSC	lines	was	measured	at	both	the	mRNA	(fig.	3)	and	protein	level	(fig.	4)	across	a	wide	panel	of	lines.		All	 these	genes	are	expressed	at	a	detectable	 level	 and	show	an	expression	pattern	that	remarkably	mirrors	gene	dosage	(fig.	3A,	4A),	especially	for	genes	expressed	at	a	high	level	(fig	3B,	4B).	mRNA	levels	were	measured	with	Nanostring,	a	hybridization-based	 technology	 that	 quantifies	 single	 mRNA	 molecules	 in	 a	 chip	 and	 quantifies	them	with	an	optical	signal.	mRNA	are	precisely	quantified	by	counting	the	fields	of	view	 (FOV)	 in	 which	 the	 signal	 is	 detected.	 The	 expression	 pattern	 is	 still	 clearly	detectable	at	the	protein	level,	although	slightly	more	variable	and	with	a	less	clear-cut	reflection	of	gene	dosage.	This	could	be	due	to	technical	variability	arising	 from	differences	 in	 the	 type	 of	 measurements	 performed	 in	 mass	 spectrometry-based	technologies,	 in	which,	 instead	 of	 sequence	 reads,	 different	 peptides	 from	different	proteoforms	are	measured	(see	Discussion).		The	expression	levels	and	patterns	of	these	genes	prompted	the	question	whether	a	molecular	phenotype,	i.e.	transcriptional	dysregulation,	could	be	captured	already	at	the	iPSC	stage.				
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	Figure	3:	WBSCR	genes	mirror	gene	dosage	at	the	mRNA	level	 in	iPSCs.	A)	heatmap	showing	 Z-score	 of	 expression	 levels	 for	 all	 the	 WBSCR	 transcripts,	 measured	 by	Nanostring.	 B)	 average	 mRNA	 expression	 levels	 of	 EIF4H,	 WBSCR22,	 BAZ1B	 and	GTF2I	in	each	genotype.	Error	bars	represent	standard	deviation.	FOV:	Field	Of	View.		 				
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	Figure	4:	WBSCR	genes	mirror	gene	dosage	at	the	protein	level	in	iPSCs.	A)	heatmap	showing	 Z-score	 of	 expression	 levels	 for	 the	 uniquely	 identified	 WBSCR	 proteins,	measured	 by	 SWATH-MS	 label-free	 quantification.	 B)	 average	 protein	 expression	levels	of	EIF4H,	WBSCR22,	BAZ1B	and	GTF2I	in	each	genotype.	Error	bars	represent	standard	deviation.				 	
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3.	 Transcriptional	 programs	 are	 already	 dysregulated	 in	 pluripotency	 and	map	
onto	disease-associated	pathways			When	 performing	 differential	 gene	 expression	 analysis	 on	 transcriptomes	 obtained	by	RNA-seq	of	the	27	iPSC	lines	we	found	757	differentially	expressed	genes	(DEGs	-	see	Annex	1	for	the	list).		Interestingly,	 we	 found	 that	 DEGs	 were	 enriched	 for	 Gene	 Ontology	 categories	entailing	biological	processes	and	molecular	functions	closely	related	to	the	systems	and	the	developmental	pathways	that	are	likely	perturbed	in	WBS	or	7dup	(figure	5).			
		Figure	5:	treemap	representing	Gene	Ontology	terms	for	which	there	is	a	statistically	significant	 enrichment	 among	 RNA-seq	 DEGs.	 Parent	 categories	 with	 enriched	children	 were	 removed.	 The	 size	 of	 each	 box	 is	 proportional	 to	 the	 statistical	significance	 of	 the	 enrichment.	 Colours	 are	 assigned	 based	 on	 the	 top-most,	 non-overlapping	parent	category.	Redrawn	from	Adamo	et	al.	2015		Owing	 to	 the	 functional	 involvement	 in	 translation	 of	 EIF4H	 and	 WBSCR22,	 and	based	on	their	dosage,	we	then	set	out	to	investigate	the	broad	effect	of	the	CNV	in	the	translatomes	and	proteomes	of	 these	 iPSC	lines,	by	ribosome	profiling	and	SWATH-MS	label-free	quantification	respectively.		
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4.	Generation	of	reporter	iPSC	lines	to	assess	global	changes	in	translation			Since	normalization	methods	used	in	ribosome	profiling	data	analysis	work	under	the	assumptions	that	there	is	no	global	effect	in	translation,	we	devised	a	reporter-based	strategy	that	would	allow	us	to	measure,	and	possibly	normalize	by,	any	such	global	differences.	 	 The	 initial	 strategy	 envisaged	 the	presence	of	 a	 cricket	 paralysis	 virus	(CrPV)	IRES	in	the	5’UTR	of	the	reporter	(fig.	6A).		CrPV	IRES	can	initiate	translation	by	 directly	 recruiting	 an	 80S	 monosome	 to	 the	 translation	 start	 site,	 effectively	bypassing	all	 initiation	 factors.	We	reasoned	 that	 reporters	with	 the	 IRES	would	be	able	 to	 show	 any	 global	 effect	 that	 was	 not	 depending	 on	 changes	 in	 EIF4H	abundance.	 We	 subcloned	 in	 a	 lentiviral	 backbone	 the	 luciferase	 cDNA	 with	 and	without	the	CrPV	IRES,	under	the	control	of	the	UbC	promoter.	Since	only	the	Firefly	luciferase	cDNA	was	cloned,	 the	 lentiviral	backbone	does	not	allow	to	normalize	on	another	 signal	 such	 as	Renilla	 luciferase.	 To	 avoid	 this	 issue,	we	 use	 the	 total	 RNA	level	 of	 Firefly	 for	 normalization	 and	 use	 differences	 in	 translation	 efficiency	 as	 a	measure	of	the	global	effect.		To	test	their	activity,	we	transfected	both	constructs	in	HeLa,	 together	with	 the	original	dual-luciferase	commercial	constructs	as	a	positive	control	 (pMirGLO)	 and	 the	 modified	 dual-luciferase	 construct	 harbouring	 an	additional	 pair	 of	 restriction	 sites	 to	 insert	 the	 IRES	 DNA	 (pMirGLO-host).	Unfortunately,	 only	 the	 lentiviral	 construct	 containing	 the	 IRES	 did	 not	 expresses	
Firefly	 luciferase	 (fig.	 6B),	 making	 our	 initial	 strategy	 unsuitable	 for	 our	 purposes.	Nonetheless,	we	 decided	 to	 use	 the	 lentiviral	 construct	 lacking	 the	 IRES,	 reasoning	that	a	short	5’UTR	would	still	have	little	sensibility	to	changes	in	EIF4H	abundances.	Moreover,	 the	 hygromycin	 antibiotic	 resistance,	 under	 the	 control	 of	 the	 EF1a	promoter,	can	serve	as	an	additional	reporter	in	RNA-based	measurements.		
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		Figure	6:	Reporter-based	strategy	to	assess	global	differences	 in	 translation.	A)	 two	constructs	 were	 derived	 by	 subcloning	 the	 Firefly	 luciferase	 cDNA	 in	 a	 lentiviral	backbone	 under	 the	 control	 of	 the	 UbC	 promoter.	 In	 pUBC-CrPV-Luc,	 a	 cricket	paralysis	 virus	 (CrPV)	 IRES	 has	 been	 inserted,	 together	 with	 the	 obligatory	alternative	 start	 codon	CTG,	 needed	 to	 initiate	 translation	with	 this	 IRES.	 In	 pUBC-Luc,	 only	 the	 luciferase	 cDNA	 has	 been	 inserted.	 B)	 Luciferase	 assay	 in	 HeLa	 cells	transfected	with	pMirGLO,	pMirGLO-host,	 pUbC-Luc	and	pUbC-CrPV-Luc.	The	 levels	of	 the	 IRES-containing	 reporter	 are	 indistiguishable	 from	 background.	 Light	 green:	
Firefly	luciferase.	Dark	green:	Renilla	luciferase.	Each	bar	represents	one	experiment.			All	 iPSC	 lines	 were	 infected	 with	 lentiviral	 particles	 containing	 the	 pUbC-Luc	construct,	and,	upon	selection,	a	 subset	of	 them	was	assayed	 for	 luciferase	 to	make	sure	that	the	reporter	was	not	being	silenced	(fig.	7).		
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	Figure	 7:	 reporter	 expression	 in	 a	 sample	 of	 iPSC	 lines	 infected	 with	 pUbC-Luc	lentiviral	particles.	All	lines	were	antibiotic-selected.	The	reporter	was	expressed	at	a	detectable	level,	showing	successful	integration	and	expression	of	the	construct.	Each	measurement	has	been	done	twice.	Error	bars	represent	standard	deviation.			
5.	Assessment	of	 transcriptome	and	 translatome	dysregulation	 in	 iPSC	 lines	by	
ribosome	profiling			In	 order	 to	 gain	 a	 specific	 insight	 on	 the	 extent	 and	 the	 magnitude	 of	 translation	dysregulation	at	the	pluripotent	stage,	we	performed	ribosome	profiling	on	a	subset	of	11	iPSC	lines,	each	derived	from	a	different	patient	(3	WBS,	1	atypical	WBS,	3	CTL,	3	7dup),	with	the	exception	of	a	7dup	patient	for	whom	we	included	2	lines	(because	at	 the	 time	we	did	not	have	available	cells	 from	a	 third	7dup	patient).	We	used	 the	ribosome	profiling	protocol	to	generate	total	RNA	and	ribosome-protected	fragment	(RPF)	 libraries	 simultaneously.	 Only	 uniquely	 mapping	 reads	 were	 retained.	 RPF	reads	 were	 subdivided	 in	 silico	 by	 unequivocally	 assigning	 reads	 to	 5’UTR,	 coding	sequence	 (CDS)	and	3’UTR	of	each	 transcript,	 in	order	 to	avoid	confounding	effects	due	 to	 ribosome	 footprints	 in	 untranslated	 regions	 with	 a	 regulatory	 function,	 or	arising	 as	 experimental	 artefacts.	 As	 expected,	most	 of	 the	 reads	map	 on	 the	 CDS,	
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followed	by	a	fraction	mapping	on	the	5’UTR	and	a	remarkably	smaller	portion	on	the	3’UTR	(fig.	8).		
	Figure	8:	distributions	of	ribosome-protected	fragment	reads	on	different	regions	of	the	 transcript.	 The	 majority	 of	 reads	 is	 expectedly	 mapped	 on	 the	 CDS	 portion	 of	transcripts.	Dark	blue:	5’UTR;	purple:	CDS;	light	purple:	3’UTR.			To	better	appreciate	the	influence	of	translation	regulation,	a	simple	calculation	that	is	 routinely	 performed	 is	 translation	 efficiency	 (TE),	 i.e.	 the	 ratio	 between	 the	abundance	of	RPF	reads	over	their	respective	total	RNA	abundances.	Since	only	reads	aligned	 in	 the	 CDS	 are	 used	 to	 quantify	 translation,	 the	 same	 in	silico	 division	 has	been	carried	out	on	total	RNA	transcripts,	so	that	TE	can	be	calculated	using	exactly	the	same	portions	of	transcripts.	TE	can	serve	as	a	readily	interpretable	value	of	the	extent	to	which	a	gene	is	regulated	on	translation.			While	 the	 quantification	 of	WBS	 genes	 expression	 at	 the	 level	 of	RNA	 (fig.	 9A)	 and	RPF	(fig.	9B)	still	mirrors	gene	dosage,	there	appear	to	be	no	major	differences	in	TE	across	genotypes	(fig.	9C).	However,	as	will	be	discussed	later	on,	the	high	variability	of	these	measurements	invites	some	caution	in	their	interpretation.			
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	Figure	9:	Heatmaps	of	Z-scores	for	WBSCR	genes	at	the	total	RNA	level	(A),	the	RPF	level	(B)	and	Translation	Efficiency	(C).			We	performed	differential	gene	expression	analysis	by	doing	pairwise	comparisons	of	groups	of	patients	according	to	their	condition:	WBS	vs	control,	7dup	vs	control,	7dup	vs	WBS.	When	 including	 the	 atypical	WBS	 sample	 in	 the	 analysis,	 the	 number	 and	identity	 of	 DEGs	 would	 greatly	 change	 based	 on	 whether	 it	 was	 grouped	 together	with	the	WBS	or	the	control;	 in	any	case	it	would	be	reduced.	Since	we	do	not	have	more	 than	1	atypical	patient	 in	our	 cohort,	we	do	not	 reach	a	minimum	amount	of	replicates	 that	 would	 allow	 for	 statistically	 significant	 comparisons	 with	 other	samples.	For	this	reason	we	decided	to	exclude	the	atypical	WBS	sample	at	this	stage	of	 the	 analysis.	 We	 then	 considered	 the	 union	 of	 differentially	 expressed	 genes	passing	 a	 false	 discovery	 rate	 (FDR)	 threshold	 of	 0.1	 to	 represent	 the	 set	 of	 genes	dysregulated	by	dosage	imbalances	in	the	CNV.		We	found	96	differentially	expressed	genes	at	the	RNA	level	(fig.	10).	About	half	of	them	show	an	expression	pattern	that	goes	in	the	same	direction	as	that	of	WBSCR	genes.	GO	enrichment	analysis	using	the	whole	 transcriptome	 as	 a	 background	 did	 not	 score	 any	 statistically	 significant	enrichment.	 However,	 several	 differentially	 expressed	 genes	 are	 involved	 in	pathways	 that	map	 onto	 disease-associated	 phenotypes	 and	 functions	 (tab.	 1).	 The	high	level	of	variability	across	samples	with	the	same	genotype	invites	caution,	as	it	is	
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possible	 that	 technical	 isssues	 in	 library	 preparation	 may	 inflate	 variability.	Nevertheless,	it	is	also	possible	that	differences	between	genetic	backgrounds	(inter-individual)	 account	 for	 a	 portion	 of	 the	 observed	 variability,	 in	 a	 way	 that	 is	remarkably	high	at	the	mRNA	level.	
Gene	 Function	 Reference	
SOX3	
SRY-box	transcription	factor,	regulates	neural	differentiation,	when	mutated	
causes	X-linked	intellectual	disability	with	panhypopituitarism	
(Laumonnier	et	al.,	
2002;	Woods	et	al.,	
2005)	
RPS16,	
RPLP1	
40S	ribosomal	subunits	 	
MRPL12,	
MRPL26	
Mitochondrial	ribosomal	subunits	 (Serre	et	al.,	2013)	
TRDN	
Ion	channel	involved	in	cardiovascular	defects	causing	arrhythmogenic	
tachycardia	
(Altmann	et	al.,	2015)	
PCDHA3,	
PCDHB3,	
PCDHB5	
Protocadherins	possibly	involved	in	the	formation	of	neural	connections	in	the	
CNS	
(Zipursky	and	Sanes,	
2010)	
HISTH1A	 Histone	H1,	associated	with	schizophrenia	in	a	GWAS	on	Ashkenazi	jews	 (Goes	et	al.,	2015)	
BANF1	
Involved	in	nuclear	envelope	formation,	
when	mutated	causes	Nestor-Guillermo	progeria	syndrome	
(Puente	et	al.,	2011)	
ALCAM	
Cell	adhesion	molecule	involved	in	neurite	extension,	mesenchymal	stem	cell	
differentiation	and	cardiac	morphogenesis	
(Burns	et	al.,	1991;	
Gessert	et	al.,	2008)	
HSPB1	
Actin-binding	protein	involved	in	stress	response,	when	mutated	causes	
Charcot-Marie-Tooth	neuropathy,	axonal,	type	2f	
(Evgrafov	et	al.,	2004)	
RFX3,	IER2	
Regulate	left-right	polarity	in	embryogenesis,	important	for	proper	neural	tube	
formation	
(Hong	and	Dawid,	
2009;	Magnani	et	al.,	
2015)	
GPR1	 Found	in	GWAS	for	schizophrenia	 (Bergen	et	al.,	2012)	
PDPK1	
Master	kinase	in	the	mTOR	pathway	
Essential	for	neuronal	development	
(Lawlor,	2002;	
Watatani	et	al.,	2012)		Table	 1:	 DEGs	 found	 in	 the	 total	 RNA	 dataset	 that	 show	 overlaps	 with	 clinical	 or	molecular	features	of	the	two	syndromes.	
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	Figure	10:	Heatmap	of	the	Z-scores	for	differentially	expressed	genes	(FDR	<	0.1)	at	the	Total	RNA	level	according	to	edgeR’s	generalized	linear	model.					
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When	performing	differential	gene	expression	analysis	on	the	translatome	in	the	RPF	layer,	the	number	of	DEGs	passing	a	FDR	threshold	of	0.1	is	nearly	halved	(42	DEGs	–	fig.	 11).	 Almost	 all	 the	 DEGs	 in	 this	 dataset	 have	 an	 expression	 pattern	 that	 is	concordant	with	that	of	WBSCR	genes.	Interestingly,	only	16	of	them	were	also	called	as	DE	in	the	total	RNA	dataset,	among	which	6	are	WBSCR	genes.	These	findings	hint	at	buffering,	at	the	translation	level,	of	perturbations	originating	in	the	transcriptome.	The	 remaining	 26	 genes,	 among	 which	 3	 are	 WBSCR	 genes,	 are	 called	 as	 DE	exclusively	 in	 the	 RPF	 dataset	 (fig.	 12).	 Among	 these	 26	 genes	 we	 found	 some	important	 regulators	 of	 neuronal	 development	 (tab.	 2)	 associated	 to	 phenotypes	reminiscent	 of	 the	 clinical	 characteristics	 of	 these	 syndromes.	 Importantly,	 neither	Luciferase	 nor	 Hygromycin	were	 detected	 as	 differentially	 expressed	 in	 any	 of	 the	two	 datasets,	 thus	 pointing	 to	 a	 lack	 of	 global	 effects	 affecting	 the	 reporters	 that	would	be	dependent	on	initiation.	For	this	dataset,	variability	seems	to	be	much	less	prominent,	either	pointing	to	buffering	of	inter-individual	differences,	or	a	less	severe	impact	of	technical	artifacts.	The	fact	that	242K	and	242J,	two	samples	coming	from	different	iPSC	clones	of	the	same	individual,	have	a	similar	pattern	at	the	RNA	level,	would	point	to	the	first	hypothesis.	
Gene	 Function	 Reference	
ANKRD1	
Probable	transcription	factor	that	also	interacts	with	sarcomeric	
proteins,	involved	in	dilatative	cardiomyopathies	
(Moulik	et	al.,	2009)	
POU3F3	
Homeobox	transcription	factor	involved	in	neuronal	development	and	
in	the	development	of	inner	ear	epithelium	
(Dheedene	et	al.,	2014;	
Dominguez	et	al.,	2013)	
CPEB2	 RNA-binding	protein	involved	in	dorso-ventral	axis	formation	
(Hafer	et	al.,	2011;	
Turimella	et	al.,	2015)	
CEBPB	 Neuronal	transcription	regulator	
(Sterneck	and	Johnson,	
1998)	
PCDHGB1,	PCDHGB3,	PCDHGB5	
PCDHGA3	
Protocadherins	possibly	involved	in	the	formation	of	neural	
connections	in	the	CNS	
(Zipursky	and	Sanes,	
2010)		Table	2:	DEGs	exclusively	found	in	the	RPF	dataset	that	show	overlaps	with	clinical	or	molecular	features	of	both	syndromes.					
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	Figure	11:	heatmap	of	the	Z-scores	for	differentially	expressed	genes	(FDR	<	0.1)	at	the	RPF	level	according	to	edgeR’s	generalized	linear	model.			
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	Figure	12:	Venn	diagrams	representing	the	overlaps	of	DEGs	across	molecular	layers.			
6.	Assessment	of	proteomic	dysregulation	by	mass	spectrometry		To	 gain	 further	 insight	 into	 the	 dysregulation	 caused	 by	 7q11.23	 CNVs	 in	 the	proteome,	 we	 performed	 high-throughput	 mass	 spectrometry	 using	 a	 data-independent	mass-spectrometry	approach,	SWATH-MS.	We	analyzed	the	proteome	of	25	 iPSC	 lines	 derived	 from	 10	 individuals	 (4	 WBS	 patients,	 3	 controls,	 3	 7dup	patients).	Differential	 expression	 analysis	was	 performed,	 as	 for	 transcriptome	 and	translatome,	 by	making	 pairwise	 comparisons	 between	 genotypes	 and	 considering	the	 union	 of	 differentially	 expressed	 proteins	 (DEPs)	 passing	 the	 FDR	 threshold	 of	0.1.	We	found	41	DEPs	(fig.	13),	among	which	roughly	60%	follows	WBSCR	dosage.	Only	8	DEPs	are	also	DEGs	in	the	translatome.	Besides	6	WBSCR	proteins,	only	CAT	was	differentially	expressed	in	both	transcriptome	and	translatome,	whereas	EPCAM	was	 differentially	 expressed	 in	 the	 transcriptome	 only,	 and	 ABHD11	 in	 the	translatome	only.	 Lowering	 the	FDR	 threshold	 for	DEP	 identification	 to	0.2	did	not	increase	 the	number	of	overlapping	proteins	across	 layers.	These	observations	hint	again	at	a	 layer-specific	 regulation,	buffering	 the	 transition	 from	actively	 translated	
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mRNA	to	final	protein	abundance,	and	introducing	other	perturbations	exclusively	in	the	 proteome.	 It	 is	 possible,	 however,	 that	 the	 intrinsic	 differences	 between	sequencing-based	 measurments	 and	 mass-spectreometry	 measurements,	 together	with	 unavoidable	 differences	 in	 the	 statistical	 tests	 used	 to	 measure	 differential	expression,	may	mask	 the	overlap	of	 some	other	differentially	expressed	genes	and	proteins.	 Further	 validation	 steps	 are	 needed	 to	 assess	 the	 technical	 and	 the	biological	differences,	and	how	each	of	them	impacts	gene	expression	measurements.	
	Figure	13:	heatmap	of	the	Z-scores	for	differentially	expressed	proteins	(FDR	<	0.1)	according	to	pairwise	categorical	t-tests.		
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As	 already	 observed	 in	 both	 total	 RNA	 and	 RPF	 datasets,	 several	 differentially	expressed	proteins	map	onto	 functions	 and	pathways	 that	overlap	with	 the	 clinical	and	molecular	characteristics	of	both	syndromes	(tab.	3).		
Protein	 Function	 Reference	
HLA-A/HLA-C	
Members	of	the	Major	Histocompatibility	Complex,	class	I,	reported	as	risk	factor	for	type	I	
diabetes	
(Noble	and	
Valdes,	2011)	
SMARCA1/	
SMARCA5	
Member	of	SWI/SNF	chromatin	remodeling	complex.	SMARCA1	promotes	neurite	
outgrowth.	
(Barak	et	al.,	
2004)	
HPGD	
Involved	in	prostaglandin	metabolism,	when	mutated	causes	cranioosteoarthropathy	and	
patent	ductus	arteriosum	
(Seifert	et	al.,	
2009)	
ITPA	
Involved	in	nucleotide	metabolism,	when	mutated	causes	early	infantile	encephalopathy,	
with	brain	abnormalities,	seizures	and	cardiac	defects	
(Kevelam	et	al.,	
2015)	
SERPINH1	
Serine	peptidase	inhibitor,	when	mutated	causes	type-X	osteogenesis	imperfecta	with	
bone	fragility,	craniofacial	dysmorphisms	and	hearing	loss	
(Christiansen	et	
al.,	2010)	
SPTLC1	
Enzyme	of	the	sphingolipid	biosynthesis	pathway,	when	mutated	causes	peripheral	
neuropathy	
(Auer-
Grumbach	et	
al.,	2013)	
ALPL	
Alkaline	phosphatase	specific	for	liver,	bone	and	kidney,	when	mutated	causes	infantile	
hypophosphatasia,	a	severe	skeletal	disorder	due	to	abnormal	bone	mineralization	
(Weiss	et	al.,	
1988)	
ATP6V0A1	 V-ATPase	subunit	involved	in	neural	crest	migration	
(Tuttle	et	al.,	
2014)	
IMPDH1	
Involved	in	nucleotide	metabolism,	when	mutated	causes	Leber	Congenital	Amaurosis	
with	retinal	dystrophy	
(Mortimer	and	
Hedstrom,	
2005)	
PSMC5	 Regulatory	subunit	of	the	26S	proteasome	
(Makino	et	al.,	
1997)	
UBE2T	 E2-ubiquitin	conjugating	enzyme	
(Longerich	et	
al.,	2009)	
RPL10	
Ribosomal	subunit,	when	mutated	is	a	risk	factor	for	autistic	spectrum	disorders,	especially	
X-linked	autism	
(Brooks	et	al.,	
2014;	Klauck	et	
al.,	2006)	
EIF2D	 Translation	initiation	factor	involved	in	Met-tRNA	delivery	
(Dmitriev	et	al.,	
2010)		Table	 3:	 DEPs	 found	 in	 the	 protein	 dataset	 and	 their	 overlaps	 with	 clinical	 or	molecular	features	of	both	syndromes.		
7.	Generation	of	knock-down	and	sineUP	lines	for	EIF4H			Given	 the	 changes	 in	differential	 expression	at	 each	 level,	 it	 becomes	 interesting	 to	gain	more	mechanistic	 insight	 into	 these	differences	by	artificially	manipulating	 the	dosage	in	iPSCs	of	a	key	contributor	to	translational	regulation	that	has	already	been	
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linked	 to	 several	 WBS-related	 phenotypes,	 EIF4H.	 The	 interfered	 lines,	 especially	when	analyzed	at	the	level	of	translatome,	are	particularly	useful	to	deconvolute	the	transcriptional	 and	 translational	 effect	of	EIF4H	on	differential	 gene	expression.	To	lower	 the	 abundance	 of	 EIF4H	 we	 cloned	 2	 short	 hairpins	 for	 RNA	 interference	(shRNA)	 in	 a	 lentiviral	 backbone.	 Conversely,	 to	 increase	 its	 abundance,	we	 cloned	sineUP	constructs	in	the	same	lentiviral	backbone.	SineUPs	(Zucchelli	et	al.,	2015)	are	small,	 single-stranded	 RNA	 molecules	 that	 recognize	 target	 mRNAs	 at	 their	 5’	 by	sequence	complementarity	and	enhance	their	translation	by	mechanisms	still	under	investigation.	 While	 shRNAs	 target	 mRNAs	 for	 degradation,	 thus	 lowering	 their	abundance,	 sineUPs	 increase	 their	 translation,	 leaving	 their	 mRNA	 abundance	unchanged.	 For	 each	 construct	 a	 scrambled	 construct	 was	 included	 (shSCR	 and	sineUP-SCR)	as	a	control.	A	single	control	iPSC	line	(MIFF3)	was	infected	with	sineUP	and	 shRNA	 lentiviral	 particles	 and	 selected	 with	 puromycin.	 Unfortunately,	 the	sineUP	construct	did	not	 cause	 the	expected	up-regulation	 (fig.	14B),	whereas	both	shRNAs	were	successfully	down-regulating	 their	 target	 (fig.	14A).	The	 failure	of	 the	sineUP	modulation	may	be	due	to	an	absence	of	the	necessary	molecular	mechanisms	for	its	function	specifically	in	iPSCs,	or	to	a	suboptimal	design	of	the	sineUP	construct	that	would	 require	 additional	 tweaking.	 For	 the	 time	being,	we	decided	 to	proceed	with	shRNAs	only.					
	 95	
	Figure	14:	Validation	of	EIF4H	knock-downs	and	sineUP.	A)	Western	blot	on	EIF4H	and	GAPDH	 to	evaluate	 the	effect	of	both	short	hairpins.	B)	Western	blot	on	EIF4H	and	GAPDH	to	evaluate	the	effect	of	the	sineUP	and	its	scramble	counterpart.			Since	 both	 EIF4H	 shRNAs	 worked	 well,	 we	 included	 both	 lines	 (sh1	 and	 sh2)	 for	further	downstream	analysis	by	ribosome	profiling	and	SWATH-MS.	Owing	to	small	sample	size,	we	decided	not	 to	perform	differential	gene	expression	analysis	on	the	two	hairpins	compared	to	the	scramble,	but	rather	use	these	datasets	as	a	validation	tool	for	differential	expression.	By	assessing	the	effect	of	EIF4H	on	the	RNA	 level	 of	 DEGs	 found	 in	 the	 transcriptome	 (fig.	 15)	 we	 can	 appreciate	 a	substantial	down-regulation	of	more	than	half	of	the	transcripts,	with	9	genes	having	a	 log2(FC)	over	scramble	of	 less	than	-1,	corresponding	to	a	negative	2-fold	change,	using	both	hairpins.	Two	genes	(MTRNRL1	and	MTRNRL	8)	are	instead	up-regulated	by	more	than	1	log2(FC)	upon	EIF4H	knockdown	using	both	hairpins.			
GAPDH
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Figure	15:	Barplot	of	log2(FC)	at	the	RNA	level	of	DEGs	found	in	the	RNA	dataset.	In	blue,	 genes	 that	 are	 down-	 or	 up-regulated	more	 than	 2-fold	 by	 both	 EIF4H	 short	hairpins	 compared	 to	 the	 scramble	 hairpin.	 The	 black	 dotted	 line	 represents	 +/-	 1	log(FC),	corresponding	to	a	2-fold	change.		The	 down-regulation	 is	 also	 visible,	 albeit	 at	 a	 lesser	 extent,	 when	 computing	 the	log2(FC)	 of	 these	 genes	 in	 the	 translatome	 (fig.	 16),	 and	 it	 is	 counterbalanced	by	 a	remarkable	part	of	up-regulated	DEGs	upon	EIF4H	knock-down.			
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	Figure	16:	Barplot	of	log2(FC)	at	the	RPF	level	of	DEGs	found	in	the	RNA	dataset.	In	blue,	 genes	 that	 are	 down-	 or	 up-regulated	more	 than	 2-fold	 by	 both	 EIF4H	 short	hairpins	 compared	 to	 the	 scramble	 hairpin.	 The	 black	 dotted	 line	 represents	 +/-	 1	log(FC),	corresponding	to	a	2-fold	change.		By	plotting	changes	in	TE	with	respect	to	scramble	of	genes	that	are	called	as	DE	only	in	the	total	RNA	dataset	(fig.	17),	it	becomes	evident	that	more	than	half	of	the	genes	have	a	decrease	in	translation	efficiency,	with	16	genes	for	which	TE	is	decreased	by	more	 than	 2-fold	 in	 both	 hairpins,	 pointing	 to	 a	 strongly	 predominant	 effect	 of	translation	over	transcription	in	this	subset.	The	number	of	these	genes	increases	to	22	when	considering	a	more	lenient	threshold	of	1.5-fold	decrease	in	TE.	This	down-regulation	 points	 to	 a	 possible	 masking	 of	 the	 transcriptional	 effect	 by	 EIF4H,	
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although	 it	 does	 not	 allow	us	 to	 discern	whether	 it	 is	 a	 direct	 or	 indirect	 effect	 on	specific	mRNAs.		
	Figure	17:	Barplot	of	differences	in	log2(FC)	TE	of	DEGs	found	exclusively	in	the	RNA	dataset.	In	blue,	genes	whose	TE	is	down-	or	up-regulated	more	than	1.5-fold	by	both	EIF4H	 short	 hairpins	 compared	 to	 the	 scramble	 hairpin.	 The	 black	 dotted	 line	represents	 +/-	 1	 log(FC),	 corresponding	 to	 a	 2-fold	 change,	 the	 red	 dotted	 line	represents	+/-	0.6	log(FC),	corresponding	to	a	1.5-fold	change.		When	 applying	 the	 same	TE	 analysis	 to	 genes	 that	were	differentially	 expressed	 in	the	 translatome	 (fig.	 18),	we	 can	appreciate	 an	almost	 constant	down-regulation	of	translation	efficiency	of	DE	genes,	with	6	of	them	being	down-regulated	by	2-fold	in	2	hairpins	(9	genes	by	1.5	fold).	With	the	exception	of	ANKRD1,	the	drop	in	TE	of	these	genes	upon	EIF4H	knock-down	is	consistent	with	their	trend	of	expression	in	the	RPF	
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dataset,	which	correlates	with	EIF4H	levels.	These	9	genes	may	be	directly	regulated	by	EIF4H,	although	it	is	not	possible	to	discern	between	direct	and	indirect	effects	at	this	stage	of	the	analysis.			
	Figure	18:	Barplot	of	differences	in	log2(FC)	TE	of	DEGs	found	in	the	RPF	dataset.	In	blue,	 genes	whose	 TE	 is	 down-	 or	 up-regulated	more	 than	 1.5-fold	 by	 both	 EIF4H	short	hairpins	compared	to	the	scramble	hairpin.	The	black	dotted	line	represents	+/-	1	 log(FC),	 corresponding	 to	 a	 2-fold	 change,	 the	 red	 dotted	 line	 represents	 +/-	 0.6	log(FC),	corresponding	to	a	1.5-fold	change.						
8.	 A	 regression-based	 approach	 reveals	 the	 modes	 of	 propagation	 of	 changes	
through	molecular	layers		Pairwise	 comparisons	 between	 samples	 are	 informative	 on	 the	 type	 and	 extent	 of	dysregulation	 occurring	 between	 a	 particular	 disorder	 and	 a	 control,	 but	 provide	
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limited	 insight	 into	how	the	dosage	of	genes	 in	 the	WBSCR	affects	gene	expression.	The	presence	of	 key	 regulators	of	 gene	 expression	 at	 the	 level	 of	 transcription	 and	translation,	 and	 the	 availability	 of	 genome-wide	 measurements	 of	 three	 different	expression	layers,	allows	to:	1)	make	specific	hypotheses	on	the	relationship	between	the	abundance	of	WBSCR	genes	and	differences	 in	gene	expression	across	 samples,	and	2)	measure	 the	extent	 to	which	differences	 in	gene	expression	 in	one	 layer	are	propagated	to	another.	In	 order	 to	 understand	 the	 effect	 on	 differential	 expression	 caused	 by	 changes	 in	dosage	 and	 abundance	 of	 key	 regulators	 of	 gene	 expression,	 we	 adopted	 a	 novel	strategy	that	uses	linear	regression	on	the	abundance	of	single	proteins	(measured	by	SWATH-MS)	 to	 infer	 the	 magnitude	 and	 direction	 of	 changes	 in	 DEGs	 and	 DEPs.	Briefly,	we	used	 the	 log-normalized	 intensity	 of	 “query”	 proteins	 as	 covariates	 in	 a	generalized	 linear	model	(based	on	the	negative	binomial	distribution	 implemented	by	 edgeR)	 for	 total	 RNA	 and	RPF,	 and	 in	 the	 standardized	major	 axis	 (SMA)	 linear	regression	for	the	proteome.	In	other	words,	we	checked	whether	there	was	a	linear	relationship	between	 the	 log-transformed	values	of	RNA	or	RPF	abundance	 in	each	sample,	 and	 the	 log-transformed	 intensity	 values	 of	 a	 query	 protein	 in	 the	 same	samples,	 and	 whether	 this	 relationship	 was	 statistically	 significant.	 These	 linear	relationships	were	constructed	using	not	only	the	samples	from	patients,	but	also	the	EIF4H	knock-down	and	scramble	samples.	For	every	gene	in	each	layer	we	obtained	a	slope	 (corresponding	 to	 the	 log-fold	 change	 for	RNA	and	RPF,	 and	 the	 slope	 of	 the	SMA	 linear	 model	 for	 the	 proteome)	 whose	 sign	 and	 value	 serve	 as	 a	 response	coefficient	 to	 the	query	protein,	 and	whose	p-value	describes	 the	goodness	of	 fit	 in	the	 linear	 model.	 A	 gene	 with	 a	 statistically	 significant	 slope	 of	 +1	 is	 perfectly	correlating	with	the	query	protein,	meaning	that	changes	in	the	independent	variable	(query)	 result	 in	 proportional	 changes	 in	 the	 response	 variable.	 A	 gene	 with	 a	
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negative	slope	is	anticorrelated.	Genes	with	slopes	that	deviate	from	1	are	potentially	targeted	by	one	or	more	mechanisms	 that	exacerbate	or	attenuate	 their	correlation	with	the	query	protein.	Genes	with	no	statistically	significant	slope	are	not	correlated	to	 the	 query	 protein	 in	 that	 layer,	 possibly	 because	 they	 are	 not	 responsive	 to	changes	 in	query	protein	abundance.	Although	 this	method	does	not	allow	 to	draw	precise	causal	links,	it	still	allows	to	generate	hypotheses	in	a	mechanistic	framework	which	will	be	validated	with	more	 targeted	approaches.	The	use	of	 slopes	becomes	particularly	relevant	when	they	are	compared	across	layers.	We	computed	slopes	on	RNA,	RPF	and	proteome	datasets	using	EIF4H	as	query.	Even	though	read	counts	in	total	 RNA	 and	 RPF	 have	 remarkable	 differences	 in	 their	 magnitude	 compared	 to	protein	intensities,	slopes	represent	relative	changes	in	abundance,	thus	making	RNA	and	protein	measurements	numerically	comparable	(fig.	19).			
	Figure	19:	 Total	RNA,	RPF	 and	protein	 slopes	 are	 numerically	 comparable.	Density	plots	showing	the	distribution	of	slopes	by	regressing	on	EIF4H	(x	axis)	for	all	three	layers.	The	bimodal	distribution	of	protein	slopes	 is	due	 to	 the	SMA	regression	 test	that	assigns	a	non-zero	value	to	each	slope	regardless	of	its	statistical	significance.		In	 principle,	 this	 method	 can	 be	 applied	 to	 all	 genes	 for	 which	 we	 can	 identify	 a	statistically	significant	slope,	with	the	proviso	that	many	of	them	are	unlikely	to	pass	multiple	test	correction	due	to	the	high	heterogeneity	of	samples,	thus	allowing	us	to	perform	only	a	descriptive	analysis	of	distribution	of	slopes.	For	each	analysis	we	can	
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analyse	 the	universe	of	 statistically	 significant	 slopes	 (Fig.	 20A),	which	 can	 then	be	deconvoluted	 into	 three	 components:	 intersection	 of	 genes	 with	 statistically	significant	 slopes	 in	 both	 total	 RNA	 and	 RPFs	 (Fig.	 20B),	 genes	 with	 statistically	significant	slopes	only	in	total	RNA	(Fig.	20C)	and	genes	with	statistically	significant	slopes	 only	 in	 RPF	 (Fig.	 20D).	 The	 fact	 that	 RNA	 and	 RPF	 slopes	 occupy	 almost	exclusively	 quadrants	 I	 and	 III	 (fig.	 20A)	 shows	 that	 most	 of	 the	 changes	 that	 are	correlated,	positively	or	negatively	with	EIF4H	 levels,	 are	 carried	 forward	 from	 the	transcriptome	to	 the	 translatome.	As	expected,	genes	 that	have	significant	slopes	 in	both	 datasets	 lie	 close	 to	 the	 diagonal	 (fig.	 20B),	 meaning	 that	 their	 changes	 in	transcription	 are	 substantially	 promoted	 to	 translation.	 However,	 two	 interesting	subsets	of	genes	can	be	appreciated	by	 looking	at	slopes	that	are	significant	only	 in	one	of	the	two	layers	(fig.	20C,D).	These	subsets,	which	will	be	referred	to	as	“RNA-only”	(fig.	20C)	and	“RPF-only”	(fig.	20D),	are	delimited	by	including	only	those	genes	which	have	a	statistically	significant	slope	in	one	layer	and	not	in	the	other,	pointing	to	a	regulation	(or,	at	 least,	a	correlation)	 that	 is	pre-eminently	acting	 in	one	of	 the	two	layers.	Genes	with	significant	slopes	only	in	total	RNA	(fig.	20C)	may	be	subjected	to	 buffering	 events	 that	 dampen	differences	 at	 the	 level	 of	 translation,	while	 genes	with	 significant	 slopes	 only	 in	 RPF	 (fig.	 20D)	 are	 affected	 by	 post-transcriptional	regulatory	processes	that	are	not	detectable	in	the	transcriptome.	When	performing	GO	enrichment	analysis	on	genes	that	have	significant	slopes	in	only	one	of	the	two	layers,	 we	 find	 that	 genes	 exclusive	 to	 the	 RNA	 layer	 are	 enriched	 in	 processes	involved	 in	 cytoskeleton	 reorganization,	 protein	 localization	 and,	 strikingly,	axonogenesis	(fig.	21),	thus	confirming	that	iPSCs	present,	at	the	transcriptional	level,	perturbations	that	affect	disease-relevant	pathways.		The	 RPF-exclusive	 layer	 genes	 have	 different	 GO	 enrichments	 for	 processes	 more	related	to	RNA	metabolism	and	post-transcriptional	regulation,	and	in	particular	are	
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enriched	 for	 processes	 involved	 in	 cell	 cycle	 regulation	 and	 genes	 localized	 in	 the	nucleus	(fig.	22).	 	These	findings	point	again	at	layer-specific	modes	of	regulation	of	different	 cellular	 processes	 that	 can	 be	 appreciated	 only	 by	 integrating	 and	comparing	different	datasets.			
	Figure	20:	Quadrant	graphs	of	statistically	significant	(p	<	0.05)	slopes	 in	total	RNA	and	RPF	allow	to	readily	visualize	the	type	and	extent	of	correlation	with	EIF4H,	and	its	propagation	across	molecular	layers.	Each	gene	is	represented	by	a	coloured	dot.		A)	Union	of	all	genes	with	statistically	significant	slopes	in	either	layer	(light	blue).	B)	Intersection	of	genes	with	statistically	significant	slopes	in	both	layers	(dark	blue).	C)	Genes	with	 statistically	 significant	 slopes	only	 in	 total	RNA	 (purple).	D)	Genes	with	statistically	significant	slopes	only	in	RPF	(green).	Red	dotted	lines	indicate	diagonals,	black	dotted	lines	delimit	quadrants	(roman	numbers	displayed	in	each	corner).				
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	Figure	 21:	 Treemap	 representing	 Gene	 Ontology	 terms	 for	 which	 there	 is	 a	statistically	 significant	 enrichment	 among	 RNA-exclusive	 genes	 in	 the	 RNA	 vs	 RPF	comparison.	Parent	categories	with	enriched	children	were	removed.	The	size	of	each	box	is	proportional	to	the	statistical	significance	of	the	enrichment.	Between	brackets	the	p-value	adjusted	using	Benjamini-Hochberg	correction.		
	Figure	 22:	 Treemap	 representing	 Gene	 Ontology	 terms	 for	 which	 there	 is	 a	statistically	 significant	 enrichment	 among	 RPF-exclusive	 genes	 in	 the	 RNA	 vs	 RPF	comparison.	Parent	categories	with	enriched	children	were	removed.	The	size	of	each	box	is	proportional	to	the	statistical	significance	of	the	enrichment.	Between	brackets	the	p-value	adjusted	using	Benjamini-Hochberg	correction.		
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Taking	in	consideration	that	EIF4H	is	a	translation	initiation	factor,	we	expect	to	see	that	 most	 of	 the	 genes	 respond,	 at	 the	 level	 of	 translation,	 to	 increases	 in	 EIF4H	abundance	in	a	positive	and	dosage-sensitive	fashion.		And	indeed	our	slope	analysis	shows	 the	 expected	 trend	 (Fig.	 20D).	 However,	 since	 other	 genes	 of	 the	 WBSCR	necessarily	follow	a	trend	that	closely	mirrors	that	of	EIF4H,	this	evidence	alone	does	not	warrant	 a	 specific	 causal	 implication	of	EIF4H	 in	 the	 regulation	of	 these	 genes.	Such	a	 link	can	be	 further	probed	 in	depth	by	 looking	at	 this	subset	of	genes	 in	 the	context	of	 the	EIF4H	knock-down.	 	We	therefore	asked	whether	genes	clustering	 in	the	first	and	fourth	quadrant	of	the	RPF-only	graph	were	significantly	less	translated	in	 both	 RPF	 EIF4H	 knock-down	 datasets	 when	 compared	 to	 their	 scramble	counterpart.	Indeed,	log-transformed	TE	distributions	for	genes	in	quadrants	I	and	IV	have	 a	 statistically	 significant	 (p	 <	 2.2x10-16)	 difference	 when	 compared	 to	 the	scramble	(fig.	23),	showing	a	median	reduction	of	0.63	log	(MIFF3	scramble	vs	MIFF3	EIF4H	sh1)	and	0.39	log	(MIFF3	scramble	vs	MIFF3	EIF4H	sh2),	corresponding	to	a	~1.8	fold	and	~1.5	fold	reduction	respectively.				
	 106	
	Figure	23:	Effect	of	EIF4H	knock-down	on	RPF-exclusive	genes.	Distributions	of	log-transformed	FPKM	of	RPF	reads	for	RPF-exclusive,	I+IV	quadrant	genes	in	the	context	of	EIF4H	knock-down.	Both	short	hairpins	against	EIF4H	reduce	translation	levels	of	these	genes	in	a	statistically	significant	way	(p	<	2.2x10-16	according	to	a	two-sample	t-test).	The	black	bar	indicates	the	median	of	each	distribution.			By	 applying	 the	 same	 analysis	 of	 slopes	 to	 the	 comparison	 of	 translatome	 and	proteome	(fig.	24)	we	can	immediately	visualize	a	remarkable	shift	in	the	distribution	of	slopes,	with	a	large	portion	of	genes	clustering	in	the	second	quadrant	(fig.	244A).	A	large	subset	of	genes	in	this	quadrant	has	significant	slopes	in	the	RPF	dataset	only	(fig.	24C),	pointing	to	a	specific	compensation	of	changes	in	translation	at	the	level	of	co-	or	post-translational	regulation.	Genes	 in	the	second	quadrant	with	a	significant	slope	 in	 the	 protein	 dataset	 only	 (fig.	 24D)	 are	 likely	 being	 dysregulated	 in	 the	absence	of	significant	changes	in	translation.	The	presence	of	a	sizeable	proportion	of	genes	 in	 the	 first	quadrant	 indicates	 that	 the	 increases	 in	 translation	 that	 correlate	with	EIF4H	levels	mostly	result	in	increases	in	protein	abundance,	again	as	expected	given	the	role	of	EIF4H	in	translation.		GO	enrichments	for	RPF-exclusive	genes	in	this	analysis	 partially	 overlap	 with	 those	 found	 in	 the	 transcriptome	 vs	 translatome	
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comparison	(fig.	25),	pointing	to	a	strongly	translation-specific	regulation	of	cell	cycle	and	RNA	metabolism.			
Figure	 24:	Quadrant	 graphs	 of	 statistically	 significant	 (p	 <	 0.05)	 slopes	 in	RPF	 and	proteins.	A)	Union	of	all	genes	with	statistically	significant	slopes	in	either	layer	(light	blue).	B)	Intersection	of	genes	with	statistically	significant	slopes	in	both	layers	(dark	blue).	 C)	 Genes	 with	 statistically	 significant	 slopes	 only	 in	 total	 RNA	 (purple).	 D)	Genes	 with	 statistically	 significant	 slopes	 only	 in	 RPF	 (green).	 Red	 dotted	 lines	indicate	diagonals,	black	dotted	lines	delimit	quadrants	(roman	numbers	displayed	in	each	corner).			
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	Figure	 25:	 Treemap	 representing	 Gene	 Ontology	 terms	 for	 which	 there	 is	 a	statistically	significant	enrichment	among	RPF-exclusive	genes	in	the	RPF	vs	protein	comparison.	Parent	categories	with	enriched	children	were	removed.	The	size	of	each	box	is	proportional	to	the	statistical	significance	of	the	enrichment.	Between	brackets	the	p-value	adjusted	using	Benjamini-Hochberg	correction.			On	 the	 other	 hand,	 protein-exclusive	 genes	 (fig.	 26)	 are	 mainly	 related	 to	 energy	metabolism	and	protein	modification	 in	 the	endoplasmic	 reticulum,	albeit	with	 less	significant	 enrichments	 and	 broadly	 specified	 parent	 categories.	 Taken	 together,	these	 results	 hint	 at	 a	 widespread	 remodeling	 of	 the	 proteome	 in	 the	 pluripotent	state	 that,	 in	 many	 cases,	 reverts	 the	 effect	 of	 transcriptional	 and	 translational	imbalances.				
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	Figure	 26:	 Treemap	 representing	 Gene	 Ontology	 terms	 for	 which	 there	 is	 a	statistically	 significant	 enrichment	 among	 protein-exclusive	 genes	 in	 the	 RPF	 vs	protein	 comparison.	 Parent	 categories	 with	 enriched	 children	 were	 removed.	 The	size	 of	 each	 box	 is	 proportional	 to	 the	 statistical	 significance	 of	 the	 enrichment.	Between	brackets	the	p-value	adjusted	using	Benjamini-Hochberg	correction.		
9.	Regression-based	approach	on	DEGs			Yet,	 if	 we	 limit	 our	 analysis	 to	 the	 set	 of	 DEGs	 for	 which	we	 have	 good	 statistical	confidence,	 i.e.	 the	union	of	DEGs	 found	 in	 the	 initial	RNA-seq	 experiment,	 and	 the	DEGs	 and	 DEPs	 found	 in	 this	 study,	 we	 can	 query	 them	 without	 losing	 statistical	power,	 thus	making	more	 robust	 claims	 about	 types	 and	 level	 of	 dysregulation	 for	single	 genes	 (fig.	 27,	 28).	 Therefore,	 besides	 observing	 the	 global	 distributions	 of	genes,	we	can	infer	how	differences	between	layers	are	propagated	for	specific	genes.	We	observed	again	that	changes	in	the	transcriptome	are	substantially	promoted	to	the	 translatome	 (fig.	 27A),	 even	 more	 so	 when	 considering	 genes	 with	 significant	slopes	in	both	RNA	and	RPF	datasets	(fig.	26B),	with	the	exception	of	BANF1,	that	lies	in	quadrant	IV.		RPF-only	DEGs	(fig.	27D)	cluster	more	in	the	positive	RPF	quadrants	(I	 and	 IV)	 than	 in	 the	negative	quadrants	 (II	 and	 III),	whereas	RNA-only	DEGs	 (fig.	
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27C)	tend	to	be	more	down-regulated	according	to	EIF4H	levels.		Comparing	slopes	in	RPF	and	proteome	(fig.	28)	it	can	still	be	appreciated	that	a	fraction	of	protein	slopes	changes	direction	in	the	II	quadrant	(fig.	28C,	28D),	underscoring	the	compensatory	effect	 on	 genes	 and	 proteins	 that	 have	 a	 statistically	 significant	 difference	 in	expression.	However,	it	must	be	pointed	out	that	when	comparing	RPF	and	proteome	we	are	limited	by	the	number	of	confidently	identified	proteins	included	in	the	union	of	DEGs,	which	considerably	lowers	the	number	of	available	slopes	to	96.		
	Figure	27:	Quadrant	 graphs	of	 statistically	 significant	 (p	<	0.05)	 slopes	 for	DEGs	 in	total	RNA	and	RPF.	A)	Union	of	all	genes	with	statistically	significant	slopes	in	either	layer	(light	blue).	B)	Intersection	of	genes	with	statistically	significant	slopes	in	both	layers	 (dark	 blue).	 C)	 Genes	 with	 statistically	 significant	 slopes	 only	 in	 total	 RNA	(purple).	D)	Genes	with	statistically	significant	slopes	only	in	RPF	(green).	Red	dotted	lines	 indicate	 diagonals,	 black	 dotted	 lines	 delimit	 quadrants	 (roman	 numbers	displayed	in	each	corner).	
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	Figure	28:	Quadrant	graphs	of	statistically	significant	(p	<	0.05)	slopes	for	DEGs	and	DEPs	in	RPF	and	proteome.	A)	Union	of	all	genes	with	statistically	significant	slopes	in	either	layer	(light	blue).	B)	Intersection	of	genes	with	statistically	significant	slopes	in	both	layers	(dark	blue).	C)	Genes	with	statistically	significant	slopes	only	in	total	RNA	(purple).	D)	Genes	with	statistically	significant	slopes	only	in	RPF	(green).	Red	dotted	lines	 indicate	 diagonals,	 black	 dotted	 lines	 delimit	 quadrants	 (roman	 numbers	displayed	in	each	corner).			Having	 obtained	 slopes	 for	 all	 three	 layers	 of	 DEGs	 for	 which	 we	 have	 statistical	confidence,	 it	 is	 interesting	 to	 observe	 their	 trajectories	 from	 transcriptome	 to	proteome	 (fig.	 29).	 	 Hierarchical	 clustering	 of	 slopes	 identifies	 up	 to	 5	 different	groups	 that	 follow	 similar	 trajectories,	 which	 we	 term	 archetypes.	 An	 expression	archetype	 is	an	 ideal	shape	drawn	by	the	 line	connecting	slopes	 in	the	three	 layers.	Borrowing	 a	 simple	metaphor	 from	 geography,	 we	 can	 identify	 several	 theoretical	archetypes	 that	 resemble	 topographical	 elements,	 e.g.	 genes	whose	 slope	 peaks	 on	
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translation	resemble	hills,	genes	whose	slopes	increase	constantly	are	creeks,	and	so	on.	Out	of	all	the	possible	shapes	we	identify	5	archetypes	that	we	term	cliff	(fig.	30A),	
shore	(fig.	30B),	hill	(fig.	30C),	plateau	(fig.	30D)	and	creek	(fig.	30E)	corresponding	to	the	5	clusters	in	the	heatmap	(fig.	29).			Strikingly,	3	of	these	archetypes	are	enriched	for	different	gene	ontology	categories,	with	 the	 remarkable	example	of	morphogenesis	 and	neuronal	differentiation	 in	 the	
creek	archetype.	This	division	and	representation	serves	as	a	functional	classification	of	genes	according	to	their	gene	expression	patterns,	in	a	way	that	takes	into	account	the	way	they	are	transferred	from	one	layer	to	the	other,	and	captures	novel	patterns	of	information	that	result	from	the	integration	of	all	three	layers	of	expression.	
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	Figure	29:	Trajectories	of	changes	in	expression	across	layers.	Heatmap	of	Z-score	for	slopes	in	each	layer.	On	the	left,	the	schematic	representation	of	archetypes.	
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	Figure	30:	Representation	and	division	of	trajectories	in	their	respective	archetypes,	and	 GO	 enrichments	 for	 hill,	 plateau	 and	 creek	 archetypes.	 The	 black	 line	 in	 the	enrichment	plots	represents	adjP	=	0.05.					
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10.	Determination	of	protein	degradation	rates	and	gene	expression	modeling		Our	combination	of	datasets	probing	different	molecular	layers	allows	to	pose	more	general	 questions	 regarding	 the	 regulation	 of	 gene	 expression	 in	 pluripotency.	 	 By	integrating	 these	 datasets	 with	 a	 proteome-wide	 measurement	 of	 protein	degradation	kinetics,	 two	goals	can	be	achieved:	gaining	a	deeper	understanding	on	how	 differentially	 expressed	 genes	 are	 regulated	 at	 different	 steps,	 and	 verify	 a	mathematical	model	of	gene	expression	with	our	experimental	data.	To	 perform	 a	 proteome-wide	 estimation	 of	 degradation	 rates	 we	 applied	 pulsed-Stable	 Isotope	 Labeling	 of	 Aminoacids	 in	 Culture	 (pSILAC)	 to	 a	 subset	 of	 our	 iPSC	lines.	Briefly,	 in	a	pSILAC	design	cells	grow	in	a	normal	medium	until	a	certain	time	t0.	 At	 t0,	 the	 culture	 medium	 is	 completely	 swapped	 with	 a	 “heavy”	 medium	 that	contains	arginine	and	lysine	aminoacids	labeled	with	heavy,	non-radioactive	nitrogen	and	carbon	isotopes.	Upon	incorporation	in	newly	synthesized	proteins,	these	heavy	aminoacids	confer	to	proteins	a	heavier	molecular	weight.	This	mass	shift	is	visible	by	mass	spectrometry,	thus	allowing	to	make	quantitative	comparisons	between	labeled	and	 unlabeled	 samples.	 Proteins	 are	 harvested	 during	 a	 time-course,	 and	 for	 each	time	point,	a	mixture	of	“light”	or	“old”	proteins,	i.e.	synthesized	in	the	medium	prior	to	t0,	and	“heavy”	or	“new”	proteins,	synthesized	during	the	pulse,	will	be	present	in	the	 lysate.	Processing	 these	proteins	by	mass-spectrometry	yields	 the	simultaneous	identification	and	quantification	of	both	heavy	and	light	proteins.	For	each	protein	at	each	 time	point	 the	 intensity	of	 “heavy”	proteins	 can	be	divided	by	 the	 intensity	of	their	 respective	 “light”	 counterpart,	 with	 the	 advantage	 that,	 since	 each	 of	 these	amounts	 is	relative,	no	normalization	 is	needed.	 In	order	to	use	a	data-independent	approach	 such	 as	 SWATH-MS,	 it	 is	 first	 necessary	 to	 perform	 a	 more	 traditional	Shotgun-MS	 measurement,	 so	 that	 a	 spectral	 library	 for	 pSILAC	 pairs	 can	 be	generated	 and	 used	 to	 instruct	 the	 SWATH-MS	 identification	 and	 quantification	
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routine.	 Log-transformed	heavy-over-light	 (log(H/L+1))	 values	 can	 be	 drawn	 along	the	time	course	in	order	to	infer	the	turnover	rate	of	each	protein,	which	is	the	slope	coefficient	 of	 the	 linear	model	 that	 describes	 the	 relationship	 between	 log(H/L+1)	and	time.	In	other	words,	we	assume	that	there	is	a	 linear	relationship	between	the	increases	in	the	log(H/L	+	1),	measured	at	each	time	point,	and	the	increases	in	time.	The	coefficient	of	this	linear	relationship	(slope)	will	be	the	turnover	rate.		However,	 protein	 turnover	 is	 the	 combined	 effect	 of	 synthesis	 and	 degradation	 of	proteins.	 To	 infer	 degradation	 rates,	 we	 need	 to	 take	 into	 account	 the	 differential	equation	known	for	first-order	kinetics:		 !"!# = %&'( + " ∙ %+,-		where	in	each	interval	dt,	an	amount	of	protein	is	gained,	determined	by	its	synthesis	rate	Ksyn		and	a	different	amount	of	protein	is	lost,	determined	by	its	degradation	rate	Kdeg	and	the	amount	of	protein	at	the	beginning	of	the	interval.	This	equation	can	be	easily	solved	with	the	assumption	that,	at	steady	state,	the	protein	amount	does	not	change:	 !"..!# = 0		 0 = %&'( + ".. ∙ %+,-		which	brings	us	to	a	simple	determination	of	both	constants		
".. = %&'(%+,-	
	 117	
An	 important	 implication	 of	 the	mass	 action	 law	 is	 that	 differences	 in	 steady-state	protein	amounts	are	directly	influenced	by	degradation	rather	than	synthesis.	There	 are	 several	 ways	 to	 determine	 Kdeg	 starting	 from	 heavy	 and	 light	 protein	abundances	in	this	experimental	design.	We	use	a	slightly	modified	version	of	Pratt’s	Relative	Isotope	Abundance	(R.I.A)	(Pratt	et	al.,	2002),	which	assumes	that	the	sum	of	heavy	and	light	proteins	is	equivalent	to	the	steady	state	in	each	sample:		
0. 2. 3. = 45 + 4		Since	 our	 experimental	 design	 entails	 a	 total	 replacement	 of	 L	 aminoacids	 with	 H	ones,	the	L	abundance	is	bound	to	decrease	in	time,	and	from	the	change	of	R.I.A.	of	each	protein	in	time	we	can	infer	the	degradation	rate:		
0. 2. 3. # = 4656 + 46		At	each	time	point,	R.I.A.	will	be	influenced	by	the	degradation	of	the	light	protein	in	the	previous	 time	point,	and	 the	presence	of	newly	synthesized	heavy	proteins.	We	will	 assume	 that	 the	 total	 amount	 of	 proteins,	 represented	 by	 the	 sum	 of	 H	 and	 L	proteins,	is	constant	and	equivalent	to	the	steady	state.		Solving	this	equation	in	continuous	time	leads	to	the	expression	that	links	R.I.A.	and	time	by	means	of	an	exponential	decay:		 0. 2. 3. # = 0. 2. 3. #0 ∙ 	89:;<=∙6		Where	R.I.A.(t0)	is	R.I.A.	at	the	starting	point.	
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It	is	reasonable	to	assume	that,	at	the	beginning	of	the	time	series,	there	are	no	heavy	isotopes,	so	that	R.I.A.(t0)	is	equal	to	1.	At	an	infinite	time,	R.I.A.	decays	exponentially	from	1	to	0.	Therefore,	Kdeg	can	be	simply	obtained	by	fitting	an	exponential	model	to	experimental	values	of	R.I.A.	over	time,	or	fitting	a	linear	model	to	log(R.I.A.)	values	in	time.	 	 An	 initial	 pilot	 experiment	was	 performed	 on	 a	 single	 control	 iPSC	 line	 (fig.	31A),	harvesting	proteins	at	1.5,	4.5	and	13.5	hours	as	done	by	Schwannhausser	and	colleagues	 (Schwanhausser	 et	 al.,	 2011),	 in	 order	 to	 perform	 a	 preliminary	assessment	of	how	heavy	aminoacids	were	impacting	cell	culture,	and	the	resolution	of	data	that	can	be	obtained.	Each	sample	was	prepared	in	duplicate.		Indeed,	the	number	of	MS2	spectra	(i.e.	spectra	of	the	fragment	ions,	identified	in	the	second	part	 of	 the	 analysis	 upon	precursor	 selection	 in	MS1)	with	 a	 SILAC	pattern	that	 can	 be	 identified	 and	 quantified	 increases	 with	 time	 and	 shows	 consistency	between	duplicates,	suggesting	a	good	dynamic	range	and	a	regular	heavy	aminoacid	incorporation	rate	in	the	analyzed	timeframe	(fig.	31B).	Interestingly,	we	found	that	proteins	related	 to	cell	adhesion	had	a	high	 turnover	when	compared	to	 the	rest	of	the	proteins	(fig.	32)	in	iPSCs,	an	observation	that	dovetails	with	the	regulatory	role	of	 the	 cell-extrinsic,	 contact-dependent	 signals	 that	 regulate	 pluripotency.	 This	dataset	was	used	to	validate	a	novel	computational	tool,	TRIC	(Röst	et	al.,	2016),	that	addresses	the	need	to	reliably	quantify	several	SWATH-MS	datasets	simultaneously,	especially	when	measurements	of	the	same	protein	must	be	performed	across	many	samples.	 This	 pSILAC	 dataset	 represented	 a	 valuable	 opportunity	 to	 verify	 the	performance	of	TRIC	compared	with	more	traditional	alignment-based	methods.		
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	Figure	31:	Experimental	design	and	performance	of	the	pSILAC	pilot	experiment.	A)	scheme	describing	the	experimental	setup:	cells	growing	in	light	(L)	medium	receive	a	 complete	 medium	 exchange	 with	 heavy	 (H)	 medium	 at	 time	 0.	 Proteins	 are	harvested	at	1.5,	4.5	and	13.5	hours,	with	each	 time	point	 containing	an	 increasing	number	 of	 heavy-labeled	proteins	 (orange	 circles).	Mass	 spectra	with	 pSILAC	pairs	show	the	same	patterns,	with	a	positive	shift	in	mass	caused	by	heavy	aminoacids.	B)	MS2	spectra	with	a	SILAC	pattern	measured	by	Shotgun-MS,	displaying	the	expected	pattern	of	increase	in	aminoacid	incorporation.			
	Figure	 32:	Degradation	 rates	 of	 adhesion	molecules	 are	 higher	 than	 the	 proteome-wide	average.	Redrawn	from	(Röst	et	al.,	2016).	
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	We	 then	 chose	a	 subset	of	 iPSC	 lines	 (3	WBS	 lines,	 3	 controls	 and	2	7dup	 lines)	 to	profile	extensively	the	effect	of	protein	degradation	caused	by	the	7q11.23	CNV.		In	 order	 to	 avoid	 confounding	 effects	 imputable	 to	 non-linearity	 of	 cell	 duplication	reaching	 confluence,	 we	 decided	 to	 sample	 a	 narrower	 time	 frame	 (2	 to	 8	 hours),	which	is	below	half	of	the	duplication	time	for	iPSCs	(~17	hours)	and	should	render	the	 effect	 of	 cell	 duplication	 negligible.	 Moreover,	 we	 decided	 to	 increase	 the	precision	of	our	measurements	by	preparing	each	sample	in	triplicate,	resulting	in	96	pSILAC	proteomes.	We	reliably	identified	3434	proteins	with	a	pSILAC	pattern	in	at	least	3	samples,	out	of	which	2535	proteins	have	enough	data	points	to	fit	the	R.I.A.	exponential	model	and	determine	Kdeg	in	at	least	3	samples.	Globally,	degradation	rates	show	a	small	but	significant	(p	=	0.023	for	an	ANOVA	on	median	Kdeg)	trend	that	is	inversely	correlated	with	CNV	dosage	(fig.	33A).		If	we	limit	our	observations	to	proteins	for	which	we	can	construct	an	exponential	decay	model	with	a	good	fit,	i.e.	with	a	minimum	of	6	data	points	and	a	relative	error	of	the	model	below	0.1,	we	obtain	a	subset	of	698	proteins.	This	subset,	however,	leads	to	a	similar	conclusion	on	the	global	distribution	(fig.	33B),	with	significant	differences	in	median	Kdeg	(ANOVA	p	=	0.019).		
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	Figure	33:	Boxplot	of	distributions	of	Kdeg	values	per	sample.	A)	Distribution	of	Kdeg	for	all	proteins.	B)	Distribution	of	Kdeg	for	proteins	with	a	good	exponential	fit.	In	both	cases,	the	trend	is	inversely	correlated	with	CNV	dosage.			
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When	subsetting	our	Kdeg	dataset	with	all	 the	DEGs,	we	reproduce	again	the	 inverse	trend	in	degradation	(fig.	33).		
	Figure	34:	Distribution	of	Kdeg	values	for	DEGs	with	a	good	exponential	fit.			Unfortunately,	no	protein	located	in	the	second	quadrant	nor	in	the	fourth	quadrant	of	 the	proteome	 comparisons	 (fig.	 28C,	 28D)	was	 reliably	 identified	 in	 this	dataset,	leaving	open	the	question	whether	changes	in	degradation	can	explain	inverse	trends	in	translation	and	protein	abundance.		Moreover,	degradation	rates	for	proteins	that	are	differentially	expressed	and	 follow	gene	dosage	 still	maintain	 the	 inverse	 trend	(fig.	 35A,	 35B),	which	 suggests	 that	 the	 final	 protein	 abundance	 is	 not	 buffered	 by	degradation.	Indeed,	the	fact	that	the	expression	trend	persists	independently	of	the	global	effect	on	degradation	implies	that	it	 is	slightly	affected	by	it	 in	a	manner	that	escapes	 straightforward	 explanations.	 The	 variability	 in	 Kdeg	 estimation	 between	samples	 is	 again	 evident,	 albeit	 smaller	 than	 the	 variability	 in	 steady	 state	 protein	
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quantification,	still	posing	the	question	on	what	portion	of	the	missing	link	between	one	dataset	and	the	other	can	be	ascribed	to	technical	issues.		
	Figure	35:	Trends	 in	protein	degradation	and	protein	abundance.	A)	Heatmap	of	Z-scores	of	Kdeg	 for	protein	DEGs.	Only	Kdeg	models	with	a	good	exponential	 fit	were	selected.	B)	Heatmap	of	Z-scores	of	protein	intensity	for	the	same	subset	of	proteins.		Although	 Kdeg	 values	 do	 not	 seem	 to	 explain	 changes	 in	 protein	 abundance	 of	differentially	 expressed	 genes,	 we	 probed	 their	 explanatory	 value	 when	 including	them	 in	 a	 simple	 gene	 expression	 model	 derived	 from	 the	 aforementioned	 mass	action	 law.	 In	 fact,	we	 can	 integrate	data	 from	 the	protein	dataset,	 the	RPF	dataset	and	the	Kdeg	dataset	in	a	simple	equation	derived	from	our	steady-state	assumption:	
".. = %&'(%+,-	Where	Ksyn	can	be	represented	by	RPF	abundance	values,	which	serve	as	a	proxy	for	the	rate	of	protein	synthesis,	while	Pss	 is	derived	 from	the	 label-free	quantification	used	for	differential	expression	and	slope	computation:	
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4>?	@A#8AB@#C = 0">%+,-	The	ratio	of	RPF	and	Kdeg	is,	in	other	words,	the	“estimated”	amount	of	protein	that	takes	into	account	experimental	values	of	translation	and	degradation.		In	 fact,	 RPF	do	 provide	 a	 better	 correlation	with	 protein	 abundance	 than	RNA	 (fig.	36A,	36B),	consistently	with	what	is	reported	in	literature	(Ingolia	et	al.,	2011).		
Figure	36:	Global	correlation	between	proteome	and	RNA	or	RPF	for	a	representative	sample.	 A)	 Scatterplot	 of	 log(RNA	 FPKM)	 and	 protein	 intensity.	 B)	 Scatterplot	 of	log(RPF	FPKM)	and	protein	intensity.				A	good	model	of	 gene	expression	 should	be	able	 to	minimize	 the	distance	between	estimated	 and	 measured	 protein	 abundances.	 We	 calculated	 correlation,	 mean	 of	squared	 residuals	 and	mean	 relative	 error	 for	 a	 linear	model	 constructed,	 in	 each	sample,	within	the	log2	of	estimated	protein	abundance	and	the	experimental	protein	abundance	as	measured	by	SWATH-MS.	Each	model	was	constructed	both	with	and	without	Kdeg.	Contrary	to	our	expectations,	by	including	experimentally-derived	Kdeg	in	the	model,	we	do	not	observe	an	increase	in	correlation,	but	rather	a	remarkable	drop	when	 using	 the	whole	 proteome	 (fig.	 37).	 Correlation	 tends	 to	 increase	 upon	restricting	the	model	by	increasing	the	minimum	number	of	peptides	used	to	quantify	
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each	 protein,	 and	 reaches	 a	 plateau	when	 using	 proteins	 quantified	 by	 at	 least	 24	peptides.			
	Figure	 37:	 Spearman	 correlation	 plot	 of	 each	model	 using	 all	 proteins.	 Each	 point	represents	a	sample.	Blue	dots:	model	with	Kdeg.	Red	dots:	model	without	Kdeg.	Solid	lines	are	smoothing	splines	calculated	by	local	regression	(LOESS).	Transparent	areas	represent	the	95%	confidence	interval	of	the	spline.			A	 similar	difference	 can	be	observed	 for	 the	mean	 relative	 error	 (fig.	 38A)	 and	 the	median	 of	 squared	 residuals	 (fig.	 38B)	 in	 all	 proteins:	 when	 including	 Kdeg	 in	 the	model,	 its	precision	decreases,	although	when	restricting	the	model	with	more	than	20-21	peptides	the	trend	is	reversed.		To	exclude	 that	 this	was	due	 to	 the	presence	of	Kdeg	values	obtained	by	suboptimal	fitting,	we	 restricted	 our	model	 to	 the	 aforementioned	 set	 of	 proteins	with	 a	 good	exponential	fit	(fig.	39).	Interestingly,	both	correlation	values	for	the	whole	well-fitted	proteome	 (i.e.	 minimum	 1	 peptide)	 increase	 compared	 to	 the	 model	 built	 on	 all	proteins,	 but	 the	 inclusion	 of	 Kdeg	 does	 not	 seem	 to	 improve	 it,	 rather	 slightly	decrease	 it.	 Mean	 relative	 error	 (fig.	 40A)	 is	 substantially	 identical,	 but	 starts	decreasing	when	 filtering	 from	 a	minimum	of	 13	 peptides.	 The	 only	 parameter	 for	which	 Kdeg	 seems	 to	 improve	 the	 precision	 of	 the	model	 is	 the	median	 of	 squared	residuals	 (fig.	 39B),	 for	 which	 a	 consistent	 trend	 is	 maintained	 along	 all	 the	thresholds.		
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	Figure	38:	Error	plots	of	 each	model	with	 and	without	Kdeg.	A)	Mean	 relative	 error	plot.	B)	Median	of	squared	residuals	plot.	Blue	dots:	model	with	Kdeg.	Red	dots:	model	without	Kdeg.	Solid	lines	are	smoothing	splines	calculated	by	local	regression	(LOESS).	Transparent	areas	represent	the	95%	confidence	interval	of	the	spline.		
	Figure	39:	Spearman	correlation	plot	of	each	model	using	only	proteins	with	a	good	exponential	fit.	Each	point	represents	a	sample.	Blue	dots:	model	with	Kdeg.	Red	dots:	
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model	without	Kdeg.	 Solid	 lines	are	smoothing	splines	calculated	by	 local	 regression	(LOESS).	Transparent	areas	represent	the	95%	confidence	interval	of	the	spline.	
	Figure	40:	Error	plots	of	each	model	with	and	without	Kdeg	using	only	proteins	with	a	 good	 exponential	 fit.	 A)	Mean	 relative	 error	 plot.	 B)	Median	 of	 squared	 residuals	plot.	 Blue	 dots:	 model	 with	 Kdeg.	 Red	 dots:	 model	 without	 Kdeg.	 Solid	 lines	 are	smoothing	 splines	 calculated	 by	 local	 regression	 (LOESS).	 Transparent	 areas	represent	the	95%	confidence	interval	of	the	spline.		These	results	indicate	that,	in	this	system,	the	role	of	protein	degradation	as	assessed	by	pSILAC	does	not	have	an	impact	on	the	relationship	between	measured	amounts	of	 proteins	 and	 their	 estimation	 by	 ribosome	 profiling,	 hinting	 at	 other	 possible	explanations	for	the	~0.4	of	missing	correlation.		
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11.	Generation	of	monoclonal	lines	for	neuronal	differentiation		Given	the	intriguing	neuro-cognitive	phenotypes	of	WBS	and	7dup	patients,	and	the	roles	 of	 translation	 regulation	 in	 neuronal	 development,	 we	 established	 a	 scalable	and	reproducible	platform	for	neuronal	differentiation	of	our	iPSC	lines.	Starting	from	the	NGN2	 neuronal	 differentiation	 protocol	 (Zhang	 et	 al.,	 2013),	 that	makes	 use	 of	two	 lentiviral	 vectors	 to	 over-express	 an	 inducible	 transcription	 factor	 that	 drives	cortical	neuronal	differentiation,	we	subcloned	37	iPSC	lines	from	9	patients	(3	WBS,	1	atypical	WBS,	3	controls,	2	7dup)	by	single-cell	cloning.	The	original	NGN2	protocol	uses	an	activator	lentivirus,	containing	the	reverse	tetracycline	transactivator	(rtTA)	constitutively	 expressed	 under	 the	 control	 of	 the	 UbC	 promoter,	 and	 an	 effector	lentivirus,	 containing	 an	NGN2-P2A-EGFP-T2A-Puro	 cDNA	 under	 the	 control	 of	 the	tetracycline	 responsive	 element.	 In	 this	 protocol	 cells	 are	 infected	 with	 both	lentiviruses,	 induced	 one	 day	 after	 infection	 and	 selected	 with	 puromycin	 the	 day	after.	The	combination	of	both	NGN2	and	rtTA	allows	to	effectively	select	only	cells	in	which	 both	 viruses	 are	 properly	 integrated	 and	 expressed	 by	 antibiotic	 selection.	Upon	 21	 days	 of	 induction	 of	 NGN2,	 infected	 iPSCs	 become	 cortical	 glutamatergic	neurons.	However,	 this	 approach	has	 the	 important	 limitation	 that	 a	 viral	 infection	should	 be	 carried	 out	 for	 each	 experiment,	 possibly	 introducing	 biases	 due	 to	differences	in	batches	of	viral	particles,	and	requiring	cumbersome	amounts	of	viral	particles	for	large-scale	experiments.	To	circumvent	this	limitations,	we	infected	9	lines	with	both	lentiviruses	but	did	not	induce	them,	letting	them	grow	until	they	were	~5x106		(fig.	41).		Upon	reaching	this	number,	infected	iPSCs	were	sorted	as	single	cells	in	96-well	plates,	selected	based	on	the	round	morphology	of	colonies	and	gradually	expanded.	Selected	lines	were	then	induced	for	one	day	adding	doxycyline	to	the	medium:	if	cells	express	GFP	(fig.	42A),	they	have	received	both	lentiviral	constructs	and	very	likely	originate	from	the	same	
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clone.	3	to	5	GFP-positive	lines	were	selected	and	expanded,	further	being	stabilized	and	characterized.	These	lines	have	the	advantage	of	being	already	infected	with	the	NGN2	dual	system	in	a	homogeneous	way,	so	that	they	can	be	expanded	to	a	virtually	unlimited	extent	in	order	to	perform	a	wide	array	of	high-throughput	experiments.		
	Figure	 41:	 Derivation	 of	 monoclonal	 NGN2	 lines.	 Schematic	 representation	 of	 the	procedure.	 iPSC	 lines	 deriving	 from	 9	 patients	 are	 infected	 with	 both	 lentiviral	particles,	expanded	and	sorted	as	single	cells.	Single	cell-deriving	lines	are	expanded	and	induced;	only	GFP-positive	lines	are	kept	for	further	analysis.	Red:	WBS,	orange:	atypical	WBS,	gray:	control,	blue:	7dup.			As	 a	 confirmation	 that	 selected	 monoclonal	 lines	 are	 able	 to	 produce	 cortical,	glumatergic	 neurons,	 they	 were	 induced	 for	 21	 days	 and	 stained	 for	 a	 panel	 of	neuronal	 markers	 that	 include	 general	 neuronal	 antigens	 (TUJ1,	 MAP2),	glutamatergic	markers	(VGLUT),	and	cortical	markers	(SATB2,	TBR1).	This	system	has	already	been	implemented	in	the	lab	for	a	series	of	different	projects,	all	 entailing	 high-throughput	 experimental	 setups	 such	 as	 RNA-seq,	 ChIP-seq,	 drug	screenings.	 An	 important	 caveat	 of	 this	 protocol	 is	 that,	 in	 order	 to	 allow	 synapse	maturation,	 NGN2-induced	 neurons	 must	 be	 co-cultured	 with	 replication-deficient	mouse	 astrocytes.	 However,	 as	 it	 was	 the	 case	 for	 iPSCs,	 murine	 cells	 add	 an	important	 confounding	variable	 in	high-throughput	experiments.	A	concerted	effort	
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in	the	 lab	 is	being	carried	out	to	replace	astrocyte	co-culture	by	using	an	astrocyte-conditioned	medium,	 that	 contains	 the	astrocyte	 secretome,	necessary	 for	neuronal	trophic	functions,	but	does	not	include	murine	cells.	These	monoclonal	lines,	and	the	technical	 advancements	 that	 will	 be	 built	 upon	 them,	 constitute	 a	 fundamental	platform	for	all	our	future	efforts	to	study	gene	expression	in	depth	in	a	cell	type	that	is	highly	relevant	to	understand	the	molecular	mechanisms	of	WBS	and	7dup.		
	Figure	 42:	 Characterization	 of	 NGN2	monoclonal	 cell	 lines.	 A)	 Induced	monoclonal	iPSCs	 express	 GFP.	 Magnification	 20X	 in	 a	 live	 brightfield	 videomicroscope.	 B)	expression	pattern	of	 the	mature	neuronal	marker	MAP2	and	glutamatergic	marker	VGLUT.	Magnification	40X.	C)	expression	pattern	of	the	cortical	markers	TBR1	and	D)	SATB2.	Magnification	20X.	E)	Expression	pattern	of	mature	neuronal	markers	MAP2	and	F)	TUJ1.	Magnification	20X.	All	 pictures	 of	 stainings	 have	been	 acquired	 at	 the	confocal	microscope.			 	
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Discussion	and	future	directions		
1.	The	analysis	of	different	layers	of	gene	expression	reveals	differences	in	gene	
regulation	at	the	pluripotent	state		To	our	knowledge,	this	is	the	first	attempt	at	measuring,	in	the	context	of	a	complex	set	 of	 developmental	 disorders	 at	 the	pluripotent	 state,	 three	 fundamental	 steps	 in	gene	expression	regulation:	transcription,	translation	and	protein	degradation.	By	profiling	 the	 transcriptome,	 translatome	and	proteome	of	patient-derived	 iPSCs,	we	 managed	 to	 greatly	 expand	 our	 view	 on	 how	 differences	 in	 gene	 expression	originating	at	the	RNA	level	are	propagated	towards	the	protein	level	in	pluripotency.	A	first	interesting	finding	pertains	to	the	exclusivity	of	some	DEGs	to	a	specific	layer.	All	DEGs	found	in	the	total	RNA	and	in	the	RPF	dataset	were	consistently	mapped	in	both	 libraries,	 meaning	 their	 exclusivity	 is	 not	 due	 to	 technical	 artifacts.	 The	proteome	dataset,	however,	has	a	much	smaller	coverage	of	the	repertoire	of	proteins	that	correspond	to	translated	mRNAs,	making	this	comparison	more	difficult.			The	 regulation	 at	 different	 levels	 of	 gene	 expression	 is	 being	 widely	 studied	 at	 a	genome-wide	 scale	 since	 the	diffusion	of	 precise	 and	 reproducible	high-throughput	technologies	 for	transcriptome,	 translatome	and	proteome	quantification	(Ingolia	et	al.,	 2011;	 Vogel	 and	 Marcotte,	 2012).	 Different	 groups,	 in	 the	 laste	 decade,	 have	attempted	 to	 give	 a	 definitive	 answer	 to	 the	 dominance	 of	 one	mode	 of	 regulation	over	the	other	(Jovanovic	et	al.,	2015;	Li	et	al.,	2014;	Schwanhausser	et	al.,	2011),	by	proposing	different	 comparisons	 of	 cellular	 abundances	 of	 transcripts	 and	proteins	and	using	different	statistical	models	and	error-calibration	strategies.		Although	a	consensus	has	not	yet	been	reached,	transcription	is	considered	to	shape	the	 proteome	 at	 steady	 state	 (reviewed	 in	 Liu	 et	 al.,	 2016).	 However,	 changes	 in	translation	rate	can	be	quite	rapid	and	serve	as	an	adaptive	response	to	changes	 in	
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the	environment,	such	as	nutrient	starvation	or	external	stimulation	(Jovanovic	et	al.,	2015).	 Importantly,	 transcription	 factors	are	mostly	under	 translation	control	upon	stimulation	(Jovanovic	et	al.,	2015).	While	it	is	true	that	our	iPSC	lines	grow	at	steady	state,	 they	 represent	 a	 very	 early	 stage	 of	 development	 that	 is	 bound	 to	 change	dramatically	 in	a	 relatively	short	 time	 frame,	by	giving	rise	 to	all	 three	germ	 layers	upon	progressive	fate	acquisition.	The	fact	that	iPSC	represent	a	cellular	snapshot	of	a	highly	 dynamic	 process	 that	 is	 artificially	 suppressed	 by	 culture	 conditions	 puts	 in	perspective	the	notion	of	“steady	state”.		In	this	thesis	I	have	tried	to	show	that,	already	by	performing	differential	expression	analysis	in	iPSCs,	we	find	that	some	genes	are	targeted	mostly,	 if	not	exclusively,	by	different	 regulatory	 mechanisms	 at	 specific	 layers.	 These	 genes	 are	 particularly	interesting	 in	 that	 they	 have	 been	 linked	 to	 molecular	 pathways	 involved	 in	 the	clinical	manifestations	of	WBS	or	7dup.		For	 instance,	 among	 RNA-exclusive	 genes	 we	 found	 that	 SOX3	 is	 differentially	expressed,	being	more	highly	expressed	in	WBS	samples	and	lower	in	7dup.		
SOX3,	a	member	of	the	SOX	(SRY-related	Homeobox)	family	of	genes	situated	on	the	X	chromosome,	 encodes	 a	 SRY-box	 transcription	 factor	 that	 has	 been	 linked	 to	hormonal	deficiencies	(Woods	et	al.,	2005),	growth	defects	and	intellectual	disability	(Jourdy	et	al.,	2016).		SOX3	is	one	of	the	earliest	markes	of	neuronal	differentiation,	and	studies	in	animal	models	 have	 shown	 that	 it	 acts	 in	 a	 tightly	 regulated	 temporal	 fashion.	 More	specifically,	 in	 pluripotent	 cells	 SOX2,	 another	 member	 of	 the	 SOX	 family,	 binds	proneural	genes	marked	by	a	bivalent	chromatin	signature,	and	pluripotency	genes	marked	by	an	activatory	signature.	During	differentiation,	SOX3	recognizes	bivalent	proneural	 genes	 bound	 by	 SOX2,	 and	 converts	 the	 signature	 to	 a	monovalent	 one,	thus	 activating	 genes	 that	 drive	 the	 transition	 from	 pluripotency	 to	 a	 neuronal	
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precursor	However,	SOX2	is	simultaneously	binding	another	set	of	bivalently	marked	genes,	 which	 in	 turn	 promote	 neuronal	 maturation,	 and	 keeps	 them	 repressed.	Further	into	differentiation,	SOX3	is	bound	by	SOX11,	which	in	turn	converts	bivalent,	SOX3-bound	marks	 to	monovalent,	 activatory	 ones,	 thus	 allowing	 differentiation	 to	continue	 (Bergsland	 et	 al.,	 2011;	 Bylund	 et	 al.,	 2003).	 Interestingly,	 SOX3	 is	antagonized	 by	 NGN2	 (Bylund	 et	 al.,	 2003),	 the	 same	 transcription	 factor	 whose	ectopic	 expression	 drives	 neuronal	 differentiation	 in	 our	 system.	 Studies	 on	 mice	models	have	demonstrated	that	SOX3	is	necessary	to	regulate	the	formation,	during	development,	of	the	hypothalamo-pituitary	axis	and	the	dorsal	telecephalon	(Rizzoti	et	 al.,	 2004).	 Tandem	 duplications	 of	 the	 locus	 encompassing	 SOX3	 have	 been	associated,	 in	 humans,	 to	 combined	 hormone	 pituitary	 deficiencies	 (CPHD),	craniofacial	 dysmorphisms,	 growth	 defects	 and	 mild	 intellectual	 disability	(Laumonnier	 et	 al.,	 2002),	 which	 are	 clinical	 manifestations	 that	 partially	 overlap	with	those	of	WBS	patients.		Another	 example	 of	RNA-exclusive	 differences	 across	 samples	 affects	RPS16,	which	encodes	 a	 protein	 of	 the	 40S	 ribosomal	 subunit,	 and	 MRPL12,	 which	 encodes	 a	protein	of	the	39S	mitochondrial	ribosome	subunit.	The	translation	efficiency	of	both	
RPS16	 and	MRPL12	 decreases	 upon	 EIF4H	 knockdown,	 again	 suggesting	 a	 role	 for	EIF4H	 in	 the	 regulation	 of	 their	 translation.	 Interestingly,	MRPL12	mutations	 have	been	 associated	 to	 growth	 retardation	 (Serre	 et	 al.,	 2013)	 and	 nonsyndromic,	autosomal	 deafness	 (Li	 et	 al.,	 2002),	 which	 partially	 overlaps	with	 another	 clinical	feature	of	WBS	patients,	sensorineural	hearing	loss.	Among	DEGs	 that	were	 found	exclusively	 in	 the	RPF	dataset	we	 found	Cytoplasmic	Binding	 Element	 –	 2	 (CPEB2),	 the	 human	 homolog	 of	 Drosophila	 Orb2,	 an	 RNA-binding	 protein	 whose	 expression	 is	 important	 for	 polarity	 formation	 in	 early	embryogenesis	 and	 nervous	 system	 development(Hafer	 et	 al.,	 2011).	 Mammalian	
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CPEB2	has	been	shown	to	act	as	a	 repressor	of	 translation	of	 the	hypoxia-inducible	factor	 HIF-1a	 during	 normoxya	 conditions	 (Chen	 and	 Huang,	 2012)	 and	 is	 highly	expressed	 in	 the	 CNS,	 where	 it	 binds	 the	 mRNAs	 of	 beta-catenin	 and	 CAMKIIa	(Turimella	et	al.,	2015).	In	 our	 samples,	 CPEB2	 is	 lowly	 expressed	 at	 the	 RNA	 level,	 and	 it	 is	 interestingly	almost	 exclusively	 translated	 in	 7dup	 iPSCs.	 Moreover,	 its	 translation	 efficiency	remarkably	and	consistently	decreases	upon	EIF4H	knockdown,	possibly	hinting	at	a	role	for	CPEB2	in	keeping	the	translation	of	selected	targets	at	a	constant	level.	Another	gene,	ankyrin-repeat	domain	containing	1	(ANKRD1),	also	known	as	Cardiac	ankyrin	 repeat	 protein	 (CARP)	 has	 been	 involved	 in	 the	 aetiology	 of	 dilated	cardiomyopathy	(Moulik	et	al.,	2009),	a	cardiovascular	disease	with	a	strong	genetic	component	in	which	the	left	ventricle	becomes	dilated	and	causes	heart	failure.	It	has	also	 been	 observed	 that	 ANKRD1	 is	 up-regulated	 in	 left	 ventricles	 of	 patients	with	cardiac	failure	(Zolk	et	al.,	2002)	compared	to	healthy	heart	biopsies.		ANKRD1	binds	sarcomeric	proteins	such	as	Titin	and	Myopalladin	 in	human	myocytes	and	 it	has	a	dual	role:	in	the	Z-disc	of	sarcomeres,	it	functions	as	a	stretch	sensor	,	whereas	upon	interaction	with	phosphorylated	ERK1/2	and	GATA4,	 it	 translocates	 to	 the	nucleus,	where	it	acts	as	a	transcriptional	repressor	(Zhong	et	al.,	2015).	As	described	in	the	introduction,	 cardiac	 failure	due	 to	heart	malformations	 is	a	 shared	burden	of	both	WBS	 and	 7dup	 patients	 and	 one	 of	 the	 most	 frequent	 causes	 of	 death	 for	 WBS	patients	(Pober,	2010).		Among	DEPs,	RPL10	 is	of	particular	 interest.	RPL10	encodes	 the	 ribosomal	protein	L10,	which	is	a	highly	conserved	component	of	the	large	ribosomal	subunit.	RPL10	is	necessary	for	the	joining	of	60S	at	initiation	(Eisinger	et	al.,	1997).	Five	distinct	mutations	within	RPL10	have	been	described	 in	 families	with	X-linked	intellectual	 disability	 (XLID)	 so	 far:	 three	 in	 the	 N-terminal	 (p.K78E,	 p.G161S	 and	
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p.A64V)	and	two	in	the	C-terminal	region	(p.L206M	and	p.H213Q).	Both	p.K78E	and	p.G161S	mutations	are	suggested	as	a	primary	cause	of	X-linked	syndromic	disorder	hallmarked	by	microcephaly,	growth	retardation,	seizures	and	minor	facial	anomalies	(Brooks	 et	 al.,	 2014).	 The	 C-terminal	 mutations	 were	 identified	 in	 families	 with	autistic	features	and	moderate	to	severe	ID,	or	normal	cognitive	development	(Klauck	et	al.,	2006).	RPL10	follows	a	trend	that	is	inversely	correlated	with	WBSCR	dosage.		Another	protein	related	to	translation,	the	eukaryotic	 initiation	factor	2D	(EIF2D)	is	expressed	with	a	trend	that	is	inversely	correlated	between	RPF	and	protein,	EIF2D	can	perform	the	GTP-independent	delivery	of	the	initiator	tRNAMet	(Dmitriev	et	al.,	2010)	a	key	step	of	translation	initiation.	Its	opposing	levels	with	EIF4H	dosage	raise	the	interesting	hypothesis	that	changes	in	a	translation	initiation	factor	may	be	counteracted	 by	 opposing	 changes	 in	 other	 initiation	 factors,	 so	 as	 to	 balance	 the	initiation	kinetics.		All	 these	 findings	 will	 have	 to	 be	 adequately	 validated	 by	 independent	 orthogonal	techniques	which	can	further	expand	the	understanding	of	these	modes	of	regulation.	While	 differences	 at	 the	 RNA	 level	 can	 be	 easily	 validated	 by	 RT-qPCR	 or	 by	Nanostring,	 and	 differences	 at	 the	 protein	 level	 can	 be	 validated	 by	 targeted	mass	spectrometry	approaches	 such	as	 Selected	Reaction	Monitoring	 (SRM)	or	 antibody-based	 techniques,	 the	 validation	 of	 differences	 in	 translation	 activity	 requires	additional	steps.	We	have	already	started	measuring	polysome	profiles	obtained	from	the	 same	 cells	 that	 were	 used	 in	 this	 study.	With	 polysome	 profiling	 we	 can	 infer	global	 changes	 in	 polysome	 or	monosome	 density	 and,	more	 importantly,	 quantify	the	RNA	present	in	each	fraction	of	the	gradient.	Changes	in	the	abundance	of	specific	mRNAs	across	fractions	and	across	samples	will	not	only	indicate	whether	the	mRNA	is	differentially	translated,	but	also	what	phase	of	 translation	 is	being	preferentially	regulated	for	that	mRNA.		
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	Although	we	can	 find	differentially	expressed	genes	 in	every	 layer,	 their	expression	profiles	are	admittedly	variable	among	samples.	This	is	especially	true	when	looking	at	 differences	 in	 gene	 expression	 at	 the	 total	 RNA	 level	 (see	 Results).	 Every	differential	 gene	 expression	 analysis	 has	 then	 to	 be	 evaluated	 carefully	 and	 even	more	carefully	validated	in	order	to	make	well-grounded	claims	about	the	extent	and	type	of	dysregulation.		Besides	 technical	 issues	 that	 can	 be	 accounted	 for	with	 the	 inclusion	 of	 additional	technical	replicates,	the	intrinsic	variability	of	different	human	genetic	and	epigenetic	backgrounds	creates	confounding	effects,	such	as	masking	differential	expression	by	means	 of	 inflating	 variance,	which	 dramatically	 reduces	 the	 confidence	with	which	genes	can	be	identified	as	differentially	expressed.	There	are	two	ways	to	circumvent	this	 problem.	 The	 first	 one	 is	 to	 increase	 the	 statistical	 power	 of	 the	 analysis	 by	processing	 more	 samples	 and	 including	 biological	 replicates.	 Two	 human	 studies	aimed	 at	 integrating	 transcriptome,	 translatome	 and	 proteome	 (Battle	 et	 al.,	 2015;	Cenik	et	al.,	2015)	make	use	of	a	large	cohort	of	well	characterized	lymbphoblastoid	cell	 lines	 	 (LCL)	 to	study	the	regulatory	consequences	of	human	variation,	with	one	study	making	 use	 of	 at	 least	 2	 replicates	 per	 sample	 (Cenik	 et	 al.,	 2015).	 Although	their	biological	question	is	remarkably	different	from	ours,	and	requires	more	power	to	 observe	 smaller	 differences,	 they	 are	 able	 to	 robustly	 identify	 differences	 in	regulatory	variation	 in	all	 three	 layers.	That	being	said,	since	our	work	involves	the	use	of	patient-derived	 iPSCs,	 the	recruitment	of	new	WBS	or	7dup	patients	and	 the	reprogramming	 and	 establishment	 of	 their	 iPSC	 lines	 requires	 a	 remarkable	 effort,	whereas	LCLs	are	readily	available.	As	for	biological	replicates,	a	possibility	would	be	to	include	different	clones	of	the	same	patient;	however,	it	is	still	unclear	whether	the	analysis	 of	 different	 clones	 would	 lead	 to	 the	 discovery	 of	 differentially	 expressed	
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genes	 that	 arise	 due	 to	 different	 genomic	 backgrounds	 rather	 than	 different	conditions.	Alternatively,	 general	 confounding	 effects	 in	 the	 data	 could	 be	 addressed	computationally,	 making	 use	 of	 differential	 gene	 analysis	 pipelines	 tailored	 to	 the	analysis	of	heterogeneous	samples.	A	very	recently	published	statistical	tool,	ELTseq	(Xu	 and	 Chen,	 2016),	 has	 been	 proposed	 for	 the	 analysis	 of	 typically	 diverse	specimens	such	as	cancer	primary	samples.	As	opposed	to	more	traditional,	negative	binomial	 distribution-based	 tools	 such	 as	 edgeR	 (used	 in	 this	 study)	 and	 DEseq,	which	work	under	the	assumption	that	each	group	of	samples	pertains	to	a	series	of	biological	 replicates,	 ELTseq	 treats	 each	 sample	 individually	 without	 making	assumptions	 on	 the	 distribution	 of	 read	 counts.	 The	 types	 of	 analysis	 presented	 in	this	work	 therefore	 take	 at	 face	 value	 the	 differential	 expression	 analysis	 that	was	performed,	 with	 the	 assumption	 that	 human	 variability	 is	 indeed	 a	 major	confounding	effect,	and	we	will	try	in	the	near	future	to	assess	the	extent	to	which	the	variability	we	observe	is	due	to	technical	artifacts	on	top	of	human	diversity.	Another	important	improvement	in	the	analysis	of	ribosome	profiling	experiments	is	being	 carried	 forward	 by	 the	 recent	 emergence	 of	 tools	 that	 perform	 differential	translation	analysis,	starting	from	count	data,	such	as	Xtail	(Xiao	et	al.,	2016),	Anota	(Larsson	 et	 al.,	 2011)	 or	 RiboDiff	 (Zhong	 et	 al.,	 2016).	 In	 fact,	 while	 count-based	methods	for	differential	expression	analysis	use	discrete	statistics,	metrics	such	as	TE	or	 log2(FC)	 represent	 a	 fraction	 of	 two	 integers	 and	 should	 be	 dealth	 with	 using	continuous	probability	distributions.	This,	in	turn,	makes	methods	based	on	negative	binomial	 distributions	 not	 suitable.	 In	 the	 near	 future,	 we	 will	 benchmark	 the	performance	 of	 these	 tools	 on	 our	 datasets	 and	 integrate	 the	 results	 with	 those	discussed	in	this	thesis.			
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2.	 A	 regression-based	 approach	 allows	 to	 readily	 visualize	 and	 classify	 genes	
according	to	the	way	their	differences	are	propagated		By	 computing	 regression	 slopes	 on	 the	 three	 layers,	 we	 can	 produce	 a	 series	 of	exploratory	 data	 visualizations	 that	 give	 us	 a	 “bird’s	 eye”	 view	 on	 the	 relative	propagation	of	gene	expression	in	pluripotency.	An	alternative	way	of	looking	at	how	differences	are	propagated	would	be	to	plot,	for	each	comparison,	the	fold	change	in	one	layer	against	the	fold	change	in	another.	However,	besides	making	the	number	of	representations	larger	and	more	difficult	to	compare	among	each	other,	it	would	not	reveal	 the	 sensitivity	 of	 gene	 expression	 to	 the	 dosage	 of	 specific	 proteins.	 The	regression-based	 representations	was	preferred	 as	 it	 offers	 a	 synthetic	 and	quickly	understandable	view	of	gene	expression	regulation.		The	use	of	EIF4H	as	a	query	protein	was	dictated,	in	our	case,	by	a	specific	hypothesis	based	 on	 the	 disease	 pathophysiology	 and	 its	 involvement	 in	 the	 development	 of	animal	models	(Capossela	et	al.,	2012).	By	including	datasets	generated	from	knock-down	 samples	 it	 is	 possible	 to	 expand	 the	 dynamic	 range,	 thus	 enhancing	 the	detection	of	differences	that	correlate	with	the	query.	However,	we	could	have	chosen	any	other	well-quantified	protein	in	our	dataset	to	observe	other	trends,	and	draw	a	different	series	of	slopes	in	the	four	quadrants.		Moreover,	even	by	 just	relying	on	patient-derived	samples	without	perturbations	of	protein	 abundance,	 one	 can	 imagine	 an	 evolution	 of	 this	 system	 in	 which	 all	differentially	 expressed	 proteins	 (or	 all	 reliably	 quantified	 proteins)	 are	 used	 as	queries,	 and	 new	 relationships	 between	 gene	 expression	 levels	 can	 be	 inferred	 by	looking	at	how	their	positions	in	the	quadrants	change.	There	 are,	 though,	 some	 caveats	 worth	 discussing.	 First,	 the	 slope	 obtained	 by	including	 a	 knock-down	 sample	may	 be	 increased	 by	 the	 exacerbation	 of	 an	 effect	that	is	not	physiologically	as	intense.	Moreover,	given	the	high	variability	of	samples,	
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slopes	 that	 are	 statistically	 significant	 may	 still	 not	 pass	 FDR	 correction,	 thus	necessarily	restricting	our	claims	to	the	distribution	of	slopes	rather	than	the	features	of	single	genes.		An	 interesting	 consequence	 of	 the	 use	 of	 slope	 comparisons	 is	 their	 partition	 into	layer-exclusive	 regulation,	 which	 is	 a	 function	 of	 the	 statistical	 significance	 of	 the	slopes.	As	shown	in	the	results,	RPF-only	slopes	show	a	pattern	that	greatly	reflects	the	 function	of	EIF4H	as	 an	 enhancer	of	 translation	 initiation.	When	 computing	GO	enrichments	 for	 each	 of	 these	 partitions,	 we	 find	 different,	 partition-specific	categories	 that	 point	 to	 a	 differential	 regulation,	 at	 each	 layer,	 of	 functional	categories.	 Considering	 that	 iPSCs	 are	 a	 static	 snapshot	 of	 an	 actually	 dynamic	 cell	type,	it	is	intriguing	to	see	that	genes	related	to	cell	cycle	regulation	are	preferentially	(dys)regulated	 at	 the	 level	 of	 translation,	 as	 already	 suggested	 in	 literature	(Tanenbaum	et	al.,	2015).	The	dynamicity	of	gene	expression	in	iPSCs	can	be	further	appreciated	by	looking	at	how	 expression	 patterns	 of	 genes	 for	 which	 we	 have	 statistical	 confidence	 are	propagated	 from	 RNA	 to	 protein.	 By	 clustering	 together	 these	 patterns,	 which	 we	termed	 archetypes,	 another	 functional,	 data-driven	 classification	 can	 be	 made.	 The	notable	 example	 of	 the	 creek	 archetype,	 for	 instance,	 includes	 a	 series	 of	 genes	involved	in	morphogenesis	and	neuronal	differentiation	whose	pattern	is	remarkably	inverted	from	RNA	to	protein,	possibly	at	multiple	regulatory	steps	in	each	layer.		While	several	attempts	have	been	made	to	reconstruct	gene	regulatory	networks	by	looking	 at	 a	 single	 layer	 (mostly	 RNA,	 Basso	 et	 al.,	 2005)	 and	 reverse	 engineering	RNA	expression	patterns	by	integrating	it	with	ChIP-seq	data	(Qin	et	al.,	2014),	there	are	 few	 studies,	 to	 my	 knowledge,	 that	 attempt	 at	 integrating	 gene	 expression	patterns	in	transcriptome,	translatome	and	proteome.	The	work	on	human	variation	performed	by	Cenik	and	colleagues	 (Cenik	et	 al.,	 2015)	makes	use	of	 two	machine-
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learning	 algorithms,	 Kohonen	 maps	 (also	 called	 self-organizing	 maps)	 and	 affinity	propagation	 clustering,	 which	 are	 able	 to	 weigh	 the	 amount	 of	 information	transferred	from	one	layer	to	the	others	and	identify	clusters	of	expression	patterns.	As	 already	 stated	while	discussing	 technical	 limitations	of	 the	 setup	 for	differential	expression	 analysis,	 an	 implementation	 of	 these	more	 sophisticated	 techniques	 on	our	 datasets	may	 yield	 an	 additional	 insight	 into	 propagation	 of	 dysregulation	 and	possibly	validate	our	archetype-based	classification.	
	
3.	Degradation	 rates	do	not	 improve	 the	 correlation	between	 translatome	and	
proteome		We	leveraged	the	unique	combination	of	our	datasets	to	better	understand	not	only	to	which	extent	each	layer	of	gene	expression	is	able	to	buffer	or	introduce	changes	in	the	system,	but	also	gene	expression	as	a	process	in	itself.		In	 our	 experimental	 setup,	 differences	 in	 degradation	 across	 samples	 are	 much	smaller	 than	 differences	 in	 transcription,	 translation	 or	 protein	 abundance.	Interestingly,	 degradation	 constants	 do	 not	 explain	 changes	 in	 protein	 abundance	across	samples,	and	they	do	not	increase	the	precision	of	the	simple	gene	expression	model	in	which	we	can	include	experimental	data	for	all	the	terms	of	the	equation.	At	a	first	glance,	 it	could	be	concluded	that	-	 in	this	system	and	with	this	experimental	setup	 -	 degradation	 is	 not	 a	 determinant	 of	 changes	 in	 protein	 abundance	 at	 the	pluripotent	 steady	 state.	However,	 other	 reasons	 for	 this	 lack	of	 correlation	 can	be	proposed.	In	a	very	recent	publication	(McShane	et	al.,	2016),	the	group	of	Matthias	Selbach	showed	how	a	small	(~10%)	subset	of	mammalian	proteins	is	degraded	in	a	non-exponential	 decay	 (NED)	 fashion,	which	 they	 term	NEDs.	The	 authors	propose	that	NEDs	are	synthesized	in	a	super-stoichiometric	fashion	relative	to	exponentially	degraded	(ED)	proteins	with	which	they	form	complexes.	While	all	ED	proteins	will	
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be	 able	 to	 engage	 in	 complexes	 with	 NEDs,	 the	 remaining	 	 -	 free	 -	 NEDs	 will	 be	degraded,	thus	undergoing	a	faster	turnover.	This	observation	stems	from	theoretical	work	done	on	the	mathematical	modeling	of	pulse-chase	experiments	for	the	determination	of	RNA	(Sin	et	al.,	2015)	and	protein	(Sin	 et	 al.,	 2016)	 degradation	 rates.	 In	 these	 reports,	 it	 is	 postulated	 that	 some	proteins	 follow	 degradation	 kinetics	 which	 cannot	 be	 well	 described	 by	 the	exponential	 decay	 function,	 but	 rather	 by	 a	 Markov	 process	 in	 which	 newly	synthesized	proteins	(state	A)	can	be	either	 immediately	degraded	(state	0)	or	pass	onto	 another	 state	 (state	 B),	 representing	 the	 interaction	 within	 a	 complex,	 a	stabilizing	 post-translational	 modification,	 subcellular	 localization,	 and	 so	 on.	Proteins	in	state	B	will	then	be	degraded	(i.e.	go	to	state	0)	with	a	different	decay	rate.		Three	kinetic	constants	should	be	then	derived:	from	a	A	to	0,	from	A	to	B	and	from	B	to	0.	This	 can	be	 accomplished	by	using	optimization	 algorithms	 that	minimize	 the	sum	of	 squared	residuals	between	experimental	data	 (such	as	 the	RIA	of	 the	heavy	protein)	and	the	equation	for	the	decay	of	a	pulse	with	no	chase	(eq.	18	in	Sin	et	al.,	2016).		The	 work	 on	 NEDs	 becomes	 particularly	 relevant	 for	 our	 study	 since	 it	 has	 been	proposed	 that	 NEDs	 are	 particularly	 enriched	 in	 aneuploidies,	 as	 super-stoichiometric	amounts	of	proteins	tend	to	be	attenuated.	The	slight	flattening	of	the	slope	 of	WBSCR	 proteins	 indeed	 points	 to	 a	 similar	 phenomenon,	 although	 not	 all	WBSCR	proteins	are	reported	to	be	in	a	complex.	Notably,	the	authors	also	report	that	50%	 of	 the	 assayed	 proteins	 follow	 neither	 exponential	 nor	 non-exponential	degradation,	 thus	 pointing	 to	 a	 cluster	 of	 “dark	 degradation	 matter”.	 However,	 as	reported	in	the	results	section,	the	lack	of	correlation	in	our	samples	also	affects	the	subset	of	proteins	for	which	there	is	a	good	exponential	fit,	thus	pointing	to	a	problem	
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that	 does	 not	 necessarily	 originate	 from	 the	 wrong	 mathematical	 model	 of	degradation.	Besides	 the	 important	 technical	 differences	 in	 sample	 preparation	 and	 analyte	acquisition	between	count-based	NGS	methods	and	spectra	and	fragmentation-based	proteomics	methods,	another	possible	explanation	lies	in	the	way	both	proteins	and	RPF	reads	are	quantified.		Protein	 abundances	 are	 calculated,	 both	 in	 the	 LFQ	 and	 the	 pSILAC	 dataset,	 by	compounding	 the	measurements	 of	 peptides	 assigned	 to	 the	 same	 protein.	 Peptide	spectra	assignment	(i.e.	identification)	and	quantification	are,	therefore,	fundamental	for	 the	correct	measurement	of	protein	 intensity.	A	 recent	 report	 (Bogdanow	et	al.,	2016)	 has	 shown	 how	 the	 existence	 of	 unforeseen	 modified	 peptides	 in	 MS	experiments	can	affect	the	assignment	of	spectra.	A	modified	peptide	that	is	not	taken	in	consideration	as	such	in	the	reference	spectral	library	can	be	easily	misassigned	to	other	proteins,	thus	creating	false	positives.	The	authors	estimate	that	up	to	50%	of	proteins	can	be	misassigned	if	modified	peptides	are	not	accounted	for.	Although	we	have	 used	 for	 LFQ	 a	 summarization	method	 that	 only	 takes	 into	 account	 the	most	correlated	peptides,	for	the	pSILAC	dataset	we	calculated	the	RIA	on	each	consistently	quantified	 peptide	 separately,	 so	 as	 to	 have	 as	 many	 data	 points	 as	 possible.	 A	reasonable	 option	 would	 be	 to	 requantify	 RIA	 values	 by	 excluding	 potentially	modified	 peptides	 and	 check	 whether	 there	 are	 changes	 in	 Kdeg	 determination.	Nevertheless,	since	we	are	assessing	relative	differences	in	degradation	rates	rather	than	 absolute	 degradation	 rates,	 this	 correction	would	make	 sense	 only	 under	 the	assumption	 that	 the	 impact	 of	 modified	 peptides	 is	 CNV-dependent.	 On	 the	 other	hand,	 RPF	 reads	 in	 our	 analysis	were	 assigned	 to	 transcripts	which	 are	 aligned	 to	collapsed	 gene	models,	without	 taking	 into	 account	 alternative	 splicing	 events	 that	greatly	enhance	the	diversity	of	the	proteomic	repertoire	(see	(de	Klerk	and	‘t	Hoen,	
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2015)	 or	 a	 review).	 This	 can	 in	 turn	 be	 further	 enhanced	 by	 the	 translation	 of	different	 parts	 of	 the	 transcripts:	 upstream	 or	 alternative	 ORFs,	 alternative	translation	start	sites,	read-through	translation	events	can	all	potentially	give	rise	to	different	proteoforms	(Floor	et	al.,	2016).	We	have	adopted	a	simplified	model	 that	works	 under	 the	 assumption	 of	 one-to-one	 correspondeces	 of	 transcribed	 DNA,	mature	 RNA,	 translated	 RNA	 and	 protein,	 meaning	 that	 some	 precision	 will	 be	inevitably	 lost	 to	 the	complexity	of	each	of	 these	steps.	Other	possible	explanations	involving	 mis-quantification	 of	 ribosome	 occupancy	 profiles	 may	 lie	 in	 the	 bias	introduced	 by	 pausing	 ribosomes.	 In	 fact,	 when	 translating	 a	 poly-proline	 tract,	ribosomes	 tend	 to	 slow	 down	 and	 stall.	 This	may	 artificially	 inflate	 the	 number	 of	reads	at	pausing	sites	and	introduce	spurious	differences	in	quantification.	Ribosome	profiling	 is	 a	 relatively	 new	 technology	 and	 many	 analytical	 tools	 and	 error-correction	strategies	are	being	increasingly	proposed.	There	is,	therefore,	much	room	for	 improvement	 on	 the	 analytical	 side	 in	 the	 near	 future,	 in	 order	 to	 refine	 our	understanding	 of	 gene	 expression	 regulation	 in	 pluripotency	 and	 in	 the	 context	 of	7q11.23	CNVs.		
4.	Adding	a	third	dimension:	disease-relevant	cell	types		While	at	the	iPSC	stage	the	transcriptional	dysregulation	might	seem	to	be	irrelevant,	not	being	reflected	in	protein	abundance,	it	is	plausible	that	this	equilibrium	between	transcriptional	and	translation	control	is	fragilized	in	a	different	cellular	state.	The	 ground-breaking	potential	 of	 iPSCs	 to	 give	 rise	 to	 virtually	 all	 cell	 types	 in	 the	body	 is	 what	 makes	 them	 especially	 relevant	 for	 disease	 modelling.	 We	 have	demonstrated	 earlier	 that	 pluripotency	 is	 already	 an	 informative	 state	 for	 the	molecular	consequences	of	WBS	and	7dup	CNVs,	and	in	this	study	I	have	shown	that	
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the	 analysis	 of	 layers	 beside	 the	 transcriptome	 can	 bring	 a	 wealth	 of	 additional	information	with	pathophysiologically	meaningful	implications.	However,	changes	in	cell	 fate	 are	much	more	 sensitive	 to	 differences	 in	 protein	 synthesis	 and	 turnover	(Kristensen	et	 al.,	 2014;	Lu	et	 al.,	 2009;	Werner	et	 al.,	 2015),	 and	 represent	 critical	points	 in	 which	 the	 CNV	 may	 start	 to	 contribute	 to	 a	 clinical	 phenotype.	 For	 this	reason,	we	have	assembled	a	panel	of	NGN2-inducible	lines	(described	in	the	Results	section)	and	a	panel	of	neural	crest	stem	cell	lines	derived	in	vitro	from	the	same	iPSC	lines	used	in	this	study	(partially	already	published	in	Adamo	et	al.,	2014),	with	the	aim	of	performing	the	same	set	of	analyses	in	two	tissues	affected	by	the	CNVs.	In	fact,	NGN2-induced	 neurons	 allow	 us	 to	 probe	 the	 type	 and	 extent	 of	 dysregulation	 in	cortical	glutamatergic	neurons,	which	are	the	best	candidates	to	study	the	molecular	and	 cellular	 features	 that	 underlie	 sociality	 and	 language	 processing	 (Hutsler	 and	Zhang,	2010).	Neural	crest	stem	cells	are	instead	the	early	progenitors	of	a	variety	of	cell	 types	 that	 give	 rise	 to	 cranial	 bones	 and	 muscles,	 smooth	 muscle	 cells,	 aortic	arches,	cartilage	and	connective	tissue,	thus	offering	us	an	important	entry	point	into	the	study	of	craniofacial	and	cardiovascular	manifestations	of	both	syndromes.		Besides	measuring	 the	propagation	of	 information	 through	 layers	 in	 each	 cell	 type,	we	 will	 be	 able	 to	 measure	 the	 propagation	 of	 information	 through	 cell	 fates,	effectively	adding	a	third	dimension	(the	first	two	being	conditions	and	layers)	to	the	regulation	of	gene	expression	in	these	syndromes.							 	
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Appendices	
Appendix	1:	DEGs	found	in	the	total	RNA	dataset,	divided	by	comparison	and	
ranked	by	log2(FC)		WBS	vs	7dup		
Gene	 log2(FC)	WBS	vs	7DUP	
CORO7-PAM16	 7.965545609	
ANKHD1-EIF4EBP3	 2.316202082	
EPCAM	 -1.299165539	
TRIM22	 -1.452383771	
EIF4H	 -1.50731784	
RFC2	 -1.659907188	
WBSCR22	 -1.669503698	
GTF2I	 -1.730595533	
FAM92A1	 -1.922358746	
ZNF772	 -1.948471795	
BAZ1B	 -2.015771021	
PCDHA3	 -2.219030747	
PCDHB5	 -2.678254054	
ZNF528	 -2.777897495	
HIST1H1A	 -3.079409806	
FAM218A	 -3.316002196	
CAT	 -3.713503487	
ZNF726	 -3.779889179	
TRDN	 -3.805645334	
HIST1H2BB	 -3.843365858	
COL22A1	 -4.250411012	
ZNF229	 -4.373393706	
ZNF300	 -5.01540476	
GOLGA6L9	 -6.971521788	
ZNF560	 -6.980700052	
ZNF728	 -8.564891818		WBS	vs	CTL		
Gene	 log2(FC)	WBS	vs	CTL	
PRR5-ARHGAP8	 7.021821998	
MAGEA6	 -7.177349673	
GATS	 -7.864540299	
NPIPA3	 -8.453526352			 	
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	CTL	vs	7dup		
Gene	 log2(FC)	CTL	vs	7DUP	
C7orf55-LUC7L2	 9.67004816	
YIPF1	 9.593671534	
TGFBR3	 8.909501057	
LY75-CD302	 7.94028697	
TAS2R19	 3.944479728	
ZNF528	 2.176261753	
MME	 2.023307779	
SLITRK4	 1.858640026	
ZNF37A	 1.830231458	
ZNF107	 1.700412421	
DAAM1	 1.691160536	
PDK1	 1.68748495	
PCDHB3	 1.655572502	
EPHA7	 1.531901415	
TMEM212	 1.470566477	
VWDE	 1.399316049	
CCNG1	 1.186953281	
ZDBF2	 1.135681944	
GLTSCR2	 -1.066231509	
UQCC3	 -1.15809764	
ATPIF1	 -1.17656681	
SCLY	 -1.181441119	
MRPS26	 -1.201324597	
BANF1	 -1.203710336	
STK11	 -1.212246089	
HEXIM1	 -1.218319377	
ZBTB12	 -1.283237923	
NUDC	 -1.406838347	
BCL2L12	 -1.50092379	
RPLP1	 -1.522696959	
CCDC9	 -1.61648646	
MEX3D	 -1.651273109	
EMILIN1	 -1.669217957	
CCDC124	 -1.681376167	
ERICH1	 -1.750113792	
MRPL12	 -1.827099067	
SOX3	 -1.854492361	
CCDC85B	 -1.862113079	
IER2	 -1.88152359	
HSPB1	 -2.071171356	
RPS16	 -2.103611664	
MTRNR2L5	 -2.554641907	
DNAJC25-GNG10	 -3.06331733	
MTRNR2L4	 -3.679767912	
NPIPB4	 -4.149696614	
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MTRNR2L3	 -4.491985162	
MTRNR2L6	 -4.545419681	
MTRNR2L1	 -4.729834655	
MTRNR2L8	 -4.941854179	
MTRNR2L12	 -4.975125751	
MTRNR2L10	 -5.012305496	
UMODL1	 -6.380614689	
CORO7-PAM16	 -7.503891435			 	
	 169	
	
Appendix	2:	DEGs	found	in	the	RPF	dataset,	divided	by	comparison	and	ranked	
by	log2(FC)		WBS	vs	7dup		
Gene	 log2(FC)	WBS	vs	7DUP	
TRIM22	 -1.394273481	
EIF4H	 -1.525684575	
RFC2	 -1.525697254	
WBSCR22	 -1.650549701	
ABHD11	 -1.652178076	
GTF2I	 -1.71696254	
ACTN3	 -1.719656287	
NSUN5	 -1.775139352	
PCDHGB1	 -2.043856112	
PCDHB3	 -2.067585376	
BAZ1B	 -2.071233546	
DNAJC30	 -2.108031991	
PCDHGB5	 -2.485500987	
ZNF300	 -3.376391537	
PCDHB5	 -3.536538934	
HIST1H1A	 -3.915754195	
CPEB2	 -3.938420519	
CES1	 -4.042795098	
HIST1H3C	 -4.266643498	
CAT	 -4.391741678	
ZNF560	 -4.777739089	
COL22A1	 -4.782345235	
ZNF229	 -5.273198484	
PCDHA3	 -5.369211071	
NKX2-3	 -5.655229804	
TRIM67	 -6.144417428	
ZNF835	 -7.767511261	
ZNF726	 -7.899961189		WBS	vs	CTL		
Gene	 log2(FC)	WBS	vs	CTL	
HSPE1-MOB4	 9.01499279	
PCDHGB3	 4.021343045	
PCDHB3	 2.180861705	
IQGAP1	 1.939059859	
PCDHGB5	 1.775102165						
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CTL	vs	7dup		
Gene	 log2(FC)	CTL	vs	7DUP	
HSPE1-MOB4	 8.782546337	
CXorf40A	 6.690733608	
ANKRD1	 3.135558081	
SLC2A14	 2.477482582	
E2F1	 -3.045628871	
CNTNAP3B	 -4.690827255	
HIST1H3C	 -4.924954956	
CAPNS1	 -5.253214866	
SERPINB5	 -5.370477795	
TBC1D2B	 -6.456628803	
ISY1-RAB43	 -7.252935923	
CEBPB	 -8.500903868	
CPEB2	 -8.827313798	
TRIM67	 -10.02779981			 	
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Appendix	3:	DEPs	found	in	the	protein	dataset,	divided	by	comparison	and	
ranked	by	log2(FC)		WBS	vs	7dup		
Gene	 lof2(FC)	WBS	vs	7DUP	
HPGD	 0.338711903	
BCL10	 0.225354189	
IMPDH1	 0.181847797	
LTA4H	 0.17914281	
UBE2T	 0.174876545	
LRRC16A	 0.147508649	
ENO2	 0.132426323	
PITHD1	 0.100725452	
ALPL	 0.08948509	
EIF2D	 0.06525309	
ITPA	 0.024563487	
RIOK2	 -0.023686976	
HLA-A	 -0.055653366	
ABHD11	 -0.061739094	
ATP6V0A1	 -0.073414655	
IGF2R	 -0.080751009	
MAPRE1	 -0.113814095	
CLIP2	 -0.124566678	
SMARCA1	 -0.13587009	
SERPINH1	 -0.143026047	
RFC2	 -0.145857385	
HSD11B2	 -0.175041966	
RCN1	 -0.213467758	
EPCAM	 -0.24199208	
KHDRBS3	 -0.253512939	
CAT	 -0.295973553	
SPTLC1	 -0.35717112	
BAZ1B	 -0.360190419	
TBL2	 -0.37886345	
WBSCR22	 -0.415526022	
GTF2I	 -0.447215704	
NSUN5	 -0.507731336	
EIF4H	 -0.587631406			 	
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	WBS	vs	CTL		
Gene	 log2(FC)	WBS	vs	CTL	
HPGD	 0.338711903	
BCL10	 0.225354189	
LTA4H	 0.17914281	
SMARCA1	 -0.13587009	
RFC2	 -0.145857385	
EPCAM	 -0.24199208	
SPTLC1	 -0.35717112	
BAZ1B	 -0.360190419	
TBL2	 -0.37886345	
WBSCR22	 -0.415526022	
GTF2I	 -0.447215704	
NSUN5	 -0.507731336	
EIF4H	 -0.587631406			7dup	vs	CTL		
Gene	 log2(FC)	DUP	vs	CTL	
HLA-A	 1.555228768	
CLIP2	 0.829262291	
ABHD11	 0.621673719	
GTF2I	 0.530783645	
ENO2	 0.482921748	
BAZ1B	 0.464556662	
ALPL	 0.377140845	
TBL2	 0.28352144	
NSUN5	 0.278563753	
RFC2	 0.217115069	
IGF2R	 0.189178131	
RIOK2	 -0.417987554			 	
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Appendix	4:	Code	
Differential	gene	expression	on	total	RNA	and	RPF			
degClinical <- function(rna, rpfcds, rpfutr, filter=T, 
atyp="exclude", nf.rna, nf.rpf){ 
 
 require(edgeR) 
rna <- round(rna) 
rpfcds <- round(rpfcds) 
rpfutr <- round(rpfutr) 
 
 samples <- c("316M", "306O", "C7", "192B", "MIFF3", 
"BU1CRE", "3391S", "242J", "242K", "CFG", "V548MB") 
 
if(filter == T){ 
 rna <- rna[which(apply(rna,1,FUN=function(x){ 
sum(x>10)>3 })),] 
 rpfcds <- rpfcds[which(apply(rpfcds,1,FUN=function(x){ 
sum(x>10)>3 })),] 
 rpfutr <- rpfutr[which(apply(rpfutr,1,FUN=function(x){ 
sum(x>10)>3 })),] 
 } 
  
 rna <- rna[,samples] 
 rpfcds <- rpfcds[,samples] 
 rpfutr <- rpfutr[,samples] 
 nf.rna <- nf.rna[samples,1] 
 nf.rpf <- nf.rpf[samples,1] 
 
 if (atyp == "control"){ 
  nc <- 4 
  ns <- 4 
  nw <- 3 
   }else 
 if (atyp == "wbs"){ 
  nc <- 3 
  ns <- 5 
  nw <- 4 
   }else 
 if (atyp == "exclude"){ 
  nc <- 3 
  ns <- 5 
  nw <- 3 
  } 
   
 d.dup.ctl <- data.frame(samples[c(ns:11)], 
condition=c(rep("CTRL", nc), rep("DUP", 4))) 
 d.wbs.ctl <- data.frame(samples[c(1:(nc+nw))], 
condition=c(rep("WBS", nw), rep("CTL", nc))) 
 d.wbs.dup <- data.frame(samples[c(1:nw, 8:11)], 
condition=c(rep("WBS", nw), rep("DUP", 4))) 
 
 rnadds <- DGEList(rna, norm.factors=nf.rna) 
 rpfcdsdds <- DGEList(rpfcds, norm.factors=nf.rpf) 
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 rpfutrdds <- DGEList(rpfutr, norm.factors=nf.rpf) 
  
 
#SUBSET NORMALIZATION FACTORS SPECIFIC FOR THE COMPARISONS 
 
 rnaDCnf <- rnadds$samples$norm.factors[c(ns:11)] 
 rnaWCnf <- rnadds$samples$norm.factors[c(1:(nc+nw))] 
 rnaWDnf <- rnadds$samples$norm.factors[c(1:nw, 8:11)] 
 
 rpfcdsDCnf <- rpfcdsdds$samples$norm.factors[c(ns:11)] 
 rpfcdsWCnf <- 
rpfcdsdds$samples$norm.factors[c(1:(nc+nw))] 
 rpfcdsWDnf <- rpfcdsdds$samples$norm.factors[c(1:nw, 
8:11)] 
 
 rpfutrDCnf <- rpfutrdds$samples$norm.factors[c(ns:11)] 
 rpfutrWCnf <- 
rpfutrdds$samples$norm.factors[c(1:(nc+nw))] 
 rpfutrWDnf <- rpfutrdds$samples$norm.factors[c(1:nw, 
8:11)] 
  
 
#MAKE MODEL MATRICES 
 
 mmDC <- model.matrix(~condition, data=d.dup.ctl) 
 mmWC <- model.matrix(~condition, data=d.wbs.ctl) 
 mmWD <- model.matrix(~condition, data=d.wbs.dup) 
 
#ESTIMATE DISPERSION 
 
 rnaddsDC <- DGEList(rna[,c(ns:11)], 
norm.factors=rnaDCnf) 
 rnaddsWC <- DGEList(rna[,c(1:(nc+nw))], 
norm.factors=rnaWCnf) 
 rnaddsWD <- DGEList(rna[,c(1:nw, 8:11)], 
norm.factors=rnaWDnf) 
 
 rnaddsDC <- estimateDisp(rnaddsDC, mmDC) 
 rnaddsWC <- estimateDisp(rnaddsWC, mmWC) 
 rnaddsWD <- estimateDisp(rnaddsWD, mmWD) 
 
 rpfcdsddsDC <- DGEList(rpfcds[,c(ns:11)], 
norm.factors=rpfcdsDCnf) 
 rpfcdsddsWC <- DGEList(rpfcds[,c(1:(nc+nw))], 
norm.factors=rpfcdsWCnf) 
 rpfcdsddsWD <- DGEList(rpfcds[,c(1:nw, 8:11)], 
norm.factors=rpfcdsWDnf) 
 
 rpfcdsddsDC <- estimateDisp(rpfcdsddsDC, mmDC) 
 rpfcdsddsWC <- estimateDisp(rpfcdsddsWC, mmWC) 
 rpfcdsddsWD <- estimateDisp(rpfcdsddsWD, mmWD) 
 
 rpfutrddsDC <- DGEList(rpfutr[,c(ns:11)], 
norm.factors=rpfutrDCnf) 
 rpfutrddsWC <- DGEList(rpfutr[,c(1:(nc+nw))], 
norm.factors=rpfutrWCnf) 
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 rpfutrddsWD <- DGEList(rpfutr[,c(1:nw, 8:11)], 
norm.factors=rpfutrWDnf) 
 
 rpfutrddsDC <- estimateDisp(rpfutrddsDC, mmDC) 
 rpfutrddsWC <- estimateDisp(rpfutrddsWC, mmWC) 
 rpfutrddsWD <- estimateDisp(rpfutrddsWD, mmWD) 
 
 
#FIT 
 
 rnaddsDCfit <- glmFit(rnaddsDC, mmDC) 
 rnaddsWCfit <- glmFit(rnaddsWC, mmWC) 
 rnaddsWDfit <- glmFit(rnaddsWD, mmWD) 
 
 rpfcdsddsDCfit <- glmFit(rpfcdsddsDC, mmDC) 
 rpfcdsddsWCfit <- glmFit(rpfcdsddsWC, mmWC) 
 rpfcdsddsWDfit <- glmFit(rpfcdsddsWD, mmWD) 
 
 rpfutrddsDCfit <- glmFit(rpfutrddsDC, mmDC) 
 rpfutrddsWCfit <- glmFit(rpfutrddsWC, mmWC) 
 rpfutrddsWDfit <- glmFit(rpfutrddsWD, mmWD) 
 
#LOG LIKELIHOOD 
 
 
 rnaddsDCLRT <- glmLRT(rnaddsDCfit, "conditionDUP") 
 rnaddsWCLRT <- glmLRT(rnaddsWCfit, "conditionWBS") 
 rnaddsWDLRT <- glmLRT(rnaddsWDfit, "conditionWBS") 
 
 rpfcdsddsDCLRT <- glmLRT(rpfcdsddsDCfit, 
"conditionDUP") 
 rpfcdsddsWCLRT <- glmLRT(rpfcdsddsWCfit, 
"conditionWBS") 
 rpfcdsddsWDLRT <- glmLRT(rpfcdsddsWDfit, 
"conditionWBS") 
 
 rpfutrddsDCLRT <- glmLRT(rpfutrddsDCfit, 
"conditionDUP") 
 rpfutrddsWCLRT <- glmLRT(rpfutrddsWCfit, 
"conditionWBS") 
 rpfutrddsWDLRT <- glmLRT(rpfutrddsWDfit, 
"conditionWBS") 
 
#SIG RESULTS 
 
 rna.res.DC <- as.data.frame(topTags(rnaddsDCLRT, 
30000)) 
 rna.res.WC <- as.data.frame(topTags(rnaddsWCLRT, 
30000)) 
 rna.res.WD <- as.data.frame(topTags(rnaddsWDLRT, 
30000)) 
  
 rpfcds.res.DC <- as.data.frame(topTags(rpfcdsddsDCLRT, 
30000)) 
 rpfcds.res.WC <- as.data.frame(topTags(rpfcdsddsWCLRT, 
30000)) 
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 rpfcds.res.WD <- as.data.frame(topTags(rpfcdsddsWDLRT, 
30000)) 
 
 rpfutr.res.DC <- as.data.frame(topTags(rpfutrddsDCLRT, 
30000)) 
 rpfutr.res.WC <- as.data.frame(topTags(rpfutrddsWCLRT, 
30000)) 
 rpfutr.res.WD <- as.data.frame(topTags(rpfutrddsWDLRT, 
30000)) 
 
degs_sig_dataframes <- list(rna.res.DC = rna.res.DC, 
rna.res.WC = rna.res.WC, rna.res.WD = rna.res.WD, 
rpfcds.res.DC = rpfcds.res.DC, rpfcds.res.WC = 
rpfcds.res.WC, rpfcds.res.WD = rpfcds.res.WD) 
 
#SIG GENES THRESHOLDED 
 
 rna_DC_sig_005 <- 
unique(row.names(rna.res.DC)[which(rna.res.DC$FDR < 0.05)]) 
 rna_DC_sig_01 <- 
unique(row.names(rna.res.DC)[which(rna.res.DC$FDR < 0.1)]) 
 
 rna_WC_sig_005 <- 
unique(row.names(rna.res.WC)[which(rna.res.WC$FDR < 0.05)]) 
 rna_WC_sig_01 <- 
unique(row.names(rna.res.WC)[which(rna.res.WC$FDR < 0.1)]) 
 
 rna_WD_sig_005 <- 
unique(row.names(rna.res.WD)[which(rna.res.WD$FDR < 0.05)]) 
 rna_WD_sig_01 <- 
unique(row.names(rna.res.WD)[which(rna.res.WD$FDR < 0.1)]) 
 
 rpfcds_DC_sig_005 <- 
unique(row.names(rpfcds.res.DC)[which(rpfcds.res.DC$FDR < 
0.05)]) 
 rpfcds_DC_sig_01 <- 
unique(row.names(rpfcds.res.DC)[which(rpfcds.res.DC$FDR < 
0.1)]) 
  
 rpfcds_WC_sig_005 <- 
unique(row.names(rpfcds.res.WC)[which(rpfcds.res.WC$FDR < 
0.05)]) 
 rpfcds_WC_sig_01 <- 
unique(row.names(rpfcds.res.WC)[which(rpfcds.res.WC$FDR < 
0.1)]) 
 
 rpfcds_WD_sig_005 <- 
unique(row.names(rpfcds.res.WD)[which(rpfcds.res.WD$FDR < 
0.05)]) 
 rpfcds_WD_sig_01 <- 
unique(row.names(rpfcds.res.WD)[which(rpfcds.res.WD$FDR < 
0.1)]) 
 
 rpfutr_DC_sig_005 <- 
unique(row.names(rpfutr.res.DC)[which(rpfutr.res.DC$FDR < 
0.05)]) 
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 rpfutr_DC_sig_01 <- 
unique(row.names(rpfutr.res.DC)[which(rpfutr.res.DC$FDR < 
0.1)]) 
 
 rpfutr_WC_sig_005 <- 
unique(row.names(rpfutr.res.WC)[which(rpfutr.res.WC$FDR < 
0.05)]) 
 rpfutr_WC_sig_01 <- 
unique(row.names(rpfutr.res.WC)[which(rpfutr.res.WC$FDR < 
0.1)]) 
 
 rpfutr_WD_sig_005 <- 
unique(row.names(rpfutr.res.WD)[which(rpfutr.res.WD$FDR < 
0.05)]) 
 rpfutr_WD_sig_01 <- 
unique(row.names(rpfutr.res.WD)[which(rpfutr.res.WD$FDR < 
0.1)]) 
 
 
#SIG GENES TABLES: ONLY DEGS 
 
 deg_DC <- list(deg_RNA_01 = rna_DC_sig_01, deg_RNA_005 
= rna_DC_sig_01, deg_RPF_CDS_01 = rpfcds_DC_sig_01, 
deg_RPF_CDS_005 = rpfcds_DC_sig_01, deg_RPF_UTR_005 = 
rpfutr_DC_sig_005, deg_RPF_UTR_01 = rpfutr_DC_sig_01) 
 deg_WC <- list(deg_RNA_01 = rna_WC_sig_01, deg_RNA_005 
= rna_WC_sig_01, deg_RPF_CDS_01 = rpfcds_WC_sig_01, 
deg_RPF_CDS_005 = rpfcds_WC_sig_01, deg_RPF_UTR_005 = 
rpfutr_WC_sig_005, deg_RPF_UTR_01 = rpfutr_WC_sig_01) 
 deg_WD <- list(deg_RNA_01 = rna_WD_sig_01, deg_RNA_005 
= rna_WD_sig_01, deg_RPF_CDS_01 = rpfcds_WD_sig_01, 
deg_RPF_CDS_005 = rpfcds_WD_sig_01, deg_RPF_UTR_005 = 
rpfutr_WD_sig_005, deg_RPF_UTR_01 = rpfutr_WD_sig_01) 
 
#SIG GENES: 1st INTERSECTION 
 
 deg_common_RNA_sig_01 <- intersect(rna_WD_sig_01, 
(intersect(rna_DC_sig_01, rna_WC_sig_01))) 
 deg_common_RPF_CDS_sig_01 <- 
intersect(rpfcds_WD_sig_01, (intersect(rpfcds_DC_sig_01, 
rpfcds_WC_sig_01))) 
 deg_common_RPF_UTR_sig_01 <- 
intersect(rpfutr_WD_sig_01, (intersect(rpfutr_DC_sig_01, 
rpfutr_WC_sig_01))) 
 
 deg_common_RNA_sig_005 <- intersect(rna_WD_sig_005, 
(intersect(rna_DC_sig_005, rna_WC_sig_005))) 
 deg_common_RPF_CDS_sig_005 <- 
intersect(rpfcds_WD_sig_005, (intersect(rpfcds_DC_sig_005, 
rpfcds_WC_sig_005))) 
 deg_common_RPF_UTR_sig_005 <- 
intersect(rpfutr_WD_sig_005, (intersect(rpfutr_DC_sig_005, 
rpfutr_WC_sig_005))) 
 
deg_common_layers <- list(RNA_sig_01 = 
deg_common_RNA_sig_01, RNA_sig_005 = deg_common_RNA_sig_005, 
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RPF_CDS_sig_01 = deg_common_RPF_CDS_sig_01, RPF_CDS_sig_005 
= deg_common_RPF_CDS_sig_005, RPF_UTR_sig_01 = 
deg_common_RPF_UTR_sig_01, RPF_UTR_sig_005 = 
deg_common_RPF_UTR_sig_005)  
 
#SIG GENES: ALL INTERSECTIONS 
 
#DEGs common to all layers 
 deg_common_all_01 <- 
intersect(intersect(deg_common_RNA_sig_01, 
deg_common_RPF_CDS_sig_01), deg_common_RPF_UTR_sig_01) 
 deg_common_all_005 <- 
intersect(intersect(deg_common_RNA_sig_005, 
deg_common_RPF_CDS_sig_005), deg_common_RPF_UTR_sig_005) 
 
#DEGs common between RNA and CDS RPF 
 deg_common_RNA_RPF_CDS_01 <- 
intersect(deg_common_RNA_sig_01, deg_common_RPF_CDS_sig_01) 
 deg_common_RNA_RPF_CDS_005 <- 
intersect(deg_common_RNA_sig_005, 
deg_common_RPF_CDS_sig_005) 
 
#DEGs common between CDS RPF and UTR RPF 
 deg_common_RPF_CDS_UTR_01 <- 
intersect(deg_common_RPF_CDS_sig_01, 
deg_common_RPF_UTR_sig_01) 
 deg_common_RPF_CDS_UTR_005 <- 
intersect(deg_common_RPF_CDS_sig_005, 
deg_common_RPF_UTR_sig_005) 
 
 
#SIG GENES: 1st UNION 
 
 deg_union_RNA_sig_01 <- union(rna_WD_sig_01, 
(union(rna_DC_sig_01, rna_WC_sig_01))) 
 deg_union_RPF_CDS_sig_01 <- union(rpfcds_WD_sig_01, 
(union(rpfcds_DC_sig_01, rpfcds_WC_sig_01))) 
 deg_union_RPF_UTR_sig_01 <- union(rpfutr_WD_sig_01, 
(union(rpfutr_DC_sig_01, rpfutr_WC_sig_01))) 
 
 deg_union_RNA_sig_005 <- union(rna_WD_sig_005, 
(union(rna_DC_sig_005, rna_WC_sig_005))) 
 deg_union_RPF_CDS_sig_005 <- union(rpfcds_WD_sig_005, 
(union(rpfcds_DC_sig_005, rpfcds_WC_sig_005))) 
 deg_union_RPF_UTR_sig_005 <- union(rpfutr_WD_sig_005, 
(union(rpfutr_DC_sig_005, rpfutr_WC_sig_005))) 
 
 
#SIG GENES: ALL UNIONS 
 
#DEGs union to all layers 
 deg_union_all_01 <- union(union(deg_union_RNA_sig_01, 
deg_union_RPF_CDS_sig_01), deg_union_RPF_UTR_sig_01) 
 deg_union_all_005 <- union(union(deg_union_RNA_sig_005, 
deg_union_RPF_CDS_sig_005), deg_union_RPF_UTR_sig_005) 
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#DEGs union between RNA and CDS RPF 
 deg_union_RNA_RPF_CDS_01 <- union(deg_union_RNA_sig_01, 
deg_union_RPF_CDS_sig_01) 
 deg_union_RNA_RPF_CDS_005 <- 
union(deg_union_RNA_sig_005, deg_union_RPF_CDS_sig_005) 
 
#DEGs union between CDS RPF and UTR RPF 
 deg_union_RPF_CDS_UTR_01 <- 
union(deg_union_RPF_CDS_sig_01, deg_union_RPF_UTR_sig_01) 
 deg_union_RPF_CDS_UTR_005 <- 
union(deg_union_RPF_CDS_sig_005, deg_union_RPF_UTR_sig_005) 
 
#SIG GENES: EXCLUSIONS OF INTERSECTION 
 
 deg_union_RNA_ex_CDS_01 <- 
setdiff(deg_union_RNA_sig_01, deg_union_RPF_CDS_sig_01)  
 deg_union_CDS_ex_RNA_01 <- 
setdiff(deg_union_RPF_CDS_sig_01, deg_union_RNA_sig_01) 
 deg_union_CDS_ex_UTR_01 <- 
setdiff(deg_union_RPF_CDS_sig_01, deg_union_RPF_UTR_sig_01) 
 deg_union_UTR_ex_CDS_01 <- 
setdiff(deg_union_RPF_UTR_sig_01, deg_union_RPF_CDS_sig_01) 
 
 deg_union_RNA_ex_CDS_005 <- 
setdiff(deg_union_RNA_sig_005, deg_union_RPF_CDS_sig_005)  
 deg_union_CDS_ex_RNA_005 <- 
setdiff(deg_union_RPF_CDS_sig_005, deg_union_RNA_sig_005) 
 deg_union_CDS_ex_UTR_005 <- 
setdiff(deg_union_RPF_CDS_sig_005, 
deg_union_RPF_UTR_sig_005) 
 deg_union_UTR_ex_CDS_005 <- 
setdiff(deg_union_RPF_UTR_sig_005, 
deg_union_RPF_CDS_sig_005) 
 
 
#DATAFRAME GENERATION 
 
 clin_deg_common_bylayer <- list(RNA_sig_01 = 
deg_common_RNA_sig_01, RNA_sig_005 = deg_common_RNA_sig_005, 
RPF_CDS_sig_01 = deg_common_RPF_CDS_sig_01, RPF_CDS_sig_005 
= deg_common_RPF_CDS_sig_005, RPF_UTR_sig_01 = 
deg_common_RPF_UTR_sig_01, RPF_UTR_sig_005 = 
deg_common_RPF_UTR_sig_005)  
 clin_deg_union_bylayer <- list(RNA_sig_01 = 
deg_union_RNA_sig_01, RNA_sig_005 = deg_union_RNA_sig_005, 
RPF_CDS_sig_01 = deg_union_RPF_CDS_sig_01, RPF_CDS_sig_005 = 
deg_union_RPF_CDS_sig_005, RPF_UTR_sig_01 = 
deg_union_RPF_UTR_sig_01, RPF_UTR_sig_005 = 
deg_union_RPF_UTR_sig_005)  
 
 clin_deg_common_acrosslayer <- list(all_common_01 = 
deg_common_all_01,  all_common_005 = deg_common_all_005, 
RNA_RPF_common_01 = deg_common_RNA_RPF_CDS_01, 
RNA_RPF_common_005 = deg_common_RNA_RPF_CDS_005, 
RPF_CDS_UTR_common_01 = deg_common_RPF_CDS_UTR_01, 
RPF_CDS_UTR_common_005 = deg_common_RPF_CDS_UTR_005)  
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 clin_deg_union_acrosslayer <- list(all_union_01 = 
deg_union_all_01,  all_union_005 = deg_union_all_005, 
RNA_RPF_union_01 = deg_union_RNA_RPF_CDS_01, 
RNA_RPF_union_005 = deg_union_RNA_RPF_CDS_005, 
RPF_CDS_UTR_union_01 = deg_union_RPF_CDS_UTR_01, 
RPF_CDS_UTR_union_005 = deg_union_RPF_CDS_UTR_005)  
 
 clin_deg_excluded_bylayer <- list(union_RNA_ex_CDS_01 = 
deg_union_RNA_ex_CDS_01,union_RNA_ex_CDS_005 = 
deg_union_RNA_ex_CDS_005, union_CDS_ex_RNA_01 = 
deg_union_CDS_ex_RNA_01, union_CDS_ex_RNA_005 = 
deg_union_CDS_ex_RNA_005,  union_CDS_ex_UTR_01 = 
deg_union_CDS_ex_UTR_01,union_CDS_ex_UTR_005 = 
deg_union_CDS_ex_UTR_005, union_UTR_ex_CDS_01 = 
deg_union_UTR_ex_CDS_01, union_UTR_ex_CDS_005 = 
deg_union_UTR_ex_CDS_005) 
 
 clin_deg_comparisons <- list(deg_WC=deg_WC, 
deg_WD=deg_WD, deg_DC=deg_DC) 
  
 table_out <- list(clin_deg_common_bylayer = 
clin_deg_common_bylayer, clin_deg_union_bylayer = 
clin_deg_union_bylayer, clin_deg_common_acrosslayer = 
clin_deg_common_acrosslayer, clin_deg_union_acrosslayer = 
clin_deg_union_acrosslayer, clin_deg_excluded_bylayer = 
clin_deg_excluded_bylayer, clin_deg_comparisons = 
clin_deg_comparisons, degs_sig_dataframes = 
degs_sig_dataframes) 
 
return(table_out) 
 
} 
 
# example call with data provided  
# clin_degs <- degClinical(rna.total$rna.total.count.agg, 
rpf.aggregated$cds.agg, rpf.aggregated$utr5.agg, filter=T, 
atyp="exclude", nf.rna=rna.nf, nf.rpf=rpf.nf) 
Slope	computation	and	plotting		
# SMA and return slope 
smab <- function(y,x,robust=F, ...){ 
         y <- as.numeric(y) 
         x <- as.numeric(x) 
         t <- try(sma(y~x, robust=robust, 
slope.test=0),silent=T) 
         if("try-error" %in% class(t)) return(NA) 
         return(as.numeric(unlist(t$coef[2])) 
    } 
     
# SMA and return p-value 
   
    smap <- function(y,x,robust=F, ...){ 
         y <- as.numeric(y) 
         x <- as.numeric(x) 
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         t <- try(sma(y~x, robust=robust, 
slope.test=0),silent=T) 
         if("try-error" %in% class(t)) return(NA) 
         return(as.numeric(t$p)) 
    } 
     
# generate protein SMA slope dataframe 
     
proteinSMAslope <- function(o, levels, robust=F, ...){ 
require(smatr) 
slopes <- apply(log(o+1), x=log(levels+1), robust=robust, 
MARGIN=1, FUN=smab) 
slopes.pval <- apply(log(o+1),x=log(levels+1), 
robust=robust, method = method, MARGIN=1, FUN=smap) 
res <- as.data.frame(cbind(slopes, slopes.pval), 
row.names=row.names(o)) 
res$FDR <- p.adjust(res[,2], method="fdr") 
res$gene <- sapply(row.names(res),FUN=function(x){  
 x <- 
unique(as.character(uniprotconv[which(uniprotconv[,1]==x),2]
)) 
 x <- x[which(!is.na(x) & x!="")]  
 paste(x,collapse=", ") 
}) 
colnames(res)[c(1,2)] <- c("slope", "p.value") 
return(res) 
} 
 
# example call: res <- proteinMechDegs(prot.ok, 
eif4h.prot.levels$int, robust=F, method="SMA") 
 
# aggregate RNA/RPF 
 
aggregateRna <- function(o){ 
  
 ag <- aggregate(o, by=list(gene=conv[row.names(o),1]), 
FUN=sum) 
  row.names(ag) <- ag$gene 
  ag$gene <- NULL 
  
 return(ag) 
} 
 
aggregateRPF <- function(o){ 
   
  cds <- o[grep("utr", row.names(o), invert=T),] 
   
  utr3 <- o[grep("utr3",row.names(o)),] 
  utr5 <- o[grep("utr5",row.names(o)),] 
   
  rownames(utr5) <- gsub(".utr5", "", 
row.names(utr5), fixed=T) 
  rownames(utr3) <- gsub(".utr3", "", 
row.names(utr3), fixed=T) 
   
  cds.agg <- aggregateRna(cds) 
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  utr5.agg <- aggregateRna(utr5) 
  utr3.agg <- aggregateRna(utr3) 
 
  ag <- list(cds.agg = cds.agg, utr5.agg = utr5.agg, 
utr3.agg = utr3.agg) 
 
 return(ag) 
} 
 
# get norm. factors for slopped transcripts 
getNF <- function(o){ 
 require(edgeR) 
  #elements <- aggregateRPF(o) 
 
 dds <- DGEList(rbind(o$cds.agg, o$utr3.agg, 
o$utr5.agg)) 
  
 dds <- calcNormFactors(dds) 
  
 nf <- as.data.frame(dds$samples$norm.factors) 
 row.names(nf) <- colnames(o$cds.agg) 
  
return(nf) 
} 
 
# get norm. factors for RNA  
 
getRNANF <- function(o){ 
require(edgeR) 
dds <- DGEList(o) 
dds <- calcNormFactors(dds) 
  
 nf <- as.data.frame(dds$samples$norm.factors) 
 row.names(nf) <- colnames(o) 
  
return(nf) 
} 
 
filterTables <- function(o, thresh){ 
   f <- o[apply(o, MARGIN = 1, function(x) all(x 
> thresh)), ] 
   return(f)} 
 
# get log(FC) for RPF  
 
rpfLogFC <- function(o, nf=rpf.nf, filter=F, mincounts=50, 
minsamples=3){ 
 require(edgeR) 
  
  if(filter == T){ 
   o <- o[which(apply(o,1,FUN=function(x){ 
sum(x>mincounts)>minsamples })),] 
  } 
   
  dds <- DGEList(o, norm.factors=nf) 
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   d <- data.frame(row.names=colnames(o), 
condition=c("WBS", "WBS", "WBS","AtWBS", "CTRL.4Hsh", 
"CTRL.4Hsh", "CTRL.Baz1B.sh", "SCR", "CTRL", "CTRL", "CTRL", 
"DUP", "DUP", "DUP", "DUP")) 
   d$EIF4H.CN <- c(1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 
2, 3, 3, 3, 3) 
   d$EIF4H.prot.levels <- c(0.7146365, 
0.7046330, 0.9349140, 1.0790609, 0.6714633, 0.3808189, 
0.8121058, 1.5301023, 1.5301023, 0.7957576, 1.3108425, 
1.5211638, 1.6774462, 1.6282297, 1.4295153) 
   d$EIF4H.rpf.levels <- c(1, 1, 1, 1, 0.2, 0.2, 
2, 2, 2, 2, 2, 3, 3, 3, 3) 
   d$EIF4H.rna.levels <- c(0.6566165, 0.8570071, 
0.7647101, 0.8001617, 0.2467174, 0.1675075, 1.9995914, 
1.3707070, 1.5250787, 0.8444991, 1.3021972, 1.9022625, 
1.8728631, 2.2141652, 1.9380043) 
 
  mm <- model.matrix(~EIF4H.prot.levels, data=d) 
  
  dds <- estimateDisp(dds, mm) 
  
  ddsfit <- glmFit(dds, mm) 
   
  ddsLRT <- glmLRT(ddsfit, "EIF4H.prot.levels") 
  
  rpfLRT <- as.data.frame(topTags(ddsLRT, 30000)) 
  
  rpflogfc <- as.data.frame(rpfLRT$logFC) 
  row.names(rpflogfc) <- row.names(rpfLRT)  
  rpflogfc$p.value <- rpfLRT$PVal 
  rpflogfc$gene <- row.names(rpflogfc) 
  rpflogfc$FDR <- p.adjust(rpflogfc$p.value, 
method="fdr") 
  colnames(rpflogfc)[c(1,2)] <- c("slope", 
"p.value") 
 
 return(rpflogfc) 
} 
 
# get log(FC) for RNA 
 
rnaLogFC <- function(o, nf=rna.nf, filter=F, mincounts=50, 
minsamples=3){ 
  
 require(edgeR) 
    
  if(filter == T){ 
   o <- o[which(apply(o,1,FUN=function(x){ 
sum(x>mincounts)>minsamples })),] 
  } 
  dds <- DGEList(o, norm.factors=nf) 
  d <- data.frame(row.names=colnames(o), 
condition=c("WBS", "WBS", "WBS","AtWBS", "CTRL.4Hsh", 
"CTRL.4Hsh", "CTRL.Baz1B.sh", "SCR", "CTRL", "CTRL", "CTRL", 
"DUP", "DUP", "DUP", "DUP")) 
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   d$EIF4H.CN <- c(1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 
2, 3, 3, 3, 3) 
   d$EIF4H.prot.levels <- c(0.7146365, 
0.7046330, 0.9349140, 1.0790609, 0.6714633, 0.3808189, 
0.8121058, 1.5301023, 1.5301023, 0.7957576, 1.3108425, 
1.5211638, 1.6774462, 1.6282297, 1.4295153) 
   d$EIF4H.rna.levels <- c(0.6566165, 0.8570071, 
0.7647101, 0.8001617, 0.2467174, 0.1675075, 1.9995914, 
1.3707070, 1.5250787, 0.8444991, 1.3021972, 1.9022625, 
1.8728631, 2.2141652, 1.9380043) 
 
  mm <- model.matrix(~EIF4H.prot.levels, data=d) 
  
  dds <- estimateDisp(dds, mm) 
  
  ddsfit <- glmFit(dds, mm) 
   
  ddsLRT <- glmLRT(ddsfit, "EIF4H.prot.levels") 
  rnaLRT <- as.data.frame(topTags(ddsLRT, 30000)) 
  
  rnalogfc <- as.data.frame(rnaLRT$logFC) 
  row.names(rnalogfc) <- row.names(rnaLRT)  
  rnalogfc$p.value <- rnaLRT$PVal 
  rnalogfc$gene <- row.names(rnalogfc) 
  rnalogfc$FDR <- p.adjust(rnalogfc$p.value, 
method="fdr") 
  colnames(rnalogfc)[c(1,2)] <- c("slope", 
"p.value") 
   
 return(rnalogfc) 
} 
 
  
# Plot genes in quadrants 
plotCompSlopes <- function(o1, o2, alpha, lim=2, sig="both", 
text=T, axes=T, fillzero=F, subset=F, ...){ 
  
 in_common <- intersect(o1$gene, o2$gene) 
  
 if(subset == T){ 
 o1 <- o1[intersect(rownames(o1),alldegs),] 
 o2 <- o2[intersect(rownames(o2),alldegs),]} 
  
 
  switch(sig, 
        both = {in_pval <- 
intersect(row.names(o1[which(o1$p.value < alpha),]), 
row.names(o2[which(o2$p.val < alpha),])); col="red"}, 
        first = {in_pval <- row.names(o1[which(o1$p.value < 
alpha),]); col="green"}, 
        second = {in_pval <- row.names(o2[which(o2$p.value < 
alpha),]); col="green"}, 
        union = {in_pval <- 
union(row.names(o1[which(o1$p.value < alpha),]), 
row.names(o2[which(o2$p.value < alpha),])); col="blue"},  
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        onlyfirst = {in_pval <- 
setdiff(row.names(o1[which(o1$p.value < alpha),]), 
row.names(o2[which(o2$p.value < alpha),])); col="orange"}, 
        onlysecond = {in_pval <- 
setdiff(row.names(o2[which(o2$p.value < alpha),]), 
row.names(o1[which(o1$p.value < alpha),])); col="purple"}, 
         stop(paste(sig,": unknown selection",sep="")) 
         ) 
          
    if(fillzero == T){ 
 o1$slope[which(o1$p.value >= alpha)] <- 0 
 o2$slope[which(o2$p.value >= alpha)] <- 0 
 } 
  
 plot(o1[in_pval,1], o2[in_pval,1], xlim=c(-lim,+lim), 
ylim=c(-lim,+lim), col=col, pch=16, cex=0.6) 
 abline(h=0,v=0, col="black", lwd=0.4, lty="dashed") 
 text(y=lim, x=lim-lim/5, label="1st quadrant") 
 text(y=-lim, x=lim-lim/5, label="2nd quadrant") 
 text(y=-lim, x=-(lim-lim/5), label="3rd quadrant") 
 text(y=lim, x=-(lim-lim/5), label="4th quadrant") 
 
 if(text == T){ 
  text(o1[in_pval,1], o2[in_pval,1], 
labels=o1[in_pval,3], cex=0.5, pos=3) 
    } 
 if(axes == T){ 
  abline(0,1, col="red", lwd=0.7, lty="dotted") 
  abline(0,-1, col="red", lwd=0.7, lty="dotted") 
  } 
  
   
} 
 
# Generate list of genes divided by quadrants 
 
listCompSlopes <- function(o1, o2, alpha, sig="both", 
subset=F){ 
   
  require(GTscripts) 
   
  name.o1 <- deparse(substitute(o1)) 
  name.o2 <- deparse(substitute(o2)) 
   
  in_common <- intersect(o1$gene, o2$gene)  
  o1 <- o1[in_common,] 
  o2 <- o2[in_common,] 
   
  if(subset ==T){ 
  o1 <- o1[intersect(rownames(o1),alldegs),] 
  o2 <- o2[intersect(rownames(o2),alldegs),]} 
   
     switch(sig, 
         both = {in_pval <- 
intersect(row.names(o1[which(o1$p.value < alpha),]), 
row.names(o2[which(o2$p.val < alpha),]))}, 
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         first = {in_pval <- row.names(o1[which(o1$p.value 
< alpha),])}, 
         second = {in_pval <- 
row.names(o2[which(o2$p.value < alpha),])}, 
          union = {in_pval <- 
union(row.names(o1[which(o1$p.value < alpha),]), 
row.names(o2[which(o2$p.value < alpha),]))},  
         onlyfirst = {in_pval <- 
setdiff(row.names(o1[which(o1$p.value < alpha),]), 
row.names(o2[which(o2$p.value < alpha),]))}, 
         onlysecond = {in_pval <- 
setdiff(row.names(o2[which(o2$p.value < alpha),]), 
row.names(o1[which(o1$p.value < alpha),]))}, 
          stop(paste(sig,": unknown selection",sep="")) 
         ) 
         
        o1 <- o1[in_pval,] 
        o2 <- o2[in_pval,] 
        res <- as.data.frame(cbind(o1, o2)) 
     res <- res[,-c(3,4,7,8)] 
                 
             
     first_quadrant_genes <- 
intersect(row.names(o1[which(o1$slope > 0),]), 
row.names(o2[which(o2$slope > 0),])) 
  second_quadrant_genes <- 
intersect(row.names(o1[which(o1$slope > 0),]), 
row.names(o2[which(o2$slope < 0),])) 
  third_quadrant_genes <- 
intersect(row.names(o1[which(o1$slope < 0),]), 
row.names(o2[which(o2$slope < 0),])) 
  fourth_quadrant_genes <- 
intersect(row.names(o1[which(o1$slope < 0),]), 
row.names(o2[which(o2$slope > 0),])) 
   
  colnames(res) <- c(paste(name.o1,".slope", 
sep=""), paste(name.o1,".p.value", sep=""), paste(name.o2, 
".slope", sep=""), paste(name.o2, ".p.value", sep="")) 
   
  first_quadrant <- 
as.data.frame(res[first_quadrant_genes,]) 
  second_quadrant <- 
as.data.frame(res[second_quadrant_genes,]) 
  third_quadrant <- 
as.data.frame(res[third_quadrant_genes,]) 
  fourth_quadrant <- 
as.data.frame(res[fourth_quadrant_genes,]) 
   
     quadrants <- list(first_quadrant=first_quadrant, 
second_quadrant=second_quadrant, 
third_quadrant=third_quadrant, 
fourth_quadrant=fourth_quadrant) 
  
 return(quadrants) 
} 
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# Make a slopematrix using slope data frames 
 
buildMatrix <- function(rna, rpf, prot, alpha=0.05, 
stringent=F){ 
  
 in_common <- intersect(intersect(row.names(rna), 
row.names(rpf)), row.names(prot)) 
  
 rna <- rna[in_common,] 
 rpf <- rpf[in_common,] 
 prot <- prot[in_common,] 
  
 rna2 <- rna[which(rna$p.value < alpha),] 
 rpf2 <- rpf[which(rpf$p.value < alpha),] 
 prot2 <- prot[which(prot$p.value < alpha),] 
  
 if(stringent == T){ 
 in_common_2 <- intersect(intersect(rownames(rna2), 
rownames(rpf2)), rownames(prot2)) 
 }else{ 
 in_common_2 <- union(union(rownames(rna2), 
rownames(rpf2)), rownames(prot2))} 
  
  
 rna <- rna[in_common_2,] 
 rpf <- rpf[in_common_2,] 
 prot <- prot[in_common_2,] 
  
 res <- cbind(rna[,c(1,2)], rpf[,c(1,2)], prot[,c(1,2)]) 
  
 matrix <- res[,c(1,3,5)] 
 colnames(matrix) <- c("RNA", "RPF", "PROT") 
  
 return(matrix) 
  
} 
Gene	expression	modeling	with	degadation	parameters		
# Formats and fetches data to be used in all modeling steps.  
# Allows to choose the minimum number of peptides (x) 
 
getData <- function(o,x){ 
 
 o$protein$nbp <- 
sapply(o$protein$peptides,FUN=function(x){ 
length(strsplit(as.character(x),", ",fixed=T)[[1]])}) 
 protein_cut <- o$protein[which(o$protein$nbp >= x),] 
 colnames(protein_cut)[3:(2+nrow(o$design))] <- 
as.character(o$design$sample) 
 row.names(protein_cut) <- protein_cut$protein 
  
 rows_used <- intersect(rownames(o$kloss), 
rownames(o$RPF)) 
 rows_used <- intersect(rows_used, 
rownames(protein_cut)) 
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 samples <- intersect(colnames(o$RPF),colnames(o$kloss)) 
  
 prot_gf <- protein_cut[rows_used, samples] 
 rpf_gf <- o$RPF[rownames(prot_gf),samples] 
 pk_gf <- o$kloss[rownames(prot_gf),samples] 
 rna_gf <- o$RNA[rownames(prot_gf),samples] 
 elements <- list(prot_gf=prot_gf, rpf_gf=rpf_gf, 
pk_gf=pk_gf, rna_gf=rna_gf) 
 return(elements) 
} 
  
  
# Plots estimatedP vs measuredP with their linear model and 
# G value by calling recursively estimateGlobalFactor with  
# doplot=T 
 
plotGlobalFactor <- function(o, x, doplot=T, kl=T, rnacor=F, 
ylim=c(0,200000)){ 
   
  layout(matrix(1:6, nrow=2)) 
  samples <- c("306O", "316M", "BU1CRE", "MIFF3", 
"CFG", "242J") 
 
   
   elements <- getData(o=o, x=x) 
    for(j in 1:length(samples)){ 
    
 estimateGlobalFactor(elements$rpf_gf[,j], 
elements$prot_gf[,j], elements$pk_gf[,j], 
elements$rna_gf[,j], main=paste("",samples[j]), doplot=T, 
kl=kl, ylim=ylim) 
           } 
       
} 
 
# Estimates the global factor with the possibility to choose 
# whether to plot and whether to use K_loss in the model.  
  
estimateGlobalFactor <- function(rpf, prot, kloss, rna, 
rnacor=F, doplot=T, main="", ylim=c(0,200000), kl=TRUE, 
protwisefactors=NULL){ 
 if(is.matrix(rpf) | is.data.frame(rpf)) stop("Your 
input is a matrix or dataframe! You should work on one 
sample at a time.") 
 if(length(unique(c(length(rpf),length(prot),length(klos
s))))!=1) stop("Each vector (rpf, prot, kloss) should 
contain the values for the same proteins, in the same 
order.") 
 library(MASS) 
 library(LSD) 
 if(kl == TRUE){ 
 estimatedP = (log2(rpf+0.1))/kloss} 
 else{ 
 estimatedP = log2(rpf+0.1)} 
 if(rnacor == TRUE){ 
 estimatedP = (log2(rna+0.1))} 
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 else{ 
 estimatedP = log2(rpf+0.1)} 
  if(!is.null(protwisefactors)) estimatedP <- 
estimatedP*protwisefactors 
 if(is.null(ylim)) ylim <- c(0, max(prot)) 
 correlation <- cor(log2(prot+0.1), estimatedP,  
use="pairwise", method="spearman") 
 if(doplot) heatscatter(estimatedP,prot,ylab=c("Measured 
P"),xlab=c("Estimated P"),main=main, ylim=ylim) 
 mod <- try(rlm(prot~estimatedP+0),silent=T) 
 if("try-error" %in% class(mod)){ 
  warning("Could not fit robust model... trying 
normal lm") 
  mod <- try(lm(prot~estimatedP+0),silent=T) 
  if("try-error" %in% class(mod)) stop("Could not 
fit model") 
 } 
 if(doplot) abline(mod,lwd=2, col="blue", lty="dashed") 
 #modelmad <- median(abs(mod$residuals)) 
 if(doplot) legend("topleft", bty="n", 
legend=paste(c("G:","MSR:","Cor 
(spearman):"),c(round(coefficients(mod)[[1]]),round(median(m
od$residuals^2)),round(correlation, digits=3)))) 
  
 gvalue <- coefficients(mod)[[1]] 
 msr <- round(median(mod$residuals^2)) 
 mre <- median(abs(mod$residuals)/mod$fitted.values) 
 meansr <- round(mean(mod$residuals^2)) 
 features <- list(gvalue=gvalue, msr=msr, meansr=meansr, 
correlation=correlation, mre=mre) 
  
  
 return(features) 
} 
 
# Gets the features of a model: global factor, median   
# squared residuals, median relative error, spearman   
# correlation, mean squared residuals. 
 
getModelFeatures <- function(o, x, kl=T, 
protwisefactors=NULL, doplot=F){ 
  
 require(reshape) 
  
 samples <- c("306O", "316M", "BU1CRE", "MIFF3", "CFG", 
"242J") 
 gf <- matrix(0, ncol=6, nrow=x, 
dimnames=list(1:x,samples)) 
 msr <- matrix(0, ncol=6, nrow=x, 
dimnames=list(1:x,samples)) 
 cors <- matrix(0, ncol=6, nrow=x, 
dimnames=list(1:x,samples)) 
 mre <- matrix(0, ncol=6, nrow=x, 
dimnames=list(1:x,samples)) 
 meansr <- matrix(0, ncol=6, nrow=x, 
dimnames=list(1:x,samples)) 
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 for(i in 1:x){ 
  elements <- getData(o=o, x=i) 
  if(is.null(protwisefactors)){ 
   pwf <- NULL 
  }else{ 
   pwf <- 
protwisefactors[row.names(elements$prot_gf)] 
  } 
  for(j in 1:length(samples)){ 
   features <- 
estimateGlobalFactor(elements$rpf_gf[,j], 
elements$prot_gf[,j], elements$pk_gf[,j], doplot=doplot, 
kl=kl, protwisefactors=pwf) 
   gf[i,j] <- features$gvalue 
   msr[i,j] <- features$msr 
   cors[i,j] <- features$correlation 
   mre[i,j] <- features$mre 
   meansr[i,j] <- features$meansr 
  } 
 } 
  
 list(gf = gf, msr = msr, cors = cors, mre = mre, meansr 
= meansr, name=deparse(substitute(o)), kl=kl) 
} 
 
 
# Plots values for features of the model, i.e. correlation, 
# median relative error, mean squared residuals along an  
# increasing number of minimum peptide thresholds 
 
plot_Cor <- function(o, x, method="correlation", ylim=NULL){ 
   
  fa <- switch(method, 
   gvalue=o$gf[x,], 
   correlation=o$cors[x,], 
   mre=o$mre[x,], 
   msr=o$msr[x,], 
   stop("unknown method!") 
   ) 
    
   
  cols <- c("red", "red", "gray", "gray", "blue", 
"blue") 
   
  plot(x=rep(x,ncol(fa)), y=as.numeric(fa), 
col=rep(cols, each=nrow(fa)), pch=16, ylim=ylim, 
ylab=paste(method), xlab="Peptide threshold", 
main=paste(method, "for", deparse(substitute(o))))  
} 
 
 
# Plots values for features of two models in the same plot  
# for comparisons along an increasing number of minimum  
# peptide thresholds 
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compare_features <- function(o1, o2, x, 
method="correlation"){ 
 
 fa <- switch(method, 
   gvalue=o1$gf[x,], 
   correlation=o1$cors[x,], 
   mre=o1$mre[x,], 
   msr=o1$msr[x,], 
   meansr=o1$meansr[x,], 
   stop("unknown method!") 
   ) 
    
 fa2 <- switch(method, 
   gvalue=o2$gf[x,], 
   correlation=o2$cors[x,], 
   mre=o2$mre[x,], 
   msr=o2$msr[x,], 
   meansr=o2$meansr[x,], 
   stop("unknown method!") 
   ) 
    
  fam <- melt(fa) 
  fam$thresh <- x 
  fa2m <- melt (fa2) 
  fa2m$thresh <- x 
   
  plot <- ggplot() + 
 geom_dotplot(data=fam, aes(x=factor(thresh), y=value), 
binaxis = "y", stackdir = "center", binpositions="all", 
colour = "NA", fill="blue", binwidth = 0.015*(max(fa)-
min(fa))) + 
 geom_smooth(data=data.frame(x=rep(1:nrow(fa),6),y=as.nu
meric(fa)), aes(x=x,y=y), fill="blue", color="blue") + 
 geom_dotplot(data=fa2m, aes(x=factor(thresh), y=value), 
binaxis = "y", stackdir = "center", binpositions="all", 
colour = "NA", fill="red", binwidth = 0.015*(max(fa)-
min(fa))) + 
 geom_smooth(data=data.frame(x=rep(1:nrow(fa2),6),y=as.n
umeric(fa2)), aes(x=x,y=y), fill="red", color="red") + 
 ggtitle(paste(method, "for minimum 1 to",x[length(x)], 
"peptides in",o1$name,"and", o2$name)) 
  
 return(plot)  
  
} 
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